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Abstract 
Friedreich’s ataxia (FRDA) is known to be provoked by an abnormal GAA-repeat 
expansion located in the first intron of the FXN gene. As a result of the GAA 
expansion, patients exhibit low levels of FXN mRNA, leading to FRDA. Here, via 
chromatin immunoprecipitation (ChIP), the presence of a RNA pol II transcriptional 
pausing site at exon 1 of the FXN gene was demonstrated. At this site, FRDA EBV-
cell lines exhibited elevated levels of the negative elongation factor NELF-E 
depending on the presence of a GAA repeat expansion compared to controls. This 
site may represent a rate-limiting step for FXN transcription and consequently 
provide a means to modify transcription levels in FRDA. Moreover, RNA pol II 
pausing site binding factors, such as NELF-E, were influenced by Nicotinamide 
treatment, a HDAC class III inhibitor. Therefore, factors sensitive to chromatin 
changes may influence the regulation of RNA pol II pausing and also balance 
otherwise positive chromatin changes. This new finding could explain the relatively 
minor effects of different drug approaches to up-regulate this gene. Furthermore, 
CTCF and the histone demethylase LSD1 were also found to be located at the FXN 
pausing site. Results suggest a function for LSD1 in demethylating H3K4me2 at the 
pausing site and potentially also in demethylating H3K9me3 in the case of frequently 
transcribed expanded GAA repeats. Therefore, LSD1 might play a crucial role in 
preventing heterochromatinisation of a euchromatic gene. Using primary transcript 
RNA-FISH, a delay in RNA pol II release from the pausing site and furthermore a 
dramatic loss of RNA pol II elongation in the presence of expanded GAA repeats was 
seen. The identified and characterised transcriptional pausing site at FXN is likely to 
play a repressive role and participates in the pathogenesis of FRDA.  
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Introduction 
 
Friedreich’s Ataxia 
Friedreich's ataxia (FRDA) is the most common autosomal recessive 
neurodegenerative disease with an incidence of one in 50,000. The carrier frequency 
varies depending on the ethnic group from 1/60-1/100 (Pandolfo, 1998; Bidichandani 
et al., 1998). FRDA is well documented in Europe, the Middle East, South Asia 
(Indian subcontinent), and North Africa. To date, FRDA has not been recognised in 
Southeast Asia, in sub-Saharan Africa, or among Native Americans. Furthermore, a 
lower than average prevalence of FRDA is documented in Mexico (Gomez et al., 
2004).  
 
FRDA is caused primarily by an abnormal GAA repeat expansion located in the first 
intron of the frataxin gene (FXN) (Fig. 1) (Campuzano et al., 1996). The FXN gene 
consists of five alternatively spliced exons, which encode one of two open reading 
frames (Ensembl). Exons 1 - 5 produce the major transcript encoding the 210- amino 
acid mitochondrial protein, Frataxin. Most individuals suffering from FRDA are 
homozygous for large GAA trinucleotide repeat expansions of the polymorphic 
(GAA)n sequence in intron 1 (Campuzano et al 1996). The size associated with 
FRDA ranges from 66 to 1700 or more triplets (Campuzano et al 1996, Durr and 
Brice, 1996; Epplen et al 1997), although the majority of alleles contain 600 to 1200 
repeats. This type of mutation is seen in 96 % of all FXN mutant alleles, only 4 % 
display point mutations inside the coding regions of FXN.  
 
 
 
 
Figure 1: Location of GAA repeat is marked in orange, CpG- islands are marked in blue. FXN 
consists of 5 exons. The length of introns is displayed in correct proportion. 
 
2000 bp 
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A normal (GAA)n repeat is situated at the centre of an Alu repeat element, showing a 
length polymorphism (Campuzano et al., 1996; Cossee et al., 1997; Montermini et 
al., 1997a). Furthermore, adjacent to the GAA triplet repeat a polymorphic 
mononucleotide tract of adenines (poly A tract) was identified (Monticelli et al., 2004). 
Unaffected individuals possess between 5 and 33 GAA repeats. Bimodal distribution 
exists among normal alleles in which 85 % have fewer than 12 GAA repeats (short 
normal) and the remainder comprise 12 - 33 repeats (long normal). Alleles longer 
than 27 GAA repeats are usually interrupted by a (GAGGAA)n sequence. However, 
the homopurine / homopyrimidine nature of the GAA tract is maintained in all 
individuals. A rare variation of a GAA triplet repeat was reported where two 
individuals were found carrying 65 tandem repeats of the GAAGGA hexanucleotide 
sequence instead of the normal GAA triplet repeat. This sequence seemed to be 
non-pathogenic (Ohshima et al., 1999).  
 
The condition is characterised by progressive gait and limb ataxia, dysarthria, 
areflexia, loss of vibratory and position sense, and distal extremity weakness. 
Additional features include hypertrophic cardiomyopathy, scoliosis and diabetes. 
However, 25 % of patients carrying a FXN mutation do not fulfil all of these 
characteristics (Durr and Brice, 1996). Usually FRDA patients show a negative 
correlation between the size of the shorter allele expansion and the age of FRDA 
onset and the use of a wheelchair. A direct correlation is seen with disease severity, 
presence of cardiomyopathy, and optic atrophy (Durr and Brice, 1996; Filla et al., 
1996; Schols et al., 1997).  
 
Since there is no evidence in vivo for an effect on RNA processing in FRDA, the 
disease results directly from reduced FXN mRNA levels followed by reduced 
amounts of Frataxin protein (Bidichandani et al., 1998; Cossee et al., 1997; Ohshima 
et al., 1998). FXN mRNA is expressed mainly in tissues with a high metabolic rate, 
including liver, kidney, brown fat and heart. High levels of expression are also found 
in the spinal cord, whereas in the cerebellum lower levels of Frataxin predominate 
(Campuzano et al., 1997; Koutnikova et al., 1997). The GAA repeat expansion 
provokes a severe drop in FXN mRNA levels, 30 % below those of normal 
individuals, leading to the development of FRDA (Pianese et al., 2002). In line with 
this, FRDA patients show abnormalities in the spinocerebellar tracts, dorsal columns 
and to a lesser extent the cerebellum and medulla. Finally, 50 % of all fatal cases 
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occur because of heart failure and 75 % of all FRDA cases demonstrate evidence of 
cardiac dysfunction (Hewer, 1968), demonstrating the necessity for adequate 
Frataxin levels in the heart. 
 
Despite a general genotype-phenotype correlation, it is not possible to predict the 
clinical outcome in an FRDA individual based on the genotype. Thus, it was 
suggested that the variability in FRDA severity is most likely caused by variations in 
individual genetic backgrounds (Montermini et al., 1997a; Montermini et al., 1997b). 
In general the size of the allele with the shorter GAA repeat expansion gives a better 
correlation with the rate of progression of FRDA (Filla et al., 1996; Monros et al., 
1997; Richter et al., 1996). Notably, in 50 % of all FRDA cases the rate of disease 
progression also correlates with the age of onset (Montermini et al., 1997a; 
Bhidayasiri et al., 2005). The age of onset of FRDA ranges from the age of five to 
beyond 50 years, suggesting that additional factors are involved in the manifestation 
of the disease. Notwithstanding, a small pool of patients exists that exhibits a late 
onset of FRDA accompanied by only mild symptoms despite having a long GAA 
repeat expansion. This phenomenon will be discussed in more detail in the following 
paragraph. 
 
FRDA types 
Late onset patients can be divided into three subgroups, namely: late onset FRDA 
(LOFA), very late onset FRDA (VLOFA) and Acadians (Berciano et al., 2002; 
Bidichandani et al., 2000). Individuals with LOFA usually possess fewer than 
500 GAA repeats in the shorter of both alleles (Durr et al., 1996, Filla et al., 1996, 
Montermini et al., 1997; Bhidayasiri et al., 2005). Individuals with VLOFA usually 
show fewer than 300 GAA repeats, at least in one of the expanded alleles (Berciano 
et al., 2002; Bidichandani et al., 2000). Nevertheless, an individual with VLOFA 
exhibiting expansions of greater than 800 repeats in each allele has been found 
(Bidichandani et al., 2000). This again emphasises the difficulty of predicting FRDA 
progression and also demonstrates the possibility of a beneficial genetic background. 
Therefore, additional factors might indeed influence the GAA expansion thus 
modifying the progression of the disease. 
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Further evidence for additional factors influencing FXN expression is given in 
Acadian FRDA patients. Acadian patients generally show a late onset, with a range 
of 18 to 44, with a mean of 27 years, accompanied by confinement to a wheelchair at 
a later stage and a much lower incidence of cardiomyopathy (Montermini et al., 
1997). Despite these clinical differences, no significant differences were found in the 
size of the GAA expansions or in the coding region of FXN in this population. 
Acadians descend from a 17th- century French colony that settled in a region 
geographically separate from Quebec called Acadia. They developed and maintained 
their own culture for more than 400 years (Faragher, 2005). In this community one 
can hypothesise the existence of a more uniform genetic background, leading to an 
improvement in the case of an abnormal GAA repeat expansion in the first intron of 
the FXN gene.  
 
Pathologic GAA repeat expansions 
It has been suggested that the development of FRDA is caused by an abnormal GAA 
repeat expansion interfering with RNA pol II elongation. This is thought to lead to a 
severe deficiency of normally spliced FXN mRNA in individuals homozygous for the 
GAA expansion (Campuzano et al., 1997; Bidichandani et al., 1998).  
 
Experiments conducted on E. coli and S. cerevisiae demonstrated in vitro and in vivo 
that the GAA triplet repeats constitute a length and orientation-dependent hindrance 
to elongation (Bidichandani et al., 1998, Grabczyk and Usdin, 2000; Ohshima et al., 
1998). Sequences with more than 59 GAA triplet repeats form a structure called 
"sticky DNA", produced by the intermolecular association of two DNA triplexes 
(Sakamoto et al., 1999). A DNA triplex is formed upon binding of a pyrimidine or a 
purine single-stranded DNA to the major groove of a double helix, forming Hoogsten 
or reverse-Hoogsten hydrogen bonds between the purine strand and the duplex (Jain 
et al., 2002; Rajeev et al., 1997). Interruption in the purity of the GAA sequence for 
example by GGA, results in destabilization of sticky DNA accompanied by a lack of 
transcriptional inhibition (Ohshima et al., 1998, Sakamoto et al., 1999; Sakamoto et 
al., 2001a). Sticky DNA is detected by reduced mobility of DNA restriction fragments 
containing GAA•TTC repeats on gel electrophoreses and most likely arises from 
intra-molecular association of long GAA repeat triplexes. However, recent 
publications indicate that although the transcription through GAA repeats is 
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hampered, it is still possible (Krasilnikova et al., 2007). The following figure 2 
extracted from review Mirkin S., (2007), illustrates schematically the triplex and sticky 
DNA configuration.  
 
Figure 2: Sticky DNA structure can result from repetitive GAA- DNA. The structure-prone strand 
of the repetitive run is shown in red, its complementary strand in green and flanking DNA in 
beige. Triplex DNA and sticky DNA formed by the (GAA)n·(TTC)n repeat. Figure 2 is extracted 
from review Mirkin S., Nature 447, 932-940, 2007.   
 
Long GAA repeats can form triplexes containing 2 purine (R) GAA strands and 1 
pyrimidine (Y) TTC stand, flanking a single-stranded pyrimidine region. The formation 
of a RRY triplex in plasmid DNA requires divalent metal ions and negative super-
coiling. A high-resolution NMR structure of a GAA•TTC•GAA triplex has been 
presented and indeed a DNA triplex structure provoked by triplet repeats within the 
FXN gene was found (Mariappan et al., 1999). Using two different monoclonal 
antibodies against triplex DNA it has been shown that parts of the chromosomal DNA 
are naturally organised as triplex configurations, scattered among and within the 
chromosomes (Agazie et al., 1996; Burkholder et al., 1988; Ohno et al., 2002). 
Furthermore, these experiments showed cell type and cell cycle dependent staining 
patterns, indicating cell type specific arrangements of DNA in the nucleus (Agazie et 
al., 1996). Nuclei double stained with antibodies against centromeric- and triplex- 
(GA/TC)n tracts revealed a close spatial association of both signals, suggesting the 
possibility of chromatin organisation via DNA triplexes (Ohno et al., 2002). 
 
On the other hand, Saveliev et al., (2003) showed that expanded GAA repeats 
introduced into the mouse genome induced position-effect variegation (PEV) of an 
adjacent reporter gene. This finding suggests that frataxin deficiency associated with 
expanded GAA repeats may also be mediated by an abnormal chromatin 
Triplex DNA              sticky DNA 
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organization. PEV occurs when a gene is located abnormally close to regions of 
heterochromatin. Silent heterochromatin is characterised by the presence of 
particular histone modifications for example, H3K9me3 and hypoacetylated histone 
tails. Further details of chromatin will be discussed in the second part of the 
Introduction. Of importance here is that mutagenesis studies have identified many 
genes, which have the potential to modify the extent of gene silencing in PEV in vivo.  
 
Such genes encode factors which are either components of chromatin such as core 
histones or enzymes modifying chromatin, for example: histone acetyltransferases, 
deacetylases or methyltransferases (Reuter and Spierer, 1992). A key component of 
constitutive heterochromatin is Heterochromatin Protein 1 (HP1) (Eissenberg et al., 
1992; Elgin, 1996). It has been shown that HP1, when over-expressed, is a powerful 
modifier of mammalian PEV which also increases GAA-repeat associated reporter 
gene silencing in transgenic mice (Festenstein et al., 1999; Saveliev et al., 2003). 
Therefore, one can hypothesise that an unusual non-B DNA structure, such as 
triplexes and/or the sticky DNA conformation adopted by GAA•TTC repeats, might 
initiate silencing of genes harbouring such repeats, as seen in the FXN locus of 
FRDA patients. Furthermore, proteins that recognise and bind these alternative DNA 
structures might initiate a cascade of events, leading to the recruitment of 
heterochromatic proteins and ultimately initiating gene silencing. 
 
Pathology in Friedreich’s ataxia results from deficiency of Frataxin and 
its function 
Frataxin protein deficiency leads to a reduced antioxidant defence, deficient 
mitochondrial function and increased oxidative damage (Lodi et al., 2001c). Affected 
individuals show poor ATP production and cellular oxygenation in post-exercise 
skeletal muscle (Lodi et. al. 2001c; Seznec et al., 2005). Frataxin is required for the 
biogenesis of the iron-sulphur-cluster (ISC) and is therefore vital for the synthesis of 
the respiratory chain complexes I-III enzymes and the aconitases (Seznec et al., 
2005). Since individuals suffering from FRDA show abnormal mitochondrial iron 
accumulation, Frataxin may also play a role in the regulation of mitochondrial iron 
content, however this could be a secondary manifestation (Bunse et al., 2003; Lodi et 
al., 2001a; Lodi et al., 2001b). 
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In mice, complete deficiency of frataxin (Fxn) leads to early embryonic lethality 
without evidence of iron accumulation (Cossee et al., 2000), indicating that Fxn is 
essential for early embryonic development and that iron accumulation is unlikely to 
be a primary pathophysiological event. A similar situation may occur in humans as to 
date no patient has been identified as having two alleles exhibiting Frataxin 
inactivating point mutations, implying homozygous lethality. Even more, during 
development homozygosity for very large GAA expansions still results in sufficient 
amounts of Frataxin (Pandolfo, 2006).  
 
The development of tissue-specific conditional knockouts of mouse Fxn have 
resulted in models displaying specific features of the FRDA phenotype, such as 
neurodegeneration in the dorsal root ganglia, cardiomyopathy and diabetes mellitus 
(Puccio et al., 2001; Ristow et al., 2003; Seznec et al., 2004; Simon et al., 2004). 
Moreover, treatment with the anti-oxidant, Idebenone, which is discussed later on, 
delays the onset of cardiac pathology and even prolongs the life span of cardiac-
specific Fxn knock-out mice (Seznec et al., 2004). 
 
FXN promoter and potential regulatory factors 
In order to develop compounds effective in increasing FXN levels, the identification of 
factors regulating its expression is required. These factors might include cis-acting 
DNA sequences and trans-acting proteins. Additionally, the influence of the 
chromatin structure at the FXN locus still needs to be assessed in normal versus 
FRDA individuals. An effort to search for FXN promoter elements identified a 
conserved initiator element and possible, so-called downstream promoter elements 
(DPE) (Sarsero et al., 2005). This work, which was achieved by using a reporter 
gene (EGFP) under the control of the proposed promoter site of FXN (FXN-EGFP 
cell line), also demonstrated that deletions downstream of the transcription initiation 
site had the most severe impact on reporter gene activity, reducing its expression by 
60 %. Therefore, downstream elements may contribute significantly to FXN promoter 
activity (Greene et al., 2007; Sarsero et al., 2005). 
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Up-regulation of frataxin expression 
Even though the regulation of FXN and specifically the down-regulation via GAA 
expansion remains unclear, a number of studies and screens have been conducted 
to identify compounds that increase the expression of FXN. As specified before, 
several ideas already exist as to how the GAA repeat expansion may negatively 
influence the transcription machinery. To date, several agents have been found to 
increase frataxin expression in cellular models such as hemin, butyric acid (Sarsero 
et al., 2005), and erythropoietin (Sturm et al., 2005). However, the mode of action for 
most of these agents and their efficiency in up-regulating FXN to adequate levels is 
unclear.  
 
Therapies under investigation 
As frataxin mRNA deficiency results in abnormal accumulation of intramitochondrial 
iron, defective mitochondrial respiration and overproduction of oxygen free radicals, 
antioxidant therapy initially appeared promising. Iron chelators were therefore 
proposed as a possible therapy for reducing the intra mitochondrial iron overload. 
Non-specific iron chelators such as desferrioxamine were used for the specific 
reduction of mitochondrial iron overload. Although in vitro studies using a 
mitochondrial-specific iron chelator (2-pyridylcarboxaldehyde) showed promising 
results (Richardson et al., 2001), a clinical trial was terminated because of lack of 
efficacy. 
 
However, free radical captors such as coenzyme Q10, vitamin E, Idebenone (a short-
chain analogue of coenzyme Q10), and more recently, mitochondrial-targeted 
Idebenone (MitoQ) are considered to be potential therapies for slowing the 
progression of FRDA (Lodi et al., 2001a). 
 
Coenzyme Q10 and vitamin E 
Following treatment with coenzyme Q10 and vitamin E over a period of three to six 
months, showed improved ATP production in the heart and skeletal muscle of 
individuals with FRDA. An open label trial of these drugs in ten individuals for 47 
months resulted in sustained improvement in bioenergetics and improved cardiac 
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function as assessed by increased fractional shortening, implying improved left 
ventricle performance (Hart et al., 2005). 
 
Idebenone  
Early clinical trials with Idebenone showed a reduction of the left ventricular mass 
and wall thickness in some FRDA individuals with cardiac hypertrophy (Buyse et al., 
2003; Mariotti et al., 2003; Rustin et al., 1999). However, the neurological condition of 
these patients continued to deteriorate slowly with Idebenone treatment (5mg/kg) 
over a seven-year follow-up. In addition, although cardiac hypertrophy decreased 
during this course, cardiac function did not improve (Ribai et al., 2007). Idebenone 
administered orally for one month at high doses of up to 75 mg/kg per day was well 
tolerated (Di Prospero et al., 2007). This finding led to a randomised placebo 
controlled trial using higher doses of up to 45mg/kg for six months. Again the higher-
dose treatment was generally well tolerated and importantly was associated with an 
improvement in neurological function in FRDA patients, in a dose dependent manner. 
Indicating, that higher doses may be necessary to have a beneficial effect on 
neurological function (Di Prospero et al., 2007).  
MitoQ and MitoVitE  
In an effort to improve the delivery of Idebenone and vitamin E to mitochondria 
(Kelso et al., 2001; Smith et al., 1999), the compounds were linked to a lipophilic 
cation to produce MitoQ and MitoVitE, respectively. In a cell culture model using 
fibroblasts from affected individuals, Jauslin et al., (2003) showed that MitoQ was 
800 times more active than Idebenone in protecting cells from endogenous oxidative 
stress. Although MitoVitE was less effective, it was still 20 times more effective than 
Idebenone. A trial of MitoQ in FRDA is planned to commence shortly. MitoQ taken 
orally accumulates in the heart and the brain of mice (Kelso et al., 2001), 
demonstrating its capacity to cross the blood brain barrier. 
 
Gene therapy  
The treatments proposed above have all improved the course of FRDA rather than 
cured the lack of Frataxin. Therefore, gene therapy would appear a desirable choice, 
addressing the cause rather than the consequences of FRDA. The first steps to 
supplement the loss of function of Frataxin via gene therapy have already been taken 
                                                                                                                                         
 
22 
(Fleming et al., 2005). Recombinant adeno-associated viral and lentiviral vectors 
expressing FXN cDNA were shown to partially correct sensitivity to oxidative stress in 
FRDA primary fibroblasts (Fleming et al., 2005). In both cellular and animal models it 
was shown that herpes simplex virus type 1 (HSV-1) amplicon vectors expressing 
either the entire FRDA genomic locus or frataxin cDNA were able to partially rescue 
the FRDA phenotype (Lim et al., 2007). Specifically, Gomez-Sebastian et al., (2007) 
found that FRDA primary fibroblasts harbouring HSV1:FXN exhibited a restored 
response to oxidative stress. In both studies a neurotropic herpes vector was used to 
correct the neurological degeneration found in FRDA. To this end, (Fleming et al., 
2007) have shown that rota-rod test deficits in mice with localised frataxin reduction 
in the brainstem can be corrected by exposure to HSV-1:FXN cDNA. Still, a 
significant amount of basic research is required before gene therapy is feasible in a 
clinical setting.  
Other gene based approaches 
The results obtained for GAA•TTC repeats and their resulting DNA and chromatin 
structure led to the hypothesis that molecules interfering with triplex or sticky DNA 
formation and/or heterochromatin formation in the FXN gene would be beneficial. 
Promoting successful elongation through expanded GAA•TTC repeats might relieve 
the deficiency in FXN mRNA and protein in affected individuals (Grabczyk and Usdin, 
2000; Saveliev et al., 2003; Vetcher et al., 2002). Furthermore, molecules that 
increase FXN promoter activity, either by acting on the DNA or the protein 
constituents of the transcription initiation or RNA chain elongation complexes, might 
also be therapeutic for FRDA (Sarsero et al., 2003).  
 
Two groups focused on the identification of small DNA ligands to alleviate the 
proposed GAA•TTC repeat-mediated gene silencing. The first group performed a 
rational screen on small molecule DNA ligands to determine their effects on EGFP 
expression in the reporter cell lines described earlier (Grant et al., 2006). This study 
was based on the results of compound screening due to the ability to discriminate 
between different nucleic acid structures in a competition dialysis experiment. Here, 
compounds such as DAPI, diminazene Hoechst 33258, distamycin and pentamidine 
were found to increase EGFP expression of the FXN-EGFP cell line. The anti-
infective pentamidine, used for the treatment of HIV-associated infections, was 
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shown to increase levels of Frataxin by 1.3 up to 2.2 fold in primary lymphocytes 
isolated from FRDA patients (Grant et al., 2006). 
 
The second group demonstrated a promising potential treatment using linear β-linked 
polyamides. These pyrrol-imidazole polyamides can be designed to bind specifically 
homopurine DNA stretches (Dervan and Edelson, 2003; Janssen et al., 2000a; 
Janssen et al., 2000b; Urbach and Dervan, 2001). Given the very high affinity of 
polyamides for their target sites, these molecules should act as a thermodynamic 
sink and lock GAA-TTC repeats into double-stranded B-type DNA, preventing the 
transition to non-B DNA structures of long GAA•TTC (review Gottesfeld, 2007). 
Importantly, polyamides bound within coding regions of genes were shown to have 
no negative effect on transcription in mammalian cells. Finally, these molecules do 
not bind to RNA; therefore the RNA processing should be unaffected. Indeed in 
FRDA EBV-cell lines, an increase in RNA of ~ 2 fold was observable, however this 
effect was not preserved in non-dividing cells.  
 
Animal models for FRDA 
Koutnikova et al., (1997) cloned the complete coding region of mouse Fxn and 
studied its pattern of expression in developing and adult tissues. They found by in 
situ hybridisation analyses that Fxn expression correlated well with the main sites of 
neurodegeneration in FRDA. Nevertheless, the expression pattern of Fxn was 
broader than expected from the pathology of the disease. Fxn mRNA was 
predominantly expressed in tissues with a high metabolic rate, including liver, kidney, 
brown fat, and the heart. They also demonstrated that mouse and yeast FXN 
homologues contain a potential mitochondrial targeting sequence in their N-terminal 
domains and that disruption of the yeast (YFH1) gene results in mitochondrial 
dysfunction (Koutnikova et al., 1997). 
 
Mice with tissue specific Fxn deficiency 
Through a conditional gene targeting approach, Puccio et al., (2001) generated, in 
parallel, a striated muscle Fxn deficient mouse line and a neuron/cardiac muscle 
frataxin deficient line, which together reproduced important progressive 
pathophysiologic and biochemical features of human FRDA. These mice displayed 
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cardiac hypertrophy without skeletal muscle involvement, large sensory neuron 
dysfunction without alteration of the small sensory and motor neurons and deficient 
activity of complexes I-III of the mitochondrial respiratory chain and of aconitases. 
This model also demonstrated time-dependent intra-mitochondrial iron accumulation 
in a frataxin deficient manner, occurring after onset of the pathology and after the 
inactivation of the Fe-S-dependent enzymes. Therefore, these mice might represent 
the first mammalian models to evaluate possible treatment strategies for FRDA 
patients (Puccio et al., 2001). 
 
Mice with GAA(230) repeat knock-in into Fxn 
Miranda et al., (2002) generated transgenic mice with a GAA repeat expansion of 
230 repeats introduced into the first intron of the mouse Fxn gene. However, the GAA 
repeat insertion is not comparable to the human location, as mice do not normally 
exhibit a GAA repeat in the first intron of Fxn. These mice showed reduced frataxin 
levels, but failed to exhibit a FRDA phenotype of motor deficits, iron overload, or 
meiotic/mitotic instability (Miranda et al., 2002). 
 
Mice possessing the human FXN locus with a GAA expansion 
Al-Mahdawi et al., (2006) generated two strains of human FXN YAC transgenic mice 
carrying pathogenic 190 or 190+90 GAA repeat expansions respectively in intron 1 of 
the human FXN gene. These mice, when crossed to rescue the Fxn-/- mice, showed 
decreased levels of human frataxin mRNA and protein expression in various tissues, 
including the brain, the heart and skeletal muscle, as well as increased levels of 
oxidised proteins. Phenotypically, these transgenic mice showed coordination deficits 
and a progressive decrease in motor activity from the age of 3 months, although 
none developed ataxia over a period of 2 years. Electrophysiological studies were 
suggestive of a mild, progressive peripheral neuropathy. Histology showed large 
vacuoles in dorsal root ganglia neurons and mild iron deposition in cardiomyocytes 
(Al-Mahdawi et al., 2006). However there is no control mouse with a normal GAA 
repeat at the FXN locus currently available. It is therefore difficult to prove that the 
observed phenomenon is based on the relatively short GAA expansion rather than on 
the construct itself.  
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Using the same mouse model, Clark et al., (2007) found that transgenic mice 
carrying expanded GAA repeats (190 or 82 triplets) in the human FXN gene showed 
tissue-specific and age-dependent somatic instability specifically in the cerebellum 
and dorsal root ganglia. The GAA(190) allele showed some instability at the age of 2 
months and a significant expansion by 12 months, which was slightly greater than 
that of GAA(82), suggesting that somatic instability was also repeat-length dependent. 
There were lower levels of repeat expansion in proliferating tissues, indicating that 
DNA replication per se was unlikely to be a major cause of age-dependent 
expansion. 
 
Mice with human FXN fused to EGFP 
Sarsero and colleagues generated transgenic mice with a BAC genomic reporter 
construct consisting of an in-frame fusion between the human FXN and the gene 
encoding enhanced green fluorescent protein (EGFP). Since the expression of EGFP 
is under the control of the FXN gene regulatory elements, compounds which might 
up-regulate FXN transcription should be easily identified in these mice. However, the 
present construct contains only six GAA repeats and therefore only permits the 
identification of molecules acting in the wild type situation. Interestingly, this group 
identified hemin and butyric acid as positive enhancers of frataxin expression, even 
though an up-regulation of less than 20 % was seen (Sarsero et al., 2005) 
 
As previously mentioned, the currently available treatment for FRDA patients is not 
satisfactory. This may in part be due to the approaches taken to date. In most cases 
the focus has been on overcoming the effects of lacking frataxin using other 
compounds. However, each affected tissue seems to suffer a specific problem 
caused by the lack of Frataxin. So far, it has proved difficult to treat FRDA with only 
one compound. Therefore, the ideal treatment may be a drug enhancing the reduced 
frataxin levels and possibly leading to an improvement in all affected organs.  
 
Since mouse models exhibiting a GAA stretch linked to a reporter gene demonstrated 
sensitivity to epigenetic modifiers, these might be good candidates as potential drug 
targets (Festenstein et al., 1999; Saveliev et al., 2003). The second part of the 
Introduction will give a general overview of epigenetics and its factors, which might 
play a role in regulating FXN transcription.  
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Epigenetics 
Overview of epigenetics 
In the field of epigenetics the main focus of research lies on factors that allow cell 
specific processing of the genetic code, without changing the latter. Each cell of an 
organism contains the same genetic information but the expression pattern can differ 
drastically from cell type to cell type. Thus, mechanisms must be available firstly to 
allow a cell to develop a certain expression pattern and secondly to maintain this 
expression pattern during following cell divisions. There are three main mechanisms 
involved in the complex epigenetic gene regulation. The first one is the packaging of 
negatively charged DNA around basic histones (Luger et al., 1997). The resulting 
chromatin can then, depending on specific modifications of the histone tails, be 
loosened up or compacted further, resulting in a polymorphic accessibility to proteins 
such as transcription factors (see review Kouzarides, 2007). The second mechanism 
is the methylation of DNA, which stays in contact with specific histone modifications, 
setting a mark for the binding of proteins, which then can act in a chromatin 
repressive mode (Bird, 2001, 2002; Ng and Bird, 1999). The third mechanism 
involves non-coding RNAs (see review Kouzarides, 2007). They can act on the 
translational as well as on the transcriptional level. Importantly, the combination of all 
three mechanisms plays a crucial role in epigenetic regulation of the genome (see 
review Kouzarides, 2007).  
 
This project focuses on the investigation of distinct histone modifications at the 
human FXN gene in FRDA patients. As discussed earlier, this GAA triplet repeat is 
known to form a non-B-triplex DNA structure possibly resulting in a more condensed 
chromatin structure. Here, the possibility of an abnormal histone code interfering with 
the otherwise open chromatin structure of the FXN locus caused by the GAA 
expansion will be investigated. Furthermore, the possibility of reversing the 
abnormally condensed structure via epigenetic modifiers will be tested.  
 
Chromatin Structure 
In eukaryotic cells, nuclear DNA is packaged into a higher ordered structure, known 
as chromatin. The basic repeating unit of chromatin is the nucleosome, consisting of 
a 147 bp DNA superhelix wrapped around a histone octamer complex consisting of 2 
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of each histone: H2A, H2B, H3 and H4 (Luger et al., 1997). An interaction between 
the DNA and histone molecules is established by electrostatic interaction between 
negative groups of the DNA and positive side chains of the histones (Ladik et al., 
2007). The N-terminal tail of each core histone protein sticks out thereby providing an 
additional site for further modifications. These can affect the chromatin structure by 
disrupting or creating binding sites for certain chromatin associated proteins, 
ultimately leading to the activation or repression of transcription. Additionally, several 
histone variants such as H2A.Z and H3.3 exist although their exact functions remain 
elusive (see review Loyola and Almouzni, 2007).  
 
Modifications of histones and their implication in chromatin structure 
The development of the chromatin immunoprecipitation (ChIP) technique in the early 
1990s allowed the investigation of proteins bound to particular DNA sequences in 
vivo. Thereby, living cells are cross-linked with formaldehyde, followed by cell lysis 
and sonication to release and break up the chromatin into smaller fragments. Using 
specific antibodies the DNA-protein complexes of interest can be 
immunoprecipitated. By reversing the cross-link and cleaning the remaining DNA, it is 
then possible to identify the protein-bound DNA sequences via the polymerase chain 
reaction (PCR) (Ebralidse et al., 1993; Orlando et al., 1997).  
 
Most histone tail modifications were discovered or at least confirmed by mass 
spectrometry prior to the development of suitable antibodies. The majority of 
modifications occur at the amino- and carboxy- terminal part of the histone tails, with 
only a few being localised to the globular domain. The most common ones are 
acetylation (ac), methylation (me), phosphorylation (ph), ubiquitylation (ub) and 
sumoylation (SUMO). Every modification exhibits a unique charge and size therefore 
potentially exerting for each one a specific effect on the chromatin structure. Several 
target sites have been identified for these different modifications and their functions 
are only partly understood (see review Berger, 2007).  
 
A crucial target site is the amino acid lysine, representing a key substrate for all the 
modifications mentioned above. The functional consequences of those modifications 
can be direct in causing structural changes or indirect through protein recruitment 
(see review Berger, 2007). For example, adding a small group, such as an acetyl or 
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methyl group produces a different effect on chromatin compared to the effects of a 
bulky ubiquitylation or sumoylation, which are nearly two-thirds of the mass of a 
histone molecule (Shahbazian et al., 2005). Moreover, methylation can occur in 
several steps from mono to tri-methylation, which can be placed symmetrically or 
asymmetrically. Again each type of methylation has its unique impact on the 
transcription of chromatin (see review Berger, 2007). Furthermore, modifications on 
lysine residues lead to opposing chromatin structures and functions depending on 
their position. For instance, the tri-methylation of H3K4 is associated with active 
chromatin (Bernstein et al., 2002; Ng et al., 2003; Pokholok et al., 2005; Santos-Rosa 
et al., 2002; Schneider et al., 2004; Schubeler et al., 2004), whereas the tri-
methylation of H3K9 mediates epigenetic silencing (Fisher et al., 2006; Ringrose et 
al., 2004; Snowden et al., 2002; Wu et al., 2007). For maximal epigenetic complexity 
and flexibility most, if not all, histone modifications are dynamic and reversible (see 
review Berger, 2007). The most common post-translational histone-tail modifications 
and their transcriptional implications are summarised and displayed below (Fig. 3).  
 
 
 
Histone post-translational 
modifications 
Sites Transcriptional Role 
Acetylated lysine (K) 
H3 (9, 14, 18, 56) 
H4 (5, 8, 13, 16) 
H2A, H2B 
Activation 
Phosphorylated serine/threonine (S/T) H3 (3, 10, 28) 
H2A, H2B 
Activation 
Methylated arginine (R) H3 (17, 23), H4 (3) Activ. / Repression  
Methylated lysine (K) H3 (4, 36, 79) 
H3 (9, 27), H4 (20) 
Activation 
Repression 
Ubiquitylated lysine (K) H2B (120) 
H2A (119) 
Activation 
Repression 
Repressive 
Marks 
 
  
 
  
 
  
Active 
Marks 
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Sumoylation lysine H2B (6/7), H2A (126) Repression 
Isomerised proline H3 (30-38) Activ. / Repression 
 
Figure 3: Model of DNA wrapped around histone octamer consisting of pairs of H2A, H2B, H3 
and H4. Each histone exhibits a flexible histone tail that can be dynamically modified. Shown 
here are histone sites with possible modifications and their implication for transcription. 
 
So far, arginine residues appear to be strictly methylated and this is associated with 
active as well as repressive regulation of transcription (Kirmizis et al., 2007). 
Similarly, the phosphorylation of H3 occurs at loci of active transcription as well as 
during silenced mitotic chromosome condensation, demonstrating the importance of 
the genomic context when interpreting chromatin modifications (see review Berger, 
2007). In the following part, selected histone tail modifications will be discussed in 
more detail. 
 
H3K4 methylation 
The methylation of H3K4 is associated with genes that are, or are destined to be, 
transcriptionally active and usually located in euchromatin (Litt et al., 2001). In line 
with this observation, H3K4me3 is primarily found at the 5’ end of genes during the 
activation of transcription (Barski et al., 2007). This phenomenon, described in yeast, 
is most likely the result of recruitment of the Set1 histone lysine methyl transferase 
(HKMT) through phosphorylated Ser-5 of the carboxy-terminal domain CTD of the 
RNA polymerase (pol) II (Rossi et al., 2001). Ser-5 phosphorylation is known to 
release the RNA pol II from the initiation complex into an early elongating complex 
(Keogh et al., 2003). The following image (Fig. 4) illustrates the proposed mechanism 
and histone marks H3K4me2 and H3K36me3, which occur at the human FXN locus. 
Here, Set1 interacts with a RNA pol II associated factor (PAF complex), regulating 
different steps of RNA metabolism and also mediating the methylation of H3K4me2 
(adapted from “Epigenetics” by Allis et al., 2007).  
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Figure 4: Proposed mechanism of H3K4 methylation by phosphorylated RNA pol II binding Set1 
domain (adapted from “Epigenetics”, Allis et al., 2007). FXN locus with location of GAA repeats 
(marked in red) and predicted second CpG-island (marked in blue) shown above ChIP results 
against H3K4me2 and H3K36me3. Histone modifications are extracted from database provided 
by Barski et al., 2007. 
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Mechanistically, the methylation of H3K4 can lead to the recruitment of specific 
factors such as the chromodomain helicase DNA binding protein 1 (CHD1) protein 
(an ATP-dependent helicase), which binds to H3K4me2 as well as me3 (Sims et al., 
2005). CHD1 also binds to the nucleosome remodeling factor (NURF) complex and is 
known to mobilize nucleosomes at active genes in Drosophila. Likewise, evidence 
exists that the nucleosomal remodeling and histone deacetylase (NuRD) repressor 
complex can no longer bind to methylated H3K4 tails (Lee et al., 2005; Martin and 
Zhang, 2005). To further enhance the sphere of action, the methylation of H3K4 
seems to communicate with other modifications. In vitro results have demonstrated 
that in the presence of H3K4me3 and H3S10ph, the binding of the suppressor of 
variegation 39 in human (SUV39H) to the inactive H3K9me3 mark was prevented 
(Dormann et al., 2006). As suggested by others, this might be an efficient way to 
avoid a repressive H3K9 modification on an actively transcribed gene (Dormann et 
al., 2006).  
 
H3K36 methylation 
In yeast, the methylation of H3K36 seems to be necessary for the efficient elongation 
of RNA pol II through coding regions and occurs predominantly towards the 3’ end of 
active genes (Muller et al., 2007). The HKMT Set2, preferentially binding to the Ser-2 
phosphorylated form of the RNA pol II is capable of methylating H3K36. Moreover, 
the recruitment of Set2 to active genes requires components of the aforementioned 
PAF complex, similar to the recruitment of Set1. Interestingly, in mammals 
H3K36me3 has been found at much lower levels around promoters of inducible 
genes (Zhang and Reinberg, 2001).  
 
H3K9 methylation  
The first HKMT identified was (SUV39H1) that methylates H3K9 (Rea et al., 2000). 
The Drosophila homolog, Su(var)3-9, was initially identified as a suppressor of 
variegation (SUV) indicating an involvement in the silencing mechanism of position 
effect variegation (PEV). This phenomenon involves the spreading of 
heterochromatin into adjacent euchromatic genes. The function of H3K9 methylation 
in pericentromeric heterochromatin formation is mainly defined through two factors, 
the SUV39H1 and its binding partner heterochromatin protein 1 (HP1) (Nakayama et 
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al., 2001). A model has been proposed whereby SUV39H1 methylates H3K9, 
thereby creating a binding site for HP1 via its chromodomain (Bannister et al., 2001; 
Lachner et al., 2001). Once HP1 binds, it is able to spread into adjacent 
nucelosomes via its association with SUV39H1, catalysing the H3K9me3 of 
neighbouring histones (Nakayama et al., 2001). Furthermore, via the chromoshadow 
domain, HP1 is able to self-associate thus facilitating the spread of heterochromatin. 
 
 
Figure 5: Heterochromatin establishment after methylation of H3K9me3 and HP1 recruitment. 
Adapted from “Epigenetics”, Allis et al., 2007. 
 
However, the model presented above seems to be valid only if a specific 
heterochromatin based recruitment for SUV39H1 exists. This previously missing link 
was demonstrated in fission yeast through the involvement of short interfering RNAs 
in heterochromatin formation (siRNAs) (Hall et al., 2002). These RNAs are 
transcribed from centromeric repeats bi-directionally and then processed into siRNAs 
by an enzyme called dicer. The siRNAs are subsequently packaged into a so-called 
RNAi effector complex RITS (RNA-induced Initiation of Transcriptional gene 
Silencing), containing the chromodomain containing protein Chp1, which binds 
methylated H3K9. Thus, the initiation stage of heterochromatin formation is mediated 
via the targeting of the RITS complex to chromatin. In S. pombe, the spreading and 
maintenance of heterochromatin over a 20 kb region requires the methylation of 
H3K9 by the Clr4, a SUV39h homolog, and the binding of Swi6 (HP1 homolog) to 
H3K9 methylated chromatin (Martin and Zhang, 2005). 
 
Since ChIP experiments revealed H3K9me3 at promoters of silenced mammalian 
genes, methylation of H3K9 might also be able to repress otherwise euchromatic 
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genes. This reasoning is of great interest for the identification of the molecular 
mechanism leading to severely reduced FXN levels. However, the mechanism 
leading to repression at euchromatic sites appears to be slightly different to that at 
heterochromatic regions. Here, the RB (retinoblastoma) protein recruits the histone 
lysine methyltransferase (HKMT) SUV39H1, which is followed by binding of HP1 to 
target genes. Unlike in heterochromatin, HP1 occupancy appears to be restricted to 
one or a few nucleosomes around the initiation site, even if H3K9 methylation occurs 
elsewhere at the promoter. The special restriction of HP1 on these euchromatic 
promoters and the prevention of spreading suggest a distinct mechanism of action for 
HP1 relative to its heterochromatic role (see “Epigenetics” by Allis et al., 2007). One 
possible explanation may be that HP1 acts as an anchor into heterochromatin-rich 
nuclear compartments (Obuse et al., 2004). Movements of gene loci within the 
interphase nucleus have been observed during the repression of euchromatic genes 
(Henikoff, 2001; Williams et al., 2006), which point toward the possibility that a 
silenced gene is displaced into a heterochromatic region. This movement appears to 
be dependent upon the gamma isoform of HP1 (Martin and Zhang, 2005).  
 
Histone modifying enzymes 
Histone modifications are of a dynamic and reversible nature allowing the epigenetic 
code to organise the DNA code. The dynamics of post-translational histone 
modifications are established via enzymes specific for each modification. Every 
modification has its own set of transferases and removing enzymes. Table 1 displays 
known histone residues and their specific histone methyltransferases (HMT) and 
demethylases present in humans. As an exception, arginine (R) methylation is 
altered by deaminases, converting it to citrulline (see review Bannister and 
Kouzarides, 2005).  
 
 
Histone and 
residue 
Methyltransferase Demethylase/Deiminase Function 
CARM1 - Activator H3R2 
- PADI4 Repressor 
H3K4 SET7/Set9 
MLL 
Smyd3 
- 
- 
- 
Activator 
Activator 
Activator 
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  LSD1/BHC110 Repressor 
  JARID1 family Activator/Repressor 
PRMT5 - Repressor H3R8 
- PADI4 Repressor 
SUV39H1 - Repressor, 
heterochromatin 
SUV39H2 - DNA methylation, 
heterochromatin 
G9a  Imprinting, repressor 
Eu-HMTase1  Repressor 
SETDB1  Repressor, DNA 
methylation 
EZH2  Repressor 
H3K9 
- JMJD2A/3A, JMJD2B, 
JMJD2C/GASC1, 
JMJD2D/2a/2b 
Activator 
CARM1 - Activator H3R17 
- PADI4 Block to transcriptional 
activation 
CARM1 - Activator H3R26 
- PADI4 Block to transcriptional 
activation 
H3K27 EZH2 - Repressor 
NSD1 
SMYD2 
SET2 
  H3K36 
 JHDM1a/b 
JMJD2A/3A 
 
 
JMJC2C/GASC1 
 
Interacts with N-CoR 
and represses 
transcription 
H3K79 DOT1L - Repressor, DNA 
damage 
PRMT1 - Activator H4R3 
- PADI4 Block to transcriptional 
activation 
Pr-SET7 - Repressor H4K20 
SUV4-20H1/H2 
 
PR-Set7/8 
- Suppressor of 
variegation  
Silent chromatin in 
euchromatic arm 
 
Table 1: Human characterised enzymes responsible for the methylation and demethylation of 
histones. Source: Bannister & Kouzarides, doi:10.1038/nature04048. 
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Although a vast number of modifying enzymes are already known, it is most likely 
that more are waiting to be discovered. However, here the focus will be enzymes 
known to modify the histone residues H3K4 and H3K9. Following the earlier theme of 
dynamic epigenetic modifications, the methylation of H3K4 and H3K9 is also 
reversible. The next paragraph will examine the demethylation of lysine residues 
H3K4 and H3K9 in more detail.  
 
Demethylation of Lysines 
The recently discovered LSD1 (gene name: AOF2) (Shi et al., 2004), an enzyme 
removing methyl groups specifically from H3K4me2 and H3K4me1, changed the 
understanding of what was previously viewed as a very stable methyl group. LSD1 is 
present in a number of different repressor complexes. Some of them allow a more 
efficient demethylation of nucleosomal H3 lysines. However, the specificity of LSD1 
can be modified via binding partners such as the androgen receptor (AR). This 
LSD1-AR complex is able to demethylate H3K9me1 and me2 rather than H3K4 and 
in this scenario acts as an activator (Metzger et al., 2005).  
 
Additionally, five relatively new demethylases were identified (see review Takeuchi et 
al., 2006), all possessing a common catalytic structure called the Jumonji (JmjC)-
domain, which is distinct from LSD1. These are found to demethylate distinct methyl 
states of H3K4, H3K9 and H3K36. The JmjC domain has been shown to demethylate 
histones in a Fe2+ and α-ketoglutarate-dependent manner (see review Klose et al., 
2006). One subclass contains a conserved N-terminal motif (JmjN domain). 
Comparison of the substrate preferences of JmjC and JmjN/JmjC-containing proteins 
has revealed that proteins with both a JmjN and JmjC domain prefer di- and 
trimethylated substrates whereas those with only a JmjC motif, demethylate mono- 
and dimethylated ones (Chen et al., 2006).  
 
Mammalian cells encode four JmjN/JmjC proteins and are collectively referred to as 
the JARID1 family: JARID1a (Rbp2), JARID1b (Plu-1), JARID1c (SMCX) and 
JARID1d (SMCY). Unlike LSD1, which catalyses the removal of mono- and 
dimethylated histone H3K4 via an amino oxidase reaction, JARID1 proteins have a 
preference for H3K4me3 (Iwase et al., 2007; Klose and Zhang, 2007; Lee et al., 
2007; Liang et al., 2007; Secombe and Eisenman, 2007). However, JARID1 activity 
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is not restricted to H3K4me3, as all four mammalian proteins are also able to 
efficiently demethylate H3K4me2 in vivo (Christensen et al., 2007; Iwase et al., 2007; 
Klose and Zhang, 2007; Lee et al., 2007), suggesting that JARID1 proteins of higher 
eukaryotes may have broader target specificity.  
 
Because H3K4me3 surrounds the start site of transcriptionally active genes 
(Bernstein et al., 2002; Bernstein et al., 2005; Santos-Rosa et al., 2002; Schneider et 
al., 2004), the demethylase activity on H3K4me3 is thought to act as a transcriptional 
repressor. JARID1 and JARID1b are highly related (76 % identity, 90 % similarity) 
and each has been directly or indirectly linked to cellular transformation. Although 
JARID1b expression is normally largely restricted to the testis, it was originally 
isolated as a gene that was over-expressed in breast carcinomas (Barret et al., 2002; 
Lu et al., 1999).  
 
Other enzymes modifying histone tails are the Ser/Thr phosphatases, which remove 
phosphate groups, ubiquitin proteases and mono-ubiquitin from H2B. Here, the focus 
lies on the methylation and acetylation status of FXN in the context of an abnormal 
GAA repeat expansion and the possibility of modifying the chromatin structure by 
histone deacetylase inhibitors (HDACi). Thus, only the histone sites of acetylation 
and their responsible enzymes will be discussed in the following section.  
 
Histone acetylation 
The steady-state acetylation level of histone proteins is achieved through the action 
of histone acetyltransferases (HATs) and histone deacetylases (HDACs) (see review 
Cheung et al., 2000; Narlikar et al., 2002). These modifications take place on the ε-
amino group of lysine (K) residues using acetyl coenzyme A (Co A). Acetylation 
affects higher order folding of chromatin fibres, loosening the contacts between DNA 
and nucleosomes and/or histone-non-histone protein interactions (Carruthers and 
Hansen, 2000; Fischle et al., 2003; Shogren-Knaak et al., 2006; Tse et al., 1998; 
Wolffe, 2001). It is noteworthy that in vitro hyperacetylation of histone tails only 
seems to weaken histone tail-DNA binding (Mutskov et al., 1998), therefore they are 
unlikely to work as block against transcription factor access.  
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The first histone specific HAT, p55, isolated from Tetrahymena was shown to be the 
homologue of the yeast GCN5 (general control non-derepressible 5) (Brownell and 
Allis, 1996). Since then, many HATs have been identified (Tab. 2). They are divided 
into five families, including the GCN5-related N-acetyltransferases (HNATs); the 
MYST related HATs; p300/CREB-binding protein (CBP); the general transcription 
factor HATs; and the nuclear hormone-related HATs.  
 
Histone tail 
modification 
Enzyme 
acetylates 
Function 
H2A K5, 
H2B K 12, 
H2B K 15 
CBP/p300 CREB-binding protein, DNA binding transcription factor 
H3 K9 PCAF 
GCN5L2 
Co-activator associated with p53 
InterPro domain with PCAF 
H3K14, H3K18 CBP/p300 
PCAF 
GCN5L2 
CREB-binding protein, DNA binding transcription factor 
Co-activator associated with p53 
InterPro domain with PCAF 
H4K5 CBP/p300 
 
MYST2 
 
HAT1 
CREB-binding protein, DNA binding transcription factor 
 
Synonyms: MOZ, YBF2/SAS3, SAS2 and TIP60 
protein, histone acetyltransferase binding to ORC1 
Histone acetyltransferase 1 
H4K8 CBP/p300 CREB-binding protein, DNA binding transcription factor 
H4K12 MYST2 
 
CBP/p300 
Synonyms: MOZ, YBF2/SAS3, SAS2 and TIP60 
protein, histone acetyltransferase binding to ORC1 
 
CREB-binding protein, DNA binding transcription factor 
 
H4K16 MYST3 
TIP60 
Histone acetyltransferase (monocytic leukemia) 3 
Transcriptional activation, catalytic site of the NuA4-
complex 
 
Table 2: Histone sites of acetylation and responsible acetylating enzymes and their functions. 
Adapted from review Yang, 2004. 
 
Although a number of acetylating enzymes and their targets are known, this thesis 
will focus on the HATs acetylating H3K9 and H4K16, which are related to the GCN5 
and MYST-family. Vertebrates additionally have a second gene encoding the 
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p300/CBP-associated factor (PCAF), which is about 73 % identical to GCN5 (Mizzen 
et al., 1996).  
 
Many known nuclear HATs possess bromodomains, which recognise acetylated 
histone tails and thus participate in acetylation-dependent chromatin remodeling 
(Zeng and Zhou, 2002). The bromodomain is an approximately 110-amino-acid 
module with suggested roles in many different chromatin-related and independent 
functions (Nagy and Tora, 2007). Structural studies of both yeast Gcn5 and human 
PCAF bromodomains in complex with histone tail peptides revealed that GCN5 binds 
to histone H4 acetylated at K16 (Hudson et al., 2000; Owen et al., 2000), while PCAF 
seems to recognise H4 acetylated on K8 and also H3 acetylated on K14 (Dhalluin et 
al., 1999).  
 
The MYST (Moz – now MYST3, YBF2, Sas2p, Tip) family is the largest but until 
recently one of the least studied families of histone acetyltransferases. TIP60 was 
originally identified in a screen for proteins interacting with the HIV tat gene product 
(Kamine et al., 1996). TIP60 seems to function as the catalytic subunit of the 
mammalian NuA4 complex (Thomas and Voss, 2007). The evolutionarily conserved 
multi-subunit complex, NuA4, is recruited by many factors to specific promoters, 
where it is thought to participate in histone acetylation and transcriptional activation.  
 
TIP60 also has transcription independent roles in DNA damage responses and 
participates in the activation of kinases such as the ataxia-telangiectasia mutated 
(ATM) and the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) following 
DNA double-strand breaks (DSB) (Squatrito et al., 2006). The first indication that 
TIP60 might have a role in DNA damage response (DDR) and/or DSB came from 
transfection experiments in HeLa cells, where over-expression of a dominant-
negative allele of TIP60 reduced the efficiency of double strand break repair (Ikura 
and Ogryzko, 2003). New experiments imply that TIP60 may be involved in damage 
sensing, signaling and repair through several independent mechanisms (Squatrito et 
al., 2006).  
 
The TIP60-NuA4 complex contains another protein kinase family member, called 
transformation-transactivation domain-associated protein (TRRAP), which is 
enzymatically inactive because of amino acid changes in its kinase domain. This 
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feature of TRRAP is conserved throughout evolution. The recruitment of TRRAP and 
Tip60 to DSBs was demonstrated by ChIP in mouse embryonic stem cells carrying a 
conditional knockout allele of TRRAP. Here the generation of a single DSB induced 
hyperacetylation of histone H4 in the surrounding chromatin. Deletion of TRRAP 
impaired Tip60 recruitment and H4 acetylation, as well as DSB repair by homologous 
recombination (Murr et al., 2006). 
 
Histone Deacetylases (HDACs) 
The enzymes removing acetyl-groups of histone tails are known as histone 
deacetylases (HDACs) and are presented by two distinct protein classes, the SIR2 
family of NAD+-dependent HDACs (class III) and the classical HDAC family. The 
latter consists of two different phylogenetic groups, namely class I and class II whose 
action is zinc dependent (Hernick and Fierke, 2005). The HDACs of class I are most 
closely related to the S. cerevisiae transcriptional regulator RPD3, whereas class II 
HDACs share homology with HDAC1, another yeast deacetylase (see review de 
Ruijter et al., 2003). In order to simplify the overwhelming number of HDACs, their 
functions and main targets are presented in the following table 3.  
 
HDAC class Name Function 
HDAC1 and HDAC2 Complex dependent (found in Sin3, NuRD 
and Co-REST, can act directly on DNA-
binding proteins (YY1, Rb binding protein 1 
and Sp1, phosphorylation required for 
function 
HDAC3 SMRT and N-CoR are necessary for activity, 
is able to form oligomers with other HDACs 
like HDAC4, 5, but mostly it interacts with 
itself, may have role in cell cycle process 
HDACs class I 
HDAC8 Similar to HDAC3, probably very low 
abundance of expression 
HDAC6 Exhibits two catalytical domains in tandem, 
has signal for ubiquitination, probably 
particularly prone to degradation, functions 
as tubulin deacetylase but it is also found in 
the nucleus together with HDAC11 
HDAC10 Exists in two splice variants, interacts with 
HDAC1, 2, 3, 4, 5, 7  
HDACs class II 
HDAC4 
HDAC5 
Exhibit binding domains for CTBP, MEF2; 
show interaction with SMRT/N-CoR, BCoR 
and, the N-termini interact with MEF2 and 
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HDAC7 blocks muscle cell differentiation. Suggested to by a link between DNA-binding recruiters 
and the HDAC3 containing complex 
 
HDAC9a, 9b, HDRP Are splice variants, whereas HDRP lacks the 
catalytic domain, but is able to recruit 
HDAC3. All three interact with MEF2, 
indicating function in muscle differentiation. 
HDAC11 HDAC11 More closely related to class I than to class II, not present in any known HDAC complex 
SIRT1 Deacetylates histones (preference for 
H4K16), PCAF/MyoD, EP300, TAF168, 
HTATSF1, TP53, XRCC6, NKRF and 
forkhead proteins; Regulation of insulin and 
glucose homeostasis; Fat reduction, Neuron 
survival 
SIRT2 Predominantly cytoplasmic, deacetylates α-
tubulin and histones, over expression delays 
mitosis, SIRT2 colocalises with chromatin 
during the G2/M transition, preference for 
H4K16 in vitro,  
SIRT3 Localised to mitochondrial matrix, in vitro 
deacetylates, multiple substrates including 
histones and tubulin, maybe important under 
conditions of energy limitation 
SIRT4 Localised to mitochondria and lacks 
detectable deacetylase activity but shows 
ADP-ribosyltransferase activity 
SIRT5 Localised to mitochondria with weak 
deacetylase activity and no apparent ADP-
ribosyltransferase activity 
SIRT6 Nuclear protein, regulates DNA repair, role in 
aging 
HDACs class III 
SIR2 family1 
SIRT7 Localised to nucleolus and promotes rRNA 
transcription, associated with RNA pol I, so 
far, no deacetylase activity measured, but 
activity NAD+-dependent  
 
Table 3: Histone deacetylase families (HDACs) and their known functions. 
 
Table 3 demonstrates, that each HDAC owns its more or less specific sphere of 
action, making it a good target for inhibition. However, to date it has proven difficult to 
develop specific inhibitors against each individual HDAC rather than an entire class. 
Despite these hurdles, investigations are underway and the subsequent paragraph 
introduces the most common HDAC inhibitors (HDACi). 
 
                                                
1 Marcia C. Haigis and Leonard P. Guarente, Mammalian sirtuins – emerging roles in 
physiology, aging, and calorie restriction. Genes & Dev. 2006 
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Histone deacetylase inhibitors (HDACi) 
HDAC inhibitors (HDACi) selectively alter gene transcription, in part through 
chromatin remodelling and through changes in the structure of proteins in 
transcription factor complexes (Gui et al., 2004). These non-histone protein targets 
are substrates such as hormone receptors, chaperon proteins and cytoskeleton 
proteins, which regulate cell proliferation and cell death. Table 4 gives a brief 
overview of areas and specific proteins influenced by HDACs.  
 
Function Proteins 
DNA binding 
transcriptional factors 
P53, c-Myc, AML1, BCL-6, E2F1, E2F2, E2F3, GATA-1, GATA-2, 
GATA-3, GATA-4, Ying yang 1 (YY1), NF-κB, MEF2, CREB, HIF-1a, 
BETA2, POP-1, IRF-2, IRF-7, SRY, EKLF 
Steroid receptors Androgen receptor, estrogen receptor a, glucocorticoid receptor 
Transcription co-
regulators 
Rb, DEK, MSL-3, HMGI(Y)/HMGA1, CtBP2, PGC-1α 
Signalling mediators STAT3, Smad7, β-catenin, IRS-1 
DNA repair enzymes Ku70, WRN, TDG, NEIL2, FEN1 
Nuclear import Rch1, importin-α7 
Chaperon protein  HSP90 
Structural protein α-tubulin 
Inflammation 
mediator 
HMGB1 
Viral proteins E1A, L-HDAg, S-HDAg, T-antigen, HIV Tat 
 
Table 4: Areas and proteins targeted by histone deacetylases. Table adapted from review 
Bolden et al., 2006. 
 
Despite the additional proteins targeted by HDACs, a large number of structurally 
diverse HDACi have been purified from natural sources or synthetically developed, 
and at least 13 have progressed to clinical development (see review Bolden et al., 
2006). HDACi can be categorised by their chemical structure inhibiting the enzymatic 
activity of HDACs with different efficiency. HDACi treatments are considered valuable 
anti-cancer drugs, as HDACi selectively induce apoptosis in tumour cells. Clinical 
trials and preclinical animal experiments have shown potent anti-cancer activities at 
concentrations that are minimally toxic to the host (see review Bi and Jiang, 2006).  
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Common HDAC inhibitors 2  
Previous studies solving the structural details of HDAC-HDACi interaction have 
provided valuable insights into the mechanism of deacetylation of acetylated 
substrates (Finnin et al., 1999; Somoza et al., 2004; Vannini et al., 2004). The 
hydroxamic acid moiety of inhibitors directly interacts with the zinc ion at the base of 
the catalytic pocket (Xu et al., 2007). Most HDACi in clinical phase I and II are tested 
against several tumour types, such as acute myeloid leukaemia or cervical cancer. 
Nonetheless, the roles of HDACs and the effects of HDACi on an entire organism are 
still in early stages of discovery (WS Xu et al., 2007). The following table 5 gives a 
brief overview of different HDACi classes and their targets.  
 
Class of HDACi Compounds HDAC target 
Hydroxamate SAHA, LBH589, PXD101, ITF-2357, PCI-24781 Class I, II 
Cyclic peptide FK228 HDAC1, 2 
MS-275 HDAC1, 2, 3 
MGCD0103 Class I 
Benzamide 
Sirtinol Class III 
Phenylbutyrate, Valproic acid Class I, II 
AN-9 Not known 
Baceca Class I 
Aliphatic acid 
Savicol Not known 
Heterocyclic compound Nicotinamide, Splitomicin Class III 
 
Table 5: Classes and names of common HDAC inhibitors and their targets. Adapted from review 
Xu et al., 2007.  
 
Several studies using FRDA patient cell lines have suggested that common inhibitors 
targeting HDAC class I and II are generally not sufficient to reverse the down-
regulation of FXN. Therefore, this thesis will focus on the possibility of treating FRDA 
patient cells with HDAC class III inhibitors such as Sirtinol, Splitomicin and 
Nicotinamide.  
 
                                                
2 WS Xu et al., 2007. Histone deacetylase inhibitors: molecular mechanisms of action. 
Oncogene 26, 5541-552. 
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HDAC class III inhibitors and targets 
One of the main targets of HDAC class III inhibitors is the SIR2 family, which 
deacetylates other proteins as well as histones (see review Blander and Guarente, 
2004). The various targets and SIRT family members in mammals have already been 
described in table 3. This paragraph gives a more detailed view on the action of the 
SIR2-family. The yeast SIR protein complex has been implicated in transcriptional 
silencing and suppression of recombination. More specifically, it represses 
transcription at the telomeres, at the mating-type loci and at the ribosomal DNA. 
Unlike Sir3 and Sir4, the Sir2 gene is highly conserved in organisms ranging from 
archaea to humans. As mentioned previously, Sir2 acts NAD+ -dependently, a feature 
conserved from bacteria to higher eukaryotes. For each acetyl-lysine that is 
deacetylated by Sir2, one NAD+ molecule is cleaved (Hoff et al., 2006; North and 
Verdin, 2004). 
 
For silencing of the yeast rDNA locus only SIR2 is required (Tanny et al., 1999). In 
mammals the deacetylation via Sir2 is involved in gene silencing, metabolic 
regulation and aging (Wood et al., 2004). In humans the majority of the SIR2 family 
members contain a motif of Cys-XX-Cys-(X)15-20-Cys-XX-Cys in the conserved 
domain, binding to a Zn+- ion (Sereno et al., 2006). However, in most cases the 
substrate specificity of the Sir2 enzyme remains elusive. In yeast, histone H4 at the 
rDNA sites is hypoacetylated in a Sir2-dependent manner (Zhao et al., 2004). 
Furthermore, a genome-wide array showed that a deletion of SIR2 leads to 
hyperacetylation of subtelomeric regions, the mating-type loci (HML and HMR), and 
the rDNA loci. The deletion of Sir2 caused an increase in H3 and H4 acetylation 
within the rDNA region. The largest increase in acetylation occurred on H3 (Kimura et 
al., 2002, Shia et al., 2006, Suka et al., 2004). In Drosophila, dSir2 is capable of 
deacetylating histone H4. In additional in vivo experiments, dSir2 was shown to be a 
requirement for heterochromatic silencing and a modest effect on position effect 
variegation was observed (Rosenberg and Parkhurst, 2002).  
 
As described earlier the “histone code” interacts in some instances with DNA 
methylation i.e. particular histone modifications are physically associated with 
methylated DNA (Bird, 2001). The following section will give a brief introduction to the 
establishment of DNA methylation and its binding proteins.  
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DNA methylation 
DNA can be covalently modified by methylation of the cytosine base in the 
dinucleotide sequence 5’CpG3’ (Holliday and Pugh, 1975; Riggs, 1975). CpG is an 
abbreviation for cytosine and guanine separated by a phosphate. In mammals, DNA 
methylation patterns are established during embryonic development and later on 
maintained (Shen et al., 2002), however this does not have to be permanent. 
Changes in DNA methylation patterns can occur throughout life as part of a 
physiological response or secondary to environmental changes (Benett and Hasty, 
2007). DNA methylation patterns are established via DNA methyltransferases 
(Dnmts). Four mammalian Dnmts are known, the so-called maintenance Dnmt1 and 
de novo Dnmt2, Dnmt3a and Dnmt3b (Bestor and Ingram, 1983; Li et al., 1992). 
Evidence exists that DNA methylation is beneficial for chromosomal stability, 
preventing in certain circumstances chromosome fusion, breakage and aneuploidy 
(Dodge et al., 2005; Ehrlich, 2003).  
 
DNA from mammalian somatic tissues is methylated in 70 % of all CpG sites (Ehrlich 
et al., 1982). Mapping studies indicate that highly methylated sequences include 
satellite DNAs, repetitive elements including transposons, non-repetitive intergenic 
DNA and exons of genes. A key exception to this CpG methylation of the mammalian 
genome, are the CpG- islands. CpG- islands were detected as a fraction of 
vertebrate DNA that was cleaved unusually frequently by methylation-sensitive 
restriction enzymes (Cooper, 1983; Cooper et al., 1983). These GC-rich sequences 
are about 1 kb in length and usually nonmethylated (Bird et al., 1985). Most, if not all, 
CpG- islands mark promoters and 5’ domains of genes. Approximately 60 % of 
human genes have CpG- island promoters (Shen et al., 2007).  
 
The effect of DNA methylation in gene expression has been tested in several ways. 
One early example was the silencing of adenine phosphoribosyltransferase via CpG 
methylation, when transfected into cultured mammalian cells (Stein et al., 1982). The 
discovery of an inhibitor of DNA methylation called 5-azacytidine allowed further 
studies on the effects of CpG- methylation (Jones and Taylor, 1980). This nucleoside 
analogue is incorporated into DNA in place of cytidine and forms covalent adducts 
with DNA methyltransferases, thereby preventing further DNA methylation (Jones 
and Taylor, 1980). 
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The interference of DNA methylation with gene expression is most likely the result of 
established interference with potential CpG binding proteins. One prominent factor 
that binds exclusively to unmethylated CpG- islands is the CCCTC-binding factor 
(CTCF). CTCF is associated with transcriptional domain boundaries (Bell et al., 
1999) and can insulate a promoter from the influence of remote enhancers 
(Felsenfeld et al., 2004; Jones et al., 2001). Another mechanism for repressing 
transcription via DNA methylation is the specific binding of proteins to methylated 
DNA. So far, the proteins of the methyl-CpG-binding domain (MBD) family (MBD1 to 
MBD4), the methyl-CpG-binding protein 2 (MeCP2) and the unrelated protein KAISO 
(Bird and Wolffe, 1999; Nan et al., 1997) have been identified. All of them seem to 
share the property of acting in a transcriptional repressive manner.  
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Hypothesis  
The observations made so far suggest that in the first intron of FXN the formation of 
a triplex DNA structure is provoked by an expansion of GAA repeats in FRDA 
patients. This structure may activate an as yet unknown silencing mechanism 
resulting in variegation of expression. Therefore, a proportion of cells would express 
FXN and another proportion of cells would have a silenced frataxin gene. If 
variegation occured, it may be possible to elicit increase in expression level of the 
repressed FXN by inhibiting factors of PEV binding to GAA-triplexes.  
 
Aim 
In order to determine whether variegation of FXN expression occurs, EBV-
transformed lymphocytes and primary lymphocytes from FRDA patients will be 
investigated at the single cell level. Furthermore, the chromatin structure of control 
versus FRDA individuals will be investigated via chromatin immunoprecipitation 
(ChIP). Also the binding of potential chromatin influencing proteins to the FRDA locus 
will be tested. Lastly, the effect of HDAC inhibitors on the pathogenic FXN locus will 
be investigated. 
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Results I 
The following chapter will examine the FXN locus of unaffected and FRDA patients. 
The samples used are Epstein-Barr Virus (EBV) transformed cell lines and primary 
lymphocytes. All EBV-cell lines were chosen from unrelated patients and tested for 
correct karyotypes prior to investigations. Here the focus will lie on the transcription 
of FXN and its chromatin structure beginning from the 5’ UTR up to the end of 
intron 1. The following figure 6 details the location of the primers used for the primary 
transcript RNA-FISH and ChIP experiments.  
 
 
 
Figure 6: A) Location of primer pairs for ChIP experiment marked in orange and location of FISH 
probe 5’ of the GAA expansion marked in blue. Bars marked in green are poly A sequences 
adjacent to the GAA repeat. Note that primer P1 lies 6000 bp 5’ of the UTR and is not given in 
proportion. B) Displays a magnification of the area close to the first CpG- island predicted using 
the program at (http://cpgislands.usc.edu/) and the area adjacent to the GAA repeat.  
 
Human cell lines and patient samples  
Because the critical tissues affected in FRDA patients are very difficult to obtain, 
such as heart, dorsal root ganglia and cerebellum, the experiments were performed 
on lymphocytes, from patients and controls. FRDA lymphocytes show a reduced 
level of FXN; and therefore, provide a valid model for investigating the underlying 
molecular mechanism of FXN silencing in Friedreich’s ataxia (Pianese et al., 2004). 
Since FRDA patients are relatively rare, most initial patient experiments were 
performed with two patient EBV-cell lines (GM15850, GM16234). For the negative 
control, a “normal” cell line GM14926 (GM14) was used throughout. Both patient cell 
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lines have the same GAA triplet repeat length but were derived from patients with 
different ages of FRDA disease onset. The GM15850 (GM15) patient had a normal 
childhood onset (~ 10 years) of FRDA, whereas the patient GM16234 (GM16) had a 
late onset where FRDA started at the age of ~ 20 years. Notably, the patient GM15 
was 13 years old and the patient GM16 was 39 years old when the blood was taken 
to derive the EBV-cell line, therefore both cell lines display potentially different FRDA 
progression states. In order to partially control the experiments for age-related 
changes at the FXN locus, the healthy cell line GM14 was chosen from a control 
whose blood was taken at the age of 38. Primary lymphocytes were obtained from a 
homozygous individual being the son of the heterozygous father. 
 
Genotyping of EBV-cell lines and primary cells 
In order to distinguish between heterozygous and homozygous samples and to 
estimate the GAA expansion state of patients, a PCR with primers flanking the GAA 
expansion site was designed (see Materials and Methods p. 135). As this PCR was 
difficult to optimise and required a specific enzyme-mix it was important to verify that 
the multiple bands obtained (Fig. 7) were GAA containing products. Thus, half of the 
PCR product was digested with the enzyme Mbo II that specifically digests the GAA 
site (5’-GAAGA(N)8^-3’). In healthy and heterozygous patients the band appearing at 
around ~ 380 bp is present, whereas it is missing in FRDA patients that exhibit a 
homozygous GAA expansion. Therefore, this PCR provides a good tool to distinguish 
between heterozygous and homozygous samples. Since the PCR does have limits in 
amplifying very long GAA repeats this technique has limitations in terms of 
measuring exact GAA expansion lengths and in discriminating between longer and 
shorter alleles.  
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Figure 7: PCR amplified DNA fragments to confirm GAA repeat expansion in intron 1 of FXN 
gene. Results are shown from the control cell line, GM14 (6-34 GAA repeats), a heterozygous 
(FRDA_Het) and a homozygous (FRDA_Hom) individual. Lines marked with a star (*) exhibit the 
PCR product digested with Mbo II to test specificity of the GAA amplification. Mbo II cuts inside 
(GAA)n, digested fragments of the band containing the normal GAA repeat are too small to be 
detectable. 
 
The first lane in each group exhibits the obtained PCR products, showing multiple 
bands of amplified GAA repeats. The second lane shows the PCR product digested 
with Mbo II, therefore PCR products containing GAA repeats have disappeared in 
this lane. The normal wild-type (wt) allele exhibits a short stretch of GAA repeats 
flanked by a stretch of unique sequences (380 bp), which is not detectable after the 
Mbo II digest.  
 
FXN mRNA levels of cell lines 
In order to verify FXN mRNA levels from all the EBV-cell lines, quantitative real-time 
reverse transcriptase Q- (RT) PCR measurements were performed. The RNA of a 
1 ml cell culture was extracted using Trizol and the cDNA was obtained using the 
Invitrogen-kit as described in the Materials and Methods section (p. 130). For the 
real-time PCR experiment the Sybr-green Kit from Sigma was used. Each reaction 
was done in triplicate and three serial dilutions were measured per cDNA sample. In 
order to account for possible differences in reverse transcription efficiency or RNA 
amounts, the ct-values obtained for FXN were normalised to beta-actin. The mean 
value of each triplet was used for further calculations using the delta/delta-method 
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(p. 141). After normalisation to beta-actin mRNA levels, GM15 and GM16 were 
normalised to GM14 FXN mRNA levels, in order to detect the relative differences 
between the patient and the healthy cell lines. 
 
 
Figure 8: Q-real-time RT-PCR measurement of FXN mRNA from EBV-cell lines derived from a 
normal (GM14) and FRDA patients (GM15 and GM16). FXN was first normalised to beta-actin, and 
then using the delta/delta-method normalised to GM14 in order to verify the fold difference of 
frataxin expression. Each result shows the mean of 3 independent experiments. The error bars 
represent the standard deviation.  
 
As shown in figure 8, while both patient FRDA EBV-cell lines exhibit a similar repeat 
length, they differ considerably in FXN expression. This is likely to be an effect of the 
different FRDA duration times, as the GM15 cell line, with a shorter progression of 
~ 5 years, shows a significantly higher level of FXN (~ 33 %) than the GM16 EBV-cell 
line, from a patient who has been displaying signs of FRDA for 19 years (~ 11 %) 
(Materials and Methods p. 133). Indeed, it is somewhat unexpected that the FXN 
level of the GM15 cell line is still relatively high, as the supposed pathogenic 
expression level lies below 30 %. This could be a phenomenon of the EBV-
transformation or a consequence of B-cell specific expression. B-cells are not known 
to be affected by FRDA (Jiralerspong et al., 1997; Puccio et al., 2001).  
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ChIP on three EBV-cell lines 
For the purpose of assessing whether histone modifications and other factors might 
play a role in regulating FXN mRNA levels in FRDA, chromatin immunoprecipitation 
(ChIP) was used to investigate the EBV-cells described earlier. These were derived 
from 2 FRDA patients with different durations of FRDA but similar GAA repeat length 
and a healthy individual. As an internal control for the healthy cell line (GM14), ChIP 
was performed on primary cells from a healthy individual and on EBV-transformed 
cells from another healthy individual, in order to verify results from GM14. Chromatin 
was prepared as described in materials and methods (p. 139) and sonicated twice for 
a total of 1 h in intervals to reduce the chromatin size to a range between 150 and 
400 bp (Fig. 9).  
 
 
 
Figure 9: Picture of an agarose gel showing extracted and sheared chromatin from EBV-cell 
lines. 10 µl of 1 ml chromatin were loaded onto the gel after 1 hour of sonication. The resulting 
chromatin is between 150 and 400 bp in length. 
 
To preserve its structure and modifications the chromatin was immediately snap-
frozen and stored at -80°C. For the immunoprecipitation, 150 µl of chromatin were 
incubated with the antibody of choice at 4°C for 30 minutes in a sonicater water bath. 
In order to determine if the GAA expansion has a direct influence on chromatin 
500bp 
GM14 GM15 GM16 
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modification the FXN gene from the promoter region up to exon 2 was investigated in 
detail (Fig. 6).  
 
In figure 10 the results of ChIP for all three EBV-cell lines are displayed following 
incubation with antibodies against RNA pol II, H3K4me2, H4K16ac and H3K9me3. 
RNA pol II was chosen in order to determine possible inhibitory effects of the GAA 
expansion to transcriptional elongation (Ohshima et al., 1998; Sakamoto et al., 
2001b; Vetcher et al., 2002). The marker for open and recently transcribed chromatin 
H3K4me2 (Bernstein et al., 2002) was used in order to validate possible chromatin 
changes of active marks caused by abnormal GAA repeat expansions. Since the 
hypothesis states that by using an HDACi such as Nicotinamide the chromatin 
structure might be opened up, the target of Nicotinamide, H4K16ac, was also 
investigated. Lastly, in order to identify possible changes from euchromatin to 
heterochromatin in the presence of GAA repeat expansions H3K9me3, a marker for 
heterochromatin was tested. 
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Figure 10: ChIP results from three EBV-cell lines against the antibodies H3K9me3, H3K4me2, 
H4K16ac and RNA pol II. A mini-map of the first part of the FXN locus is shown below. Note P1 is 
located 6000 bp upstream of FXN UTR. Each IP was performed at least twice and Q-real-time 
PCR measured three times in duplicate. Levels given are relative to H3 recovery. Presented is 
the mean of these experiments, the variation between experiments is usually +/- 5 % for each 
primer pair. GM15 and GM16 are normalised to levels obtained for GAPDH of GM14. The cell 
lines GM14 and GM15 display a RNA pol II pausing site inside exon 1. GM15 displays elevated 
levels of H4K16ac when compared to GM14 and GM16. GM16 alone displays elevated levels of 
H3K9me3. The exact primer locations are stated in Fig. 6 (p. 48). 
 
I will first describe the results obtained from the GM14 cell line derived from a normal 
individual and then will go on to discuss the changes observed in the FRDA patient-
derived cell lines GM15 and GM16. Each value is stated as the percentage of 
recovery when normalised to H3 (100%). As expected, in GM14, high levels were 
found for the “active” mark H3K4me2 as well as moderate levels for H4K16ac, and 
GM14 healthy GM15 early stage 
GM16 late stage 
H3K9me3 
H3K4me2 
H4K16ac 
RNA Pol II 
UTR Exon 1 CpG 2 
CpG 1 
 
(GAA)9-30 UTR Exon 1 
CpG 2 
CpG 1 
 
(GAA)exp. 
UTR Exon 1 CpG 2 
CpG 1 
 
(GAA)exp
. 
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except for a small peak at the beginning of intron 1, moderate levels of H3K9me3. 
Nevertheless, 6000 bp upstream of the FXN gene (*P1), high levels of H3K9me3 
were detected. In keeping with the known low level of transcription for this gene, 
RNA pol II showed rather low levels (~ 18 %) across the FXN gene, comparable with 
RNA pol II levels detected at the inactive beta-globin gene (~13 %), and in contrast to 
the active GAPDH gene, where levels of ~ 60 % were found (data not shown). 
Unexpectedly, high levels of RNA pol II (~ 80%) were detected inside exon 1 
(P1_CpG) (Fig. 10). This region is part of a mostly unmethylated CpG- island 
covering 918 bp (Fig. 6).  
 
A similar phenomenon of, so-called “RNA pol II pausing”, close to promoter regions 
inside exon or intron 1 of several genes has been described in the regulation of 
transcription (Coppola et al., 1983; Fivaz et al., 2000; Krumm et al., 1995; Li et al., 
1999; Muse et al., 2007). Such “RNA pol II pausing” is thought to play a crucial role in 
the correct regulation of the c-myc, c-fos, hsp70 and p21 genes. Given that the 
mechanism of regulation of FXN transcription is little understood, this new finding 
may point towards an important level at which this gene is regulated. The region 
around exon 1 displaying high RNA pol II levels shows, in contrast, reduced levels of 
the histone marks H3K4me2 and H4K16ac (Fig. 10), whereas H3K9me3 peaks 
slightly at the end of the CpG-island. Since all modifications were normalised to the 
unmodified histone H3 ChIP results (Fig. 11), the possibility that the missing/reduced 
histone modifications are based on the absence of nucleosomes at this site can be 
excluded. 
 
Figure 11: IP with anti-H3 antibody against chromatin of GM14 EBV-cells. Histone H3 levels are 
normalised to 10% of the Input and shown for each primer pair used. Each IP has been Q-real-
time PCR measured three times and in duplicate. Error bars indicate standard deviation. 
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Although variations of H3 levels occur across the investigated area, no major differences are 
seen. 
 
Unexpectedly, the early onset GM15 FRDA cell line exhibits significantly elevated 
levels of the so called “active marks” H3K4me2 and H4K16ac, and shows even less 
H3K9me3 compared to the normal GM14 cell line (Fig. 10). The dramatic increase of 
H3K4me2 in the presence of an abnormal GAA repeat expansion might be explicable 
by the former observation that a DNA GAA-triplex structure slows down the 
elongation process of the RNA pol II (Mariappan et al., 1999; Sakamoto et al., 1996). 
This might increase the probability of methylation of histone H3K4, as the HMTase 
Set1, that methylates H3K4 is bound to the early elongating RNA pol II (Krogan et al., 
2003). However, this simple explanation cannot account for the increased H3K4 
levels seen 5’ of the GAA repeat expansion. Strikingly, the levels of H3K4me2 and 
H4K16ac were decreased inside the CpG- island however the pronounced peak of 
RNA pol II was similar (~ 80 %) to the one in GM14.  
 
Analysis of the late stage FRDA GM16 cells revealed a very low FXN mRNA 
expression and a markedly different chromatin set-up (Fig. 10). Here, H3K4me2 was 
increased 5’ of the GAA expansion, peaking inside the mostly un-methylated CpG-
island (Fig. 32 Results II) and showing a reduced level 3’ of the GAA expansion. 
Moreover, the inactive mark H3K9me3 showed generally higher levels 5’ and 3’ of 
the GAA expansion, compared to GM14, possibly indicating heterochromatinisation 
(Lachner et al., 2001). A similar reduction of active marks in inactive genes was 
found in genes such as beta-globin (Kanduri et al., 2006). In addition, the histone 
modification for open chromatin, H4K16ac, showed slightly lower levels than the 
normal cell line. Although, RNA pol II still peaked inside exon 1 it was to a lesser 
extent than the other two cell lines (~ 40 %).  
 
ChIP against DNA binding proteins 
The ChIP method was further employed to investigate potential transcriptional 
regulating factors of the FXN gene. The following results will focus only on proteins 
tested and found to bind along the area of interest. The negative elongation factor E 
(NELF-E) was tested as a potential candidate to maintain the observed putative 
RNA pol II pausing site. In in vitro systems, the 5,6-dichloro-1β-
ribofuranosylbenzimidazol (DRB) sensitivity-inducing factor (DSIF) and NELF can 
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arrest elongation of transcripts by RNA pol II soon after transcriptional initiation. 
NELF consists of 4 subunits all of which are required for NELF to function as a 
negative elongation factor (Ping and Rana, 2001; Wu et al., 2003; Yamaguchi et al., 
1999; Zhang et al., 2007). Another important factor is PTEF-b, a cyclin-dependent 
kinase, allowing transition into productive elongation (Price, 2000). When the CTD of 
RNA pol II is phosphorylated by PTEF-b, negative regulation by DSIF-NELF is 
overcome and elongation resumes (Ping and Rana, 2001; Wu et al., 2003; 
Yamaguchi et al., 1999; Zhang et al., 2007). This mechanism, established for in vitro 
transcription, is reminiscent of transcriptional regulation involving a block to 
elongation in eukaryotic cells (Fujita et al., 2007). Additionally an interaction between 
NELF-E and nascent RNA has been suggested (Johansson et al., 2007), however 
the actual mechanism still needs to be addressed. 
 
MeCP2 was tested as a possible silencing factor (Drewell et al., 2002; Fuks et al., 
2003; Kimura and Shiota, 2003; Nan et al., 1998), as the online CpG-island finder 
(http://cpgislands.usc.edu/) predicted two CpG- islands at the FXN gene, one of them 
covering the area of the putative pausing site. All three isoforms of HP1 (CBX1, 3, 5) 
were tested in order to investigate potential heterochromatinisation mediated by the 
GAA repeat expansion (Fig. 12).  
 
A striking co-localisation of HP1-γ (CBX3) with the previously observed peak of 
RNA pol II  inside exon 1 was detected in all three lines (Fig. 12). HP1γ was not 
detected elsewhere in the locus. HP1-β, HP1-α did not exhibit any significant binding 
to the FXN locus although there is a paucity of data in the literature showing effective 
ChIP with the available antibodies for these isoforms (Fuks t al., 2003).  
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Figure 12: ChIP results on all EBV-cell lines with antibodies against MeCP2, HP1γ, NELF-E and 
RNA pol II. Again a mini-map of the first part of the FXN locus is given below. Note P1 is located 
6000 bp upstream of FXN UTR. Each IP was performed at least twice and Q-real-time PCR 
measured three times in duplicate. Levels given are relative to the recovery of H3. Each value of 
GM15 and GM16 is subsequently normalised to GM14 via GAPDH. Presented is the mean of 
these experiments, the variation between experiments is usually +/- 5 % for each primer pair. 
Only GM14 displays a peak of MeCP2 over the putative pausing site. HP1γ is found in all three 
cell lines at similar levels over the putative RNA pol II pausing site. NELF-E shows increased 
binding over the pausing site in GM15 compared to the control GM14 cell line. GM16 lacks a 
peak of NELF-E over the pausing site and shows binding further along FXN.  
 
It is thought that gene repression in mammals can be provoked via DNA methylation 
which is then stably maintained by the action of methyl-CpG binding proteins such as 
MeCP2 (Kimura and Shiota, 2003; Fuks et al., 2003). In order to assess whether 
MeCP2 might have an effect in reducing the FXN mRNA level in the case of an 
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abnormal GAA expansion, ChIP was performed (Fig. 12). As displayed, the normal 
cell line, GM14, showed MeCP2 binding inside exon 1. This was also where the 
highest level of CpG- methylation was found, as will be presented in the following 
chapter (Fig. 32). In contrast, and somewhat counter-intuitively, the patient cell lines 
expressing subnormal levels of FXN showed the least DNA methylation. In 
accordance with this, these low-expressing cell lines also showed the lowest MeCP2 
binding. Following the idea of a possible silencing mechanism through 
DNA methylation, provoked by the GAA expansion, one would have expected more 
CpG- methylation and MeCP2 in patient cell lines. As this was not the case, one 
might argue that MeCP2 binding and DNA methylation at this site may not play an 
important role in the down-regulation of the FXN gene in FRDA patient cell lines.  
 
The negative elongation factor NELF-E is known to promote RNA pol II arrest 
together with DSIF (Aida et al., 2006; Wu et al., 2003; Yamaguchi et al., 1999). Even 
though the exact regulatory mechanisms of DSIF and NELF in promoting the 
RNA pol II arrest are not well understood, it has been proposed that DSIF and NELF 
act in concert to induce polymerase arrest via their direct interaction with the nascent 
transcript (Aida et al., 2006; Wu et al., 2003; Yamaguchi et al., 1999). Intriguingly, the 
ChIP experiments of the patient GM15 cell line possess a slightly higher degree of 
NELF-E binding (~ 17 %) at the RNA pol II-pausing area (Fig. 12) than the normal 
cell line (~14 %). Since neither for the sample lacking the NELF-E antibody (data not 
shown) nor for the GM16 cell line binding for NELF-E was detectable the here 
obtained results and minor changes between cell lines are most likely highly 
significant. Consistent with hypotheses for other genes, NELF-E might also play an 
important role in the RNA pol II pausing and regulation of the FXN locus. In the 
patient GM16 cell line, NELF-E is detected at a higher level close to the expanded 
GAA repeats but hardly inside the CpG- island, NELF-Es proposed site of action 
(Fig. 12). This cell line also exhibits an abnormal chromatin pattern, a lower 
RNA pol II peak and a very low FXN expression. Interestingly, an inverse correlation 
between NELF-E binding and the RNA pol II peak and histone mark H3K4me2 was 
found (Fig. 10 and 12). 
 
FXN real-time measurement of UTR versus Exon 4 
The unexpected presence of an RNA pol II pausing site at the FXN locus made it 
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necessary to assess the possibility of prolonged pausing provoked by the GAA 
expansion. In such a case, one might expect different levels of the 5’ UTR transcript 
for each of the cell lines, as the release of the RNA pol II from the pausing site may 
also influence subsequent processing of the primary transcript RNA containing the 
UTR (Krogan et al., 2003). Moreover, in patient cell lines, an increase in the relative 
proportion of the 5’ UTR compared to the exon 4 transcripts would be expected 
because of the known inhibitory effect of the GAA expansion (Bidichandani et al., 
1998; Grabczyk and Usdin, 2000; Krasilnikova et al., 2007). To test this hypothesis, 
real time measurements of RNA levels of the 5’ UTR versus exon 4 in EBV-cell lines 
were performed. For detection of primary transcripts of exon 4 rather than total 
mRNA, the primer for exon 4 lies inside intron 3 (see Material and Methods).  
 
 
 
Figure 13: Analysis of FXN primary 5’ UTR transcripts by RT-PCR. All FXN ct-values were 
normalised to beta-actin. The data of GM15 and GM16 are expressed relative to the normal 
GM14 cell line. Each RT- measurement was performed twice and in triplicate. The error bars 
display the standard deviation of two independent experiments.  
 
On normalising the FXN 5’ UTR levels to the control GM14 cell line, the “early stage” 
GM15 cell line displayed ~ 2.2 times more 5’ UTR-RNA than the healthy cell line 
(Fig. 13). It is tempting to speculate that the increase in 5’ UTR is related to the 
increased binding of the negative elongation factor NELF-E, which may delay the 
release of the RNA pol II pausing and thereby increase the stability of the transcript. 
However, further studies are needed to explore this. Nevertheless, the GM16 cell 
line, which hardly expresses any FXN, displayed only 60 % of the measured GM14 
UTR transcript, in accordance with the disturbed RNA pol II pausing found earlier 
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(Fig. 10). One possible explanation is less efficient transcriptional initiation of GM16 
compared to the other lines, thereby limiting the amount of RNA pol II available to 
accumulate at the pausing site.  
 
The measured RNA levels of exon4 were normalised to the UTR of the respective 
cell line. Figure 14 shows that, in the case of the healthy cell line the level of primary 
RNA transcript of exon 4 is similar to that of the 5’ UTR. As both primer pairs exhibit 
different efficiencies, this is not an absolute measurement of the real distribution but 
acts as a comparator for the transcriptional situation in the FRDA patient. 
 
 
Figure 14: Primary transcript levels of Exon 4 relative to 5’ UTR of three EBV-cell lines. Each 
FXN value has been normalised to beta-actin. Each RT-PCR measurement was done twice and in 
triplicate. The error bars indicate the standard deviation of two experiments. 
 
The exon 4 primary transcript RNA level of the FRDA EBV-cell lines was significantly 
reduced relative to the 5’ UTR level in the presence of a GAA expansion (Fig. 13). 
Note that each value of exon 4 is normalised to its respective 5’ UTR value. 
Considering the 2.2 fold increase of the GM15 5’ UTR, the exon 4 levels is actually 
~ 32 % of GM14 and for the GM16 cell line, the level is ~ 11.4 % of GM14. This 
roughly matches the previously measured total mRNA levels (Fig. 8). Without 
                                                                                                                                         
 
62 
consideration of the starting 5’ UTR levels, the amount of exon 4 RNA seems to be 
similar in both patient lines, providing evidence for similar elongation efficiency in 
both patient cell lines, which indeed exhibit the same repeat length.  
 
Summarising the above, this experiment provides evidence for a two-step 
mechanism whereby the GAA expansion contributes to the dramatic reduction of 
FXN transcription. First, one may propose that the RNA pol II pausing release is 
delayed as the level of 5’ UTR product for the GM15 FRDA cell line was double that 
of the normal cell line. A similar finding was found by Gu and colleagues where 
RNA pol II pausing protected the primary transcript from nuclease activity 5’ of the 
pausing site (Gu et al., 1996). Secondly, the elongation through the GAA expansion 
is hampered. In the context of a disrupted RNA pol II pausing site, as seen for GM16, 
it seems that initiation of FXN is disordered and less 5’ UTR is initially present. The 
experiment suggests that the combination of a GAA dependent hampered release of 
the RNA pol II from its pausing site and the additionally hampered elongation through 
the GAA repeat might lead to a substantial and pathogenic decrease in FXN levels.  
 
FXN mRNA levels in primary lymphocytes 
In order to verify the experiments conducted on EBV-cell lines, the initial experiments 
were repeated on primary lymphocytes obtained from FRDA patients. To control for 
differing genetic backgrounds, FXN mRNA levels from homozygous as well as from 
heterozygous relative patients were measured by real-time RT-PCR and compared to 
levels of unaffected individuals. To ensure the validity of the normalisation process, 
each sample type was initially normalised to beta-actin, 18S rRNA and GAPDH.  
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Figure 15: Real-time RT-PCR measurement of primary cells obtained from a normal, a 
heterozygous and a homozygous individual. All three samples were normalised to beta-actin, 
18S and GAPDH. RNA was extracted using Trizol. Using the SuperScript-Kit (Invitrogen) 
according to supplier’s instructions, cDNA was produced. The heterozygous patient exhibits 
~ 51 % and the homozygous patient ~ 26 % FXN mRNA levels of the normal individual. 
 
In figure 15 each column displays the three different genotype samples normalised to 
beta-actin, 18S and GAPDH, followed by a further normalisation of the heterozygous 
sample to the unaffected one. The mean of the heterozygous sample is ~ 51 % of 
FXN mRNA level whereas the homozygous sample has ~ 26 % of the normal 
individual. To explain the discrepancy occurring in the homozygous sample when 
normalised to 18S, ct-values of 18S were further normalised to beta-actin. This 
revealed a significantly lower level of 18S in the homozygous patient sample. It was 
therefore decided to normalise all further RNA level measurements to beta-actin. 
 
Primary transcript RNA-FISH on primary cells 
In order to determine whether a mechanism similar to position effect variegation 
(PEV) occurs in FRDA patients, rather than a down-regulation of FXN in all cells, 
primary transcript RNA-fluorescence in situ hybridisation (FISH) was performed on 
primary lymphocytes. Intronic probes (Fig. 6) were used to estimate the proportion of 
FXN to beta FXN to 18S FXN to GAPDH 18S to beta
Control_wt 1 1 1 1
Father_het 0.546 0.529 0.463 1.032
Son_hom 0.206 0.319 0.250 0.665
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cells currently transcribing FXN rather than measuring the steady state level of 
mRNA. This is because the detected intronic sequences should reflect an actual 
elongation event as these are rapidly spliced from the primary transcript and 
degraded (Gribnau et al., 1998). Two different probes were used against FXN, to 
detect transcriptional changes occurring 5’ and 3’ of the GAA expansion. The exact 
location of the FISH probes is displayed in figure 6.  
 
 
Figure 16: Primary transcript RNA-FISH on primary lymphocytes from FRDA patients. Displayed 
are images of primary lymphocytes hybridised with a probe recognising FXN primary transcript 
RNA 5’ of the GAA probe (red) and the control gene CD19 (green). Usually, FXN and CD19 
signals do not appear in the same plane. The signal intensity does not differ between controls 
and FRDA patients, provided a signal for FXN is seen. Arrows indicate signal.  
 
Lymphocytes from a control group, a heterozygous and a homozygous individual for 
expanded GAA repeats were probed 5’ of the repeats and FXN signals were counted 
(Fig. 16). Three slides per probe for each affected individual were prepared and 60 
cells were counted on each slide. The control group consisted of three healthy 
individuals and for each, 2 slides were examined. The results (Fig. 17) display the 
average of two slides counted as percentage. The error bars shown for the control 
group indicate the standard deviation between healthy individuals. In order to 
minimise the potential effect of genetic background differences, the chosen 
heterozygous individual is the father of an affected homozygous son. To avoid false 
positive results through DNA hybridisation a negative control was conducted. 
Therefore, control slides were treated with RNase prior to hybridisation and no 
signals for FXN were detectable. As internal control for the RNA hybridisation, a 
probe for the B-cell marker CD19 was designed. The control probe consists of parts 
5µm 
2.5µm 
2.5µm 2.5µm 
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of CD19 intron 4 - 5 and intron 7 – 8 (see Material and Methods) that is expressed bi-
allelically and therefore is a suitable internal control (Fig. 16). 
 
 
Figure 17: Primary transcript RNA-FISH on primary cells obtained from a normal (red), a 
heterozygous (orange) and a homozygous (yellow) FRDA patient. The left diagram shows the 
results obtained using the probe 5’ of the GAA repeat. The right diagram shows the results 
obtained with the probe recognising intron 3 and 4. Each bar represents the result of three 
independent experiments where three slides (60 cells / slide) per individual were counted. The 
error bar represents the standard deviation of the results of three independent experiments.  
 
 
The control cells hybridised with the probe 5’ of the GAA repeat expansion showed 
that FXN is mainly bi-allelically expressed, as 77 % of cells showed two FXN signals. 
Cells from the heterozygous individual with a repeat length of (GAA~1000/GAA~25) 
showed two signals for FXN in only 55 % of counted cells. Cells from the 
homozygous individual with a repeat length of (GAA~1000/GAA~500), expressed FXN in 
52 % of counted cells 5’ of the GAA repeat also bi-allelically (Fig. 17). However, the 
proportion of non-expressing cells of the heterozygous (24 %) and the homozygous 
(29 %) individual was approximately twice and three times, respectively, that of the 
control group (11 %).  
 
In comparison to the 5’ probe, hybridising the cells with the probe 3’ of the GAA 
repeats, the proportion of non-expressing cells from the control increased only 
slightly to 18 %. In contrast, the heterozygous and homozygous individual revealed a 
substantial increase in the proportion of non-expressing cells to 41 % and 53 % 
respectively (Fig. 17). In line with this, the proportion of bi-allelically expressing cells 
3’ of the GAA repeats decreased considerably. Whereas 65 % of control lymphocytes 
No signal One signal Two signals No signal One signal Two signals 
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showed bi-allelic expression, this was detectable only in 33 % of heterozygous and 
28 % of homozygous cells. The proportion of mono-allelically expressing cells 
increased just for the control and the heterozygous lymphocytes. The proportion from 
the homozygous individual decreased to 19 %, indicating a further decrease of FXN 
transcription by the allele exhibiting the shorter GAA expansion, when compared to 
the wild type allele.  
 
Compared to controls, both the heterozygous and the homozygous individual showed 
a reduction in FXN expressing cells. Furthermore, this experiment shows that a 
proportion of cells are still able to express FXN bi-allelically even in the presence of a 
long GAA expansion. 
 
ChIP on primary cells of unaffected individual 
In order to investigate certain histone modifications at the FXN locus in fresh 
lymphocytes, blood samples were taken from a healthy individual, the lymphocytes 
were isolated and the chromatin extracted (see Material and Methods section). The 
amount of chromatin was limited, therefore initially only three antibodies (H3K9me3, 
H3K4me3 and RNA pol II) were used for ChIP.  
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Figure 18: ChIP on primary lymphocytes from an unaffected individual. Displayed are H3K9me3, 
H3K4me3 and RNA pol II. Presented is the mean of two independent IPs, each Q-real-time 
measured in duplicate. The variation between experiments is usually +/- 5 % for each primer 
pair. Again a peak of RNA pol II over the putative pausing site (P_1CpG) is seen. The active 
H3K4me3 histone mark gives a similar pattern seen for H3K4me2 in GM14. The H3K9me3 
modification, an indicator for silenced genes, is comparatively low compared to the signal seen 
6000 bp upstream (P1) of FXN.  
 
Similar to the ChIP results obtained from EBV-cell lines presented earlier 
(Fig. 10 + 12), the RNA pol II exhibits a peak inside exon 1, resembling a typical 
feature of known RNA pol II pausing sites (Fivaz et al., 2000; Krumm et al., 1995). 
These experiments show that the RNA pol II is present at a relatively low level 
(~ 18 %) across the FXN gene, compared to GAPDH (~ 45 %) (Data not shown). The 
active mark H3K4me3 shows a peak after the pausing site, decreasing 3’ of the 
normal GAA repeat expansion. A similar pattern was observed for H3K4me2 in the 
control GM14 and patient GM15 EBV-cell line presented before (Fig. 10). H3K9me3, 
the hallmark of heterochromatin, shows a moderate level across the pausing site. 
However, a slight increase 5’ of the GAA repeat is followed by a slight decrease 
followed by another slight increase. Unexpectedly, the overall H3K9me3 level in 
these primary “normal’ lymphocytes is comparable to the level measured in the 
barely expressing GM16 EBV-cell line, whereas GM14 and GM15 exhibit lower 
H3K9me3 levels (Fig. 10). However, in contrast to the barely expressing cell line 
GM16, which lacks H3K4me2 3’ of the pausing site, the normal primary lymphocytes 
possess a high level of H3K4me3. The observed H3K9me3 level discrepancies 
between control primary and EBV-cell lines might also be due to cell type differences, 
H3K9me3 
H3K4me3 
RNA pol II 
Unaffected primary lymphocytes  
UTR Exon 1 CpG 2 
CpG 1 
 
(GAA)9-30 
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as the primary cell chromatin extract consists of a mixed cell population of T- and B-
 cells.  
 
ChIP on primary cells from heterozygous and homozygous 
FRDA individual 
As mentioned before, the material obtained for ChIP experiments from fresh patient 
blood was limited; therefore initially only antibodies against RNA pol II and H3K4me3 
were tested. Results demonstrate a high level of the ‘open’ chromatin mark 
H3K4me3 in the presence of the GAA repeat, consistent with the high level of 
H3K4me2 seen in the patient EBV-cell line GM15. Furthermore, the RNA pol II 
pattern for both the GAA-repeat homozygous and the heterozygous individual 
revealed a much lower peak at the RNA pol II pausing site than the control (Fig. 19).  
 
 
Figure 19: ChIP on primary cells with anti-RNA pol II and anti-H3K4me3 antibodies. Displayed 
are results of a healthy, a heterozygous (father) and a homozygous individual (his son). 
Presented is the mean of one IP measured three times in duplicate. The variation between 
experiments is usually +/- 5 % for each primer pair. Both the father and the son display a 
decreased peak of RNA pol II over the pausing site, when compared to the unrelated control. 
The active H3K4me3 mark is increased in the father and the son, although in the son to a higher 
extent when compared to the control.  
 
Unexpectedly, the RNA pol II pattern of the heterozygous and homozygous individual 
is similar to the one obtained for the barely expressing patient GM16 EBV-cell line 
(Fig. 10). In contrast, the pattern for the active H3K4me3 mark is increased in both, 
the father and the son, when compared to the unrelated control, resembling a similar 
feature seen in the GM15 FRDA EBV-cell line (Fig. 10). As mentioned earlier, the 
investigated homozygous individual was severely affected by FRDA and suffered 
from the disease for over 10 years. Therefore it is possible, that the patient 
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represents an intermediate between the two extreme EBV-cell lines GM15 and 
GM16. The GAA repeat expansion is similar and the lines mainly differ in the FRDA 
duration time, apparently leading to a substantial difference in FXN expression and 
RNA pol II pausing pattern.  
 
It is also surprising that the heterozygous individual shows similar ChIP results for 
RNA pol II and H3K4me3 to the homozygote. If the expanded GAA repeat were 
simply inhibiting the RNA pol II elongation of FXN, an unaffected unexpanded allele 
would be expected to display normal RNA pol II pausing. Therefore, a peak at least 
half the size observed for a normal individual should be present. These results are 
consistent with those of the primary transcript RNA FISH (Fig. 17), which were also 
unexpected, demonstrating a similar quantitative reduction of primary transcript 5’ of 
the GAA repeat in heterozygous and homozygous individuals.  
 
Interestingly, a patient (indicated as woman HOM) possessing shorter GAA repeats 
(~300/100) displayed a similar disrupted RNA pol II pausing signal, but lower 
H3K4me3 levels than the patient with the long repeats.  
 
 
 
Figure 20: ChIP against RNA pol II and H3K4me3 on primary lymphocytes from two homozygous 
FRDA individuals. Both patients have a different length of GAA expansions, the “Woman” 
(~ 300/~ 100) and the “Son” (~ 1000 / ~ 500). Here, the pattern of RNA pol II is also changed when 
compared to the control. The level of the H3K4me3 pattern seems to depend on the length of 
the GAA repeat. Each IP was subject to Q- real-time measurement for 3 times and in duplicate. 
Presented is the mean of these experiments, the variation between experiments is usually +/- 
5 % for each primer pair.  
 
These observations on primary lymphocytes indicate that the lack of proper 
establishment of the RNA pol II pausing site might precede the change of histone 
modifications to a silenced chromatin state. The disrupted RNA pol II pausing site 
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might even be a requirement for the eventual change of histone modifications at the 
FXN locus, rather than the recruitment of heterochromatic factors by the GAA repeat 
itself. It is difficult to interpret ChIP results from the heterozygous individual, as the 
healthy allele cannot be discriminated from the expanded allele. However, as 
H3K4me3 modification levels are intermediate between the healthy heterozygous 
and the FRDA homozygous individual, the RNA pol II result is likely to be true. This 
confirms the RNA-FISH results obtained earlier where inhibition of transcription at the 
healthy allele was seen. The remarkable increase of H3K4me3 seems to be a feature 
provoked by the GAA repeat and dependent on its length, as the homozygous son 
has a much larger GAA expansion than the homozygous woman, with a 
correspondingly higher H3K4me3 pattern (Fig. 19 + 20).  
 
Data from genome-wide high resolution histone-methylation 
profiling3 
Advanced laboratory techniques and bioinformatics allow genome-wide high-
resolution screenings suitable for the investigation of various interests, although at 
high costs. Due to this fast and efficient development it was possible to extract data 
on histone methylation marks present at the FXN locus of a normal individual from 
the following data base http://dir.nhlbi.nih.gov/papers/lmi/epigenomes/hgtcall.html.  
 
The performed ChIP experiments presented in figure 10 are in accordance with the 
results displayed in this article. Therefore, the displayed antibodies in the following 
figures provide as additional valuable information. In figure 21, a magnification of the 
area of the FXN UTR up to the first half of intron 1 is shown, including the chromatin 
histone modifications H3K4me3, me2, me1 and RNA pol II. The location of the 
normal GAA repeat is indicated at the top of the figure. Each H3K4me mark seems to 
have its own unique pattern in this area. H3K4me2 is hardly present around the UTR, 
displays a peak shortly after the start of intron 1 and decreases soon after. On the 
contrary, H3K4me1 shows elevated levels at the beginning of the UTR followed by a 
gap around exon 1, increasing as soon H3K4me2 decreases. H3K4me3 seems to fill 
in the gap between H3K4me2 and H3K4me1, with a peak at the beginning of 
intron 1, sloping down to where H3K4me1 starts. The peak of RNA pol II, resembling 
                                                
3 Cell Resource, Barski et al., Cell 129, 823-837, May18, 2007, Link: 
http://dir.nhlbi.nih.gov/papers/lmi/epigenomes/hgtcall.html 
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the RNA pol II pausing site, coincides with the lower levels of H3K4me3, me2 and 
me1 around exon 1 beginning of intron 1.  
 
 
Figure 21: Chromatin modifications by genome wide ChIP analysis at the human FXN loci. 
Histone modifications displayed for H3K4me2, me1, me3 and the RNA pol II are from resting T-
cells. The black bars indicate the amount of chromatin immunoprecipitated by the respective 
antibody. No bar at all indicates data is missing for that stretch of the genome. Data were 
analysed by direct sequencing analysis of ChIP DNA samples using Solexa 1G genome 
analyser. For each antibody the highest value at the area of interest is represented by the 
number at the far left, resembling relative IP efficiency (results extracted from databank 
provided by Barski et al., 2007). 
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Figure 22 displays results obtained for the antibodies against RNA pol II, CTCF and 
H2A.Z along the entire FXN gene. Here, H2A.Z, known to locate around functional 
regulatory elements, is also found around the putative RNA pol II pausing site. Also 
CTCF was found at high levels around this regulatory site. This is well in accordance 
with previous reports that CTCF occurs around CpG-islands, also present at this 
element in the FXN gene. A recent publication performing genome-wide screening 
indicates that this set-up is indeed specific for RNA pol II pausing (Bao et al., 2007). 
Further evidence for this specificity is that the second CpG-island in intron 2 does not 
show any of the features found at the RNA pol II pausing site, as neither CTCF nor 
MeCP2 (own results) binding occurred.  
 
 
Figure 22: Entire FXN locus, ChIP results are from RNA pol II, CTCF and H2A.Z. Black bars 
indicate IP results from the beginning of the FXN 5’ UTR, no bars indicate missing data sets. 
Location of GAA repeat is indicated as a red line, location of second CpG- island is indicated 
with a blue line. Data were analysed by a direct sequencing analysis of ChIP DNA samples using 
Solexa 1G genome analyser. For each antibody the highest value at the area of interest is given 
as a number far left, resembling relative IP efficiency (results extracted from databank provided 
by Barski et al., 2007). 
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Figure 23 displays again the active histone marks H3K4me2, me1 and me3, over the 
entire FXN gene. Clearly, the most pronounced mark is H3K4me3 at the very 
beginning of the gene, whereas H3K4me2 displays a gap at this point. H3K4me2 
shows moderate levels where H3K4me3 is present, and seems to increase where 
H3K4me3 is present at low levels. H3K4me1 is the only mark to display a high peak 
at the very beginning of the gene. Only moderate levels of H3K4me1 are present 
where H3K4me2 occurs, however there is an additional peak in the middle of 
intron 1. This peak is quite distant from the GAA repeat as well as from the second 
CpG- island and its role might be worth investigating, especially as this feature is not 
present anywhere else at this locus. The rest of the FXN gene does not seem to 
show any additional interesting features of these active histone marks.  
 
 
 
Figure 23: Entire FXN locus with ChIP results of H3K4me2, me1 and me3. Location of GAA 
repeat is depicted with a red line; location of second CpG- island is indicated with a blue line. 
Black bars indicate result of IP with respective antibody. Data were analysed by direct 
sequencing analysis of ChIP DNA samples using Solexa 1G genome analyser. For each 
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antibody the highest value at the area of interest is given as a number at the far left, resembling 
relative IP efficiency (results extracted from databank provided by Barski et al., 2007). 
 
Figure 24 displays modifications correlating with the expression status of genes, such 
as H3K27me1, H3K36me3, H4K20me1 H2BK5me1 and H3K9me1. These are well 
represented at the FXN locus, indicating a constant level of activity despite low 
expression levels. Interestingly, H3K36me3, a mark for recently transcribed 
chromatin, is present more towards the 3’ end of the gene and exhibits a significantly 
lower signal around the pausing site. This might indicate constant RNA pol II 
presence at this particular part of the gene, whereas delayed transcription occurs 
after the pausing site. This observation corresponds with the finding that FXN is 
expressed at very low levels in lymphocytes exhibiting a RNA pol II pausing site. 
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Figure 24: Entire FXN locus with ChIPs of H3K27me1, H3K36me3, H3K20me1 and H2BK5me1. 
Location of GAA repeat is depicted with a red line; location of second CpG- island is indicated 
with a blue line. Black bars indicate amount of IP, no line at all indicates missing data set. Data 
were analysed by direct sequencing analysis of ChIP DNA samples using Solexa 1G genome 
analyser. For each antibody the highest value at the area of interest is given as a number on the 
far left, resembling relative IP efficiency (results extracted from databank provided by Barski et 
al., 2007). 
 
Concerning the regulation of FXN, the recently identified H2BK5me1 mark may 
provide evidence for the role of the RNA pol II pausing site. H2BK5me1 is a histone 
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mark correlated with expression (Barski et al., 2007) and exhibits elevated levels 
shortly 3’ of the pausing site. These seem to decrease following the end of intron 1, 
suggesting a regulatory role for intron 1 as a feedback mechanism for FXN 
regulation. So far, little is known about this particular modification, but it is interesting 
that the elevated level occurs 3’ of the pausing site and decreases again at the 
beginning of exon 2. 
 
 
 
Figure 25: Histone modifications H3K9me1, me2 and me3 along the entire FXN locus. Location 
of GAA repeat is depicted with a red line; location of second CpG-island is indicated with a blue 
line. Black bars indicate amount of IP, absence of a line indicates a missing data set (Barski et 
al., 2007). 
 
As presented in figure 25, the histone marks H3K9me2 and me3, known to mediate 
silencing, are absent or only present at negligible levels at the normal FXN locus, 
whereas the active mark H3K9me1 is well presented. The inactive marks 
H3K79me1, me2 and me3 are also absent (not displayed).  
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Results II 
The following chapter will examine the effect of chromatin modifiers such as HDAC 
inhibitors on the chromatin structure FXN locus and its expression. Experiments were 
conducted primarily on the three EBV-cell lines GM14, GM15 and GM16 previously 
described using the primers described in Results I (Fig. 6).  
 
Drug treatment of EBV-cell lines 
It is now well established that the chromatin state of DNA can influence gene 
expression. As stated in the Introduction, chromatin is a dynamic protein-DNA-
structure that can be modified by, amongst others, histone-acetyl-transferases 
(HATs) and histone-deacetylases (HDACs). Therefore, exposure of patient cells to 
HDAC inhibitors (HDACi) may change the chromatin structure into a more “open” 
arrangement, which might facilitate FXN mRNA expression. Thus, HDAC inhibitors 
are good candidates for positively influencing FXN gene expression in FRDA 
patients. Herman et al. were able to show that a new HDAC inhibitor increased FXN 
mRNA levels in primary resting lymphocytes as well as in EBV-cell lines derived from 
FRDA patients (Brunett et al., 2006; Herman et al., 2006). Notably, a number of 
commonly used HDAC class I and II inhibitors were not effective in reversing FXN 
silencing, indicating the specificity of this new inhibitor.  
 
Treatment of EBV-cell lines with potential drugs 
Since commonly used HDAC class I and II inhibitors are not effective in enhancing 
FXN transcription, the HDAC class III inhibitors Sirtinol and Splitomicin were tested 
here. These are known to inhibit members of the SIR2 (silent information regulator)-
 like family (Bitterman et al., 2002; Grozinger et al., 2001). These enzymes, also 
known as sirtuins, have multiple targets, act NAD+-dependently and are implicated in 
telomeric and rDNA silencing in humans (Grozinger et al., 2001). Three out of seven 
known sirtuin members are located in the nucleus (SIRT1, SIRT6 and SIRT7) 
whereas SIRT2 shuttles between the cytoplasm and the nucleus (see review Haigis 
and Guarente, 2006). Most HDAC inhibitors (HDACi) as well as the mammalian 
sirtuins have a number of different targets, one of them being histones. Here, the 
focus will lie on the activity of sirtuins on histones, since opening up the chromatin 
structure via acetylation of FXN might facilitate its expression. However, an influence 
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on FXN expression provoked by one of the other HDACi targets presented in table 4, 
can never be fully excluded. So far, the most characterised histone target of sirtuins 
is the deacetylation of the H4K16ac modification. In Drosophila it was shown that this 
modification correlates best with processes thought to “open” chromatin structure 
(Taiplae and Akhtar, 2005). Thus, it seemed reasonable to treat EBV-cell lines with 
sirtuin inhibitors, despite their diverse functions, to determine whether simply 
“opening up” the FXN locus would be sufficient to relieve the hampered FXN 
transcription in FRDA patients. 
 
Each previously described EBV-cell line was treated for 72 hours with Splitomicin 
(100 µM), Sirtinol (100 µM) and HDAC_4b (1 mM and 2 mM).  
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Figure 26: HDACi treatment of EBV-cell lines. All three EBV-transformed cell lines were treated 
with HDAC class III inhibitors and HDAC_4b. Displayed is the fold increase in FXN mRNA 
expression levels following HDACi treatment, measured by Q- (RT) PCR. Each result displayed 
is the mean of three independent experiments. Each sample was normalised to beta-actin. The 
values are expressed as a ratio to the corresponding untreated sample. The error bars indicate 
the standard deviation, after normalisation to the untreated sample. 
                                                                                                                                         
 
81 
 
The early stage FRDA GM15 cell line exhibits the best response to all drug 
treatments, whereas the later stage GM16 cell line responded in a similar manner to 
the control GM14 cell line (~ 1.5 fold). The published HDAC class I or II, HDAC_4b 
inhibitor (1 mM and 2 mM) treatment produced an expected increase of ~ 2 to 3 fold 
on the GM15 cell line. However, the EBV-cell line GM16 and the control GM14 cell 
line hardly responded to this treatment at all (~ 1.3 to 1.8 fold). The fact that the 
GM15 cell line behaved in accordance with previous reports validates the reliability of 
this technique. On treatment with the HDAC class III inhibitor Splitomicin (100 µM), 
the early stage FRDA cell line, GM15, showed a similar ~ 2 to 3 fold increase of FXN 
mRNA as had been observed following HDAC_4b treatment. The effect on FXN 
expression in the late stage FRDA GM16 cell line was less (~ 1.4 fold) than for the 
control GM14 cell line (~ 1.7 fold). Sirtinol (100 µM), the second HDAC class III 
inhibitor tested, increased FXN mRNA expression with reasonable efficiency (~ 2.3 
fold) in the early stage GM15 cell line, whereas no major increase was obtained for 
the later stage GM16 (~ 1.3 fold) or the control cell line GM14 (~ 1.1 fold).  
 
These results suggest that at early stages of FRDA (GM15), an HDAC inhibitor may 
lead to a GAA repeat expansion-dependent-increase of the FXN mRNA. However, if 
the disease has progressed further and the FXN mRNA level is already very low 
(~ 10 %), the treatment is unlikely to be effective in reviving its expression. After 
culturing these EBV-cell lines through ~ 20 passages, all three cell lines lost the 
ability to respond to the HDACi treatment, then only displaying an increase of ~ 1.3 
fold (see also Fig. 27). A trivial explanation for this would have been that the HDAC 
inhibitor was sensitive to storage or specific cell culture conditions, however, fresh 
stocks of inhibitors did not restore the previously seen effects, which were similar to 
those presented for Nicotinamide (Fig. 27). Consistent with this, Gottesfeld and 
colleagues observed a similar finding, that later passages of these cells lost their 
sensitivity to the HDAC_4b inhibitor, (personal communication, Gottesfeld). In further 
experiments it was decided to switch to another HDAC inhibitor, Nicotinamide, which 
is thought to be more stable under cell culture conditions than Splitomicin or Sirtinol 
(Posakony et al., 2004).  
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Nicotinamide treatment of EBV-cell lines and FXN mRNA levels 
As Sirtuins act NAD+-dependently, Nicotinamide can also inhibit the deacetylation of 
H4K16ac, a product of the SIRT- mediated deacetylation reaction. Here, 
Nicotinamide directly competes with NAD+ for binding to the pocket of the Sir2- family 
catalytic domain (Landry et al., 2000a; Landry et al., 2000b). 
 
FXN mRNA levels were determined by quantitative real-time reverse transcriptase 
PCR Q- (RT) PCR and normalised to the control cell line. This measurement 
revealed a FXN mRNA level of ~ 33 % for the early-stage EBV-cell line (GM15), 
whereas the cell line from a patient at a later stage (GM16) exhibited ~ 10 % of the 
normal FXN level (Fig. 27). No difference was observed for the control beta-actin 
mRNA between the three cell lines. 
 
 
 
Figure 27: Nicotinamide treatment of control and FRDA EBV-cell lines followed by quantitative 
real-time PCR measurement of FXN mRNA expression. Nicotinamide treatment for 72 h 
increased FXN mRNA in all cell lines. All values are normalised to beta-actin mRNA levels, 
which were unaffected by Nicotinamide. The fold changes in FXN mRNA compared to untreated 
control cells are approximately 1.2 - 1.4 in each cell line. Treatment of cell lines was repeated 
three times. Extracted RNA from each treatment was measured three times in serial dilutions 
and duplicate. The error bars indicate the standard deviation between results of three 
independent experiments.  
 
On treatment of the EBV-cell lines with the HDAC class III inhibitor, Nicotinamide; the 
actual FXN mRNA level increased only by ~ 1.2 - 1.4 fold in each cell line, similar to 
the levels seen after ~ 20 passages with various other HDAC inhibitors such as 
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Sirtinol, Splitomicin and HDAC_4b (not shown). An increase in FXN mRNA levels 
occurred with Nicotinamide treatment at doses of up to 5 mM whereas at 10 mM this 
declined and higher doses were toxic. 
 
Histone mark changes after Nicotinamide treatment - RNA pol II pausing 
is stable  
In order to investigate whether an HDAC class III inhibitor modifies the chromatin 
structure of the FXN locus, ChIP on treated cells was performed using the antibodies 
presented in Results I (Fig. 28). All three cell lines were treated for 72 hours with 
10 mM Nicotinamide. The histone profiles from untreated cells that were presented in 
Results I are displayed again for comparison.  
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Figure 28: Histone modifications detected at the FXN gene of untreated and Nicotinamide-
treated cell lines. The amount of FXN DNA immunoprecipitated by H3K9me3, H3K4me2, 
H4K16ac and RNA pol II antibodies was quantified by real-time PCR as described in Materials 
and Methods. Primer pair location is indicated below each figure, except P_1, which is 6000 bp 
upstream of FXN. Data displayed are an average of two independent immunoprecipitations; 
each immunoprecipitation was quantified in duplicate.  
 
As expected, the H4K16 acetylation as a target of HDAC class III (Wiren et al., 2005) 
increased in all three cell lines studied, notably to different extents (Fig. 28). Here, 
the control GM14 cell line showed the highest increase of H4K16ac (~ 2 fold after the 
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putative RNA pol II pausing site) compared to the untreated sample, whereas in the 
early stage GM15 cell line this effect was not seen. However, the untreated GM15 
sample initially exhibited a high baseline level of H4K16ac, maybe indicating a level 
of H4K16ac saturation (Fig. 28). The late stage GM16 cell line also showed an 
increase in H4K16ac but the pattern was different. Surprisingly, H3K4me2 levels 
decreased drastically in cells derived from FRDA patients but not in the control line, 
indicating that this mark was particularly sensitive to the combination of Nicotinamide 
and an abnormal GAA repeat expansion. The histone modification H3K9me3 showed 
a slight decrease in all three cell lines compared to the untreated samples. The 
amount of RNA pol II bound at the pausing site was unchanged in the GM14 and 
GM15 cell lines. In GM16 the already reduced RNA pol II peak was broader after the 
Nicotinamide treatment.  
 
Nicotinamide treatment changes binding of factors possibly influencing 
the pausing of RNA pol II 
The novel finding, presented in this thesis, that RNA pol II accumulates in exon 1 of 
the FXN locus suggests that this gene might require tight regulation, mediated via the 
RNA pol II pausing site and its binding factors. In pursuit of the hypothesis of a ‘tight-
regulation’ of the FXN locus via the RNA pol II pausing site, it was important to 
investigate the binding of factors influencing the RNA pol II pausing site. It was 
therefore investigated whether the opening of the chromatin structure via an 
increased acetylation of H4K16 would change the binding pattern of the RNA pol II 
regulating factor NELF-E.  
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Figure 29: ChIP against DNA-binding proteins on three EBV-cell lines. In order to assess the 
changes induced by Nicotinamide treatment the ChIP results presented in Results I are 
displayed again. ChIP was performed on normal and FRDA cell lines using antibodies against 
human MECP2, RNA Pol II, HP1γ and NELF-E. IP samples were subject to quantitative real-time 
PCR measurements. Each sample was measured at least twice in triplicate. Following 
Nicotinamide treatment the control cell line GM14 shows increased NELF-E binding at the 
RNA pol II pausing site, whereas GM15 and GM16 do not seem to change. Following 
Nicotinamide treatment only GM16 displays a change of RNA pol II pattern over the pausing site. 
The binding of HP1γ is unaffected in all three EBV-cell lines.  
 
As displayed in figure 29, Nicotinamide treatment might have provoked a slight 
increase of RNA pol II inside the CpG- island in the cell lines GM14 and GM15 
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compared to the untreated samples. Moreover, after Nicotinamide treatment the cell 
line GM16 exhibited an expanded RNA pol II peak along the entire CpG- island. A 
slight increase of MeCP2 binding was found towards the end of the CpG- island in 
the FRDA patient cell lines. Although borderline, these results correlate well with the 
ChIP-chop results showing corresponding de/increases in methylation levels, which 
will be discussed shortly (Fig. 32). Moreover, the observed decreased binding of 
MeCP2 in the control GM14 cell line correlates well with the observed decreased 
degree of methylation after Nicotinamide treatment. The control cell line GM14 
displayed an increase in NELF-E binding, which correlates with high increase in 
H4K16ac in this line (Fig. 28). Accordingly, the early-stage FRDA cell line GM15, 
which did not display a change in H4K16ac levels, did also not show an increase in 
NELF-E binding over the FXN putative pausing site. Furthermore, the late stage 
GM16 cell line exhibited a reverse NELF-E binding pattern following Nicotinamide 
treatment compared to the untreated sample. In short, these results suggest a 
correlation between NELF-E and RNA pol II levels inside the CpG- island, since the 
peak of NELF-E coincides with the peak of the RNA pol II. This suggests that the 
interplay between chromatin structure, NELF-E and RNA pol II binding levels might 
be an important feature in regulating the amount of FXN mRNA. 
 
LSD1 and JARID1 
The question of how Nicotinamide treatment of FRDA patient EBV transformed cells 
leads to a dramatic decrease in H3K4me2 and me3 remains elusive. Furthermore, 
the observed H3K4 methylation and demethylation seems to require the presence of 
an abnormal GAA repeat expansion. Recently, an increasing number of lysine 
demethylating enzymes have been discovered displaying potential candidates for 
demethylating H3K4 (Iwase et al., 2007). The lysine-specific demethylase 1 (LSD1) 
was the first enzyme discovered and is also referred to as BHC110 or p110b. LSD1 
was found to demethylate the specific lysine H3K4me1 and H3K4me2 using an 
amine oxidase reaction (Lawrence et al., 2004). However, LSD1 lacks the ability to 
demethylate H3K4me3. Enzymes of the JARID1-family encoding a JmjC-domain are 
able to demethylate H3K4me3 to di- and mono- forms but no further. Interestingly, 
the JARID1 family also binds to H3K9me3 indicating a cross talk between H3K9me3 
and H3K4me3 in transcriptional repression (Iwase et al., 2007).  
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Figure 30: ChIP against LSD1 on Nicotinamide treated and untreated EBV-cell lines. Each IP was 
done twice and each resulting DNA sample was quantitative real-time PCR measured in 
triplicate. Results display a dramatic increase of LSD1 over the putative RNA pol II pausing site 
for GM14 and GM15 following Nicotinamide treatment. 
 
Figure 30 shows the results of all three cell lines investigated for LSD1 binding, on 
the left untreated and on the right following Nicotinamide treatment (Fig. 30). In 
untreated all three cell lines, similar LSD1 levels are present around the RNA pol II 
pausing site, although the patient GM15 line exhibits an additional peak 5’ of the 
GAA expansion. Following Nicotinamide treatment, the control GM14 cell line as well 
as the patient GM15 cell line displayed an increase in LSD1 at the pausing site of 
more than 2 fold. In contrast the GM16 cell line exhibited a decrease of LSD1 around 
the pausing site post-Nicotinamide treatment, which was accompanied by a broader 
peak for RNA pol II (Fig. 29). In summary, following Nicotinamide treatment, an 
increase of LSD1 is seen at the pausing site independent of the GAA expansion, if 
the RNA pol II pausing site is undisturbed. In the presence of a disturbed RNA pol II 
pausing set-up, as seen for GM16, this recruitment is missing. Since the rise in LSD1 
levels are similar around the pausing site of GM14 and GM15, it seems unlikely that 
the loss of H3K4me2 in the patient cell lines is provoked by LSD1. 
 
The second potential candidate possessing demethylase activity was JARID1b with 
its ability to demethylate H3K4me3 as well as H3K4me2. Surprisingly, the untreated 
sample of GM16 displayed a peak of JARID1b, whereas the control GM14 cell line 
and the patient GM15 cell line did not display any signals for JARID1 at the FXN 
locus (Fig. 31).  
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Figure 31: ChIP against JARID1b of Nicotinamide and untreated EBV-cell lines. Results display 
in untreated samples only for GM16 a peak of JARID1b over the pausing site. Following 
Nicotinamide treatment GM15 displays a peak for JARID1b that was not detected in the 
untreated sample, whereas GM16 and GM14 do not show this feature. Each IP was done twice, 
each independent IP was quantitative real-time PCR measured in triplicate.  
 
However, following Nicotinamide treatment this situation was altered. Although the 
control GM14 cell line displayed negligible levels of JARID1b, the patient GM15 cell 
line now displayed a significant peak of JARID1b around the RNA pol II pausing site. 
In contrast, the patient GM16 cell line showed the reverse, with a reduction in the 
former peak over the RNA pol II pausing site. However both patient cell lines showed 
elevated levels 3’ of the pausing site. This finding might explain the H3K4me2 
demethylation of an active gene after Nictoinamide treatment, however the 
underlying mechanism has not yet been elucidated. 
 
ChIP-chop assay 
The ‘ChIP-chop’ technique (see Materials and Methods) was used to determine the 
degree of CpG-methylation (Preuss et al., 2007) at the predicted 918 bp CpG- island. 
In brief, the predicted island is not heavily methylated. Interestingly the GM15 patient 
cell line showed particularly low levels of DNA methylation (Fig. 32). GAPDH (exon 4) 
was used as a negative control and the second CpG-island inside intron 2 of the FXN 
gene, which exhibits a high degree of methylation, was used as a positive control 
(Fig. 32). 
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Figure 32: DNA-methylation at the FXN locus in FRDA and control EBV-cell lines. ChIP-chop 
assay of untreated and Nicotinamide treated EBV-cell lines. ChIP experiments were performed 
against histone H3. DNA of immunoprecipitate was incubated with the methylation-specific 
nuclease McrBC. Undigested DNA was quantified by Q- (RT) PCR as described in Materials and 
Methods. Graphs show the degree of DNA methylation in red. As a methylation negative control, 
GAPDH (exon 4) was used, and as a methylation positive control the CpG-island localized in 
Nicotinamide treated samples 
Untreated samples 
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intron 2 of the FXN gene was used (all primers shown in Material and Methods). Results 
represent the average of two ChIP-chop experiments; each resulting DNA sample was 
measured in triplicate. 
 
Unlike the first CpG- island covering exon 1 and the first part of intron 1 the second 
predicted CpG- island is ~ 65 % methylated in the control cell line and in the early 
stage FRDA patient cell lines (GM15). The later stage FRDA patient (GM16), exhibits 
~ 20 % of methylation at this island. Intron 1, however, seems to be consistently un-
methylated in untreated samples. Unexpectedly, after Nicotinamide treatment, 
intron 1 gained a certain degree of DNA- methylation, which was dependent on the 
abnormal GAA expansion. Furthermore, the control cell line seemed to lose DNA 
methylation in exon 1 as well as in the second CpG- island. This was not observed in 
the FRDA patient cell lines. Although these changes are rather minor, they are 
consistent with the changes in the amount of bound MeCP2 (Fig. 29). The GAPDH 
control locus was unaffected by the Nicotinamide treatment. 
 
In summary, the chromatin modifications of the FXN locus change dramatically after 
Nicotinamide treatment. Furthermore, the DNA methylation pattern, as seen in the 
ChIP-chop assay (Fig. 32), was also modified. As the level of beta-actin mRNA 
validated by Q- (RT) PCRs was unchanged by the Nicotinamide treatment all FXN 
mRNA measurements were normalised to beta-actin mRNA. However, on measuring 
actual FXN mRNA levels by Q- (RT) PCR, an increase of only 1.2 - 1.4 fold per cell 
line was observed (Fig. 27). From the obtained ChIP and Q- (RT) PCR results one 
can conclude that the chromatin structure influences the level of FXN gene 
transcription only to a certain degree. However, the putative RNA pol II pausing site 
was not sufficiently influenced by Nicotinamide, to enhance transcription enough to 
restore or raise the FXN mRNA to control cell line levels. Understanding the 
regulation of FXN is pivotal for developing rational approaches to stimulate a 
therapeutic increase in the expression of FXN at the pathogenic FXN locus. 
 
 
Treatment of patient primary lymphocytes with Nicotinamide 
In order to test the efficiency of Nicotinamide treatment in primary lymphocytes of 
FRDA patients, freshly extracted lymphocytes were cultured for 3 days in RPMI 1640 
Medium containing 10 mM Nicotinamide. This was important, as the published 
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HDAC_4b inhibitor (Herman et al., 2006) had been claimed to work in primary cells 
more reliably than in EBV-transformed cell lines (personal communication Gottesfeld 
J., Scripps). It was necessary to determine whether a similar phenomenon was true 
for the HDAC class III inhibitors. For this treatment, blood from a heterozygous father 
and his homozygous son was taken; the lymphocytes were extracted and then 
treated as stated. This blood sample was taken 18 months after that for the mRNA 
measurements presented in Results I. Interestingly, a further decrease in FXN levels 
was seen in the severely affected son. Whereas the son had previously displayed 
~ 39 % of the fathers FXN level, it now had dropped to ~ 21 %.  
 
 
 
Figure 33: FXN mRNA levels from primary lymphocytes, extracted from a heterozygous (Father) 
and a homozygous (Son) individual for the GAA expansion. Displayed are the values before and 
after a 3 day 10 mM Nicotinamide treatment. Each Q-RT-PCR measurement was done twice in 
triplicate. 
 
As shown in figure 33, Nicotinamide treatment did increase the FXN level in the 
heterozygous individual ~ 1.6 fold and in the homozygous individual ~ 1.4 fold. It is 
not surprising that the increase in the heterozygous individual is higher than in the 
homozygous one. By simply “opening-up” the chromatin structure, the RNA pol II 
elongation will still be hampered to a greater extend in the presence of two alleles 
with an abnormal GAA expansion. In this situation the HDACi treatment is unlikely to 
be able to restore the FRDA patient FXN level to non-pathogenic levels (30 % of 
normal). The son, untreated displaying ~ 10% of normal FXN levels, would 
experience an increase of only ~ 14 % . 
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Treatment of EBV-cell lines with 5-aza-2-deoxycytidine 
In order to test for possible positive effects on FXN expression, assays with different 
concentrations of a DNA methylation inhibitor, 5-aza-2-deoxycytidine, were 
performed. EBV-cells were treated with different concentrations of 5-aza-2-
deoxycytidine for 48 hours and RNA was extracted with Trizol.  
 
As shown in figure 34, the 5-aza-2-deoxycytidine treatment was counterproductive. 
When normalised to beta-actin a decrease of ~ 40 % in FXN expression occurred in 
all cell lines tested. This could be due to many factors. One possibility is that this 
drug influences other genes that regulate FXN levels. Furthermore, the observed 
methylation in the second CpG- island may be important for the correct transcription 
of FXN so a methylation change of the CpG- islands might negatively influence FXN 
expression. 
 
 
 
Figure 34: FXN levels following a 5-aza-2-deoxycytidine treatment of EBV-cell lines. EBV-cell 
line treatment was performed for 48 hours with different concentrations. Extracted RNA was 
measured with quantitative real-time PCR twice and each in triplicate. Error bars give the 
standard deviation between the means of two independent measurements. Each value for 
treated GM14 and all values for GM15 and GM16 were normalised to the untreated GM14 sample 
(set 100%). No increase in FXN expression was observable but a dramatic decrease was seen in 
normal cells as well as in FRDA patient cells. 
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Results III 
The following chapter describes experiments performed to reveal possible 
differences of the regulatory FXN pausing mechanism in the presence of a normal 
and an abnormal GAA expansion.  
 
Further testing of the RNA pol II pausing site with DRB 
In order to investigate the pausing mechanism of the RNA pol II pausing site in more 
detail a 5,6-dichloro-1β-ribofuranosylbenzimidazol (DRB) treatment was performed. 
DRB is known to inhibit the phosphorylation activity of the positive transcription 
elongation factor b (PTEF-b) on the RNA pol II CTD-S2 as well as NELF-E, thereby 
preventing the elongation of RNA pol II (Marshall et al., 1996; Chodosh, 1998). DRB 
treatment allows us to test the consequences of disrupting the phosphorylation 
activity of PTEF-b at the FXN locus. Moreover, the negative elongation factor (NELF) 
was previously found to be necessary for the negative function of DSIF (Yamaguchi 
et al, 1999). Although neither factor had any effect alone, the combination of DSIF 
and NELF slowed the elongation of RNA pol II. Importantly, this effect was eliminated 
by PTEF-b (Yamaguchi et al., 1999).  
 
All EBV-cell lines were treated with 50 µM of DRB for 5 h followed by chromatin and 
RNA extraction. Firstly ChIP results against various antibodies are presented of 
untreated and DRB treated samples. Following these results, the effect on FXN 
mRNA levels will be discussed.  
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Figure 35: ChIP result of DRB treated and untreated EBV-cells against RNA pol II S2. Displayed 
are the control (GM14) and FRDA EBV-cell lines (GM15 and GM16) untreated and for 5 hour DRB 
treated. Presented is the mean of two independent experiments, the variation between 
experiments is usually +/- 5 % for each primer pair. Following DRB treatment a severe decrease 
in RNA pol II S2 levels was seen all three lines, however for the control GM14 cell line no signal 
was detectable.  
 
As mentioned previously, S2-phosphorylated RNA pol II accumulates at the pausing 
site. Here, the control GM14 and FRDA patient GM15 exhibit similarly high levels of 
~ 80 units, whereas the EBV-cell line GM16, with low levels of FXN expression, 
displays approximately half of this RNA pol II S2 accumulation. After a 5 h DRB 
treatment, the phosphorylation of RNA pol II CTD-S2 and NELF-E is impeded and 
productive transcriptional elongation should no longer be possible. As expected, the 
control GM14 cell line does not exhibit any signs of S2-phosphorylated RNA pol II at 
the pausing site. This is not true for the FRDA patient cell lines GM15 and GM16. 
Both still exhibit roughly half of the previously detected amount of S2-phosphorylated 
RNA pol II in untreated cells. From this result two things become clear. Firstly, in 
ChIP experiments the antibody used against S2-phosphorylated RNA pol II appears 
reasonably specific, as the healthy cell line loses the signal when the 
phosphorylation activity of PTEF-b is prevented. Secondly, a simple explanation for 
the significant amount of S2-phosphorylated RNA pol II at the pausing site in FRDA 
patient cell lines is the retention of phosphorylated RNA pol II S2 at the pausing site, 
which has not been utilised during the course of a 5 h DRB treatment. This result 
supports the hypothesis that a delayed release of RNA pol II pausing seems to occur 
in the presence of a pathogenic GAA expansion in FRDA patient cells.  
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In order to verify the ChIP experimental conditions it was necessary to perform an 
additional experiment using an antibody against RNA pol II S5. The S5 modification 
is established by CDK7 (mammals) and known to occur at promoters, initiating the 
promoter escape by RNA pol II and displaying the phase of early elongation 
(Krishnamurthy et al., 2004). Therefore, as CDK7 is not a target of DRB it should 
have no direct effect on levels of RNA pol II S5. However it is important to note that 
for different antibodies the absolute recovery can vary significantly and therefore it is 
not possible to directly compare RNA pol II S5 levels to the results obtained for 
RNA pol II S2. 
 
 
 
Figure 36: ChIP against RNA pol II S5 of DRB treated and untreated EBV-cell lines. Presented is 
the mean of two independent experiments, the variation between experiments is usually +/- 5 % 
for each primer pair. Results of untreated control (GM14) and FRDA EBV-cell lines (GM15, GM16) 
show a peak for RNA pol II S5 over the pausing site. Following DRB treatment a significant 
increase for RNA pol II S5 levels is seen for the FRDA GM15 cell line. 
 
The untreated samples GM14 and GM16 exhibit similar distributions of RNA pol II S5 
and RNA pol II S2. However, GM15 shows a slightly higher level for RNA pol II S5 at 
the pausing site compared to GM14, which differs from the results obtained for 
RNA pol II S2, where GM14 and GM15 display similar levels. After DRB treatment 
the levels of RNA pol II S5 for GM14 and GM16 were similar, although, for GM14 a 
slightly higher level was found after the pausing site. Unexpectedly, the FRDA patient 
cell line GM15 exhibited a significant increase of RNA pol II S5, accompanied by a 
slight drop after the pausing site compared to the untreated sample. Reviewing the 
ChIP results of both RNA pol II modifications suggests that the presence of a GAA 
repeat expansion (in GM15) favours not only the accumulation of RNA pol II S5 at the 
pausing site but also hampers the escape of RNA pol II S2. To take the investigation 
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further the behaviour of NELF-E, also a phosphorylation target of the DRB sensitive 
PTEF-b was investigated. 
 
 
Figure 37: ChIP against NELF-E of untreated and 5 h DRB treated EBV-cell lines. Presented is 
the mean of two independent experiments, the variation between experiments is usually +/- 5 % 
for each primer pair. Following DRB treatment in all three EBV-cell lines an increase of NELF-E 
was seen over the FXN locus, however GM15 displayed the most significant increase in NELF-E 
levels over the pausing site. 
 
Untreated samples from the GM15 cell line, which express ~ 30 % FXN mRNA levels 
compared to controls, exhibit a higher peak of NELF-E compared to the healthy 
GM14 cell line. In GM16, the NELF-E peak at the pausing site is even less 
pronounced than in the control line. Furthermore, the FRDA GM16 cell line, which 
expresses low levels of FXN, displays an unusual chromatin composition that is 
accompanied by less binding of RNA pol II to the pausing site (Fig. 29).  
 
One of the functions of PTEF-b is the phosphorylation of NELF-E, which then gets 
released from the RNA pol II pausing site, thereby contributing to the pausing escape 
and proper elongation. This is supported by the observation that following DRB 
treatment all three cell lines generally display higher NELF-E levels indicating that the 
release of RNA pol II from the pausing site seems to be prevented. Interestingly, the 
effect of DRB on the FRDA patient cell line GM15 is significantly higher than on the 
control GM14 or the low level FXN expressing GM16 line. This result suggests that 
the presence of a GAA repeat expansion (GM15) can cause the recruitment of 
abnormal NELF-E levels to the transcribed FXN, thereby impeding the pausing 
escape of RNA pol II S2, thus ultimately leading to an accumulation of both 
RNA pol II phosphorylated forms S5 and S2 at the pausing site. 
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In order to further investigate this hypothesis the chromatin mark for “active” or 
recently transcribed DNA, H3K4me2, was also tested. 
 
 
 
Figure 38: ChIP against H3K4me2 of untreated and 5 h DRB treated EBV-cell lines. Presented is 
the mean of two independent experiments, the variation between experiments is usually +/- 5 % 
for each primer pair. Following treatment no major change for GM14 and GM16 was seen, but 
again GM15 displayed a significant change. Now a peak of H3K4me2 over the pausing site and a 
loss of H3K4me2 3’ of the pausing site was identified. 
 
As described in chapter 1, the “dip” of H3K4me2 around the RNA pol II pausing site 
appears more pronounced in the FRDA patient cell line GM15 and in primary cells of 
FRDA patients, than is seen in control cells. Interestingly, the increase of the 
H3K4me2 found around the GAA repeat seems to increase with the size of the GAA 
expansion, if FXN mRNA levels around 30 % are seen. The GM16 cell line that 
expresses extremely low levels of FXN, exhibits the reverse pattern, showing a peak 
of H3K4me2 at the pausing site, which is then followed by low levels. This feature 
has not yet been detected in primary cells from FRDA patients. Following a 5 h DRB 
treatment the control GM14 cell line exhibits a slight increase of H3K4me2 around 
the RNA pol II pausing site, although the overall pattern is comparable to the 
untreated sample. This result is similar for the GM16 cell line where no significant 
changes occur in levels of H3K4me2. Strikingly, the patient cell line GM15 showed a 
dramatic change. The former “dip” was transformed into a considerable peak over 
the RNA pol II pausing site and moreover the previously high levels of H3K4me2 
around the GAA expansion disappeared (Fig. 38). This observation will be discussed 
later on in the Discussion in more detail (see p. 113). 
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Since the active mark H3K4me2 after DRB treatment seemed to be diminished 3’ of 
the pausing site it was interesting to investigate whether this had an effect on the 
“inactive” chromatin mark H3K9me3.  
 
 
 
Figure 39: ChIP against H3K9me3 of untreated and 5 h DRB treated EBV-cell lines. Presented is 
the mean of two independent experiments, the variation between experiments is usually +/- 5 % 
for each primer pair. Following DRB treatment H3K9me3 levels increased 3’ of the RNA pol II 
pausing site for GM15, whereas for GM14 and GM16 only a slight decrease was detectable. 
 
Indeed in the GM15 cell line, following 5 h DRB treatment there was a ~ 2 fold 
increase in H3K9me3 levels 3’ of the pausing site. On the contrary the control GM14 
and FRDA GM16 cell line displayed a slight decrease. This mark is low in GM15 as 
long as elongation occurs. Thus the lack of sufficient elongation might be crucial 
whether heterochromatic marks, such as H3K9me3, are established at the FXN locus 
in FRDA patients. 
 
As the boundary factor CTCF was also found at RNA pol II pausing sites, its binding 
at the FXN locus was investigated, following a 5 h DRB treatment.  
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Figure 40: ChIP against CTCF of untreated and 5 h DRB treated EBV-cell lines. Presented is the 
mean of these experiments, the variation between experiments is usually +/- 5 % for each primer 
pair. Following DRB treatment GM14 and GM15 were more or less unchanged, however the 
FRDA GM16 cell line displayed a decrease over the pausing site. 
 
All untreated EBV-cell lines exhibit a pronounced peak for the CTCF DNA binding 
factor around the pausing site. GM15 exhibits ~ 40 % more binding than the other 
two lines. However, following a 5 h DRB treatment the GM16 cell line loses ~ half the 
amount of CTCF which was present previously, whereas the other two cell lines do 
not.  
 
Because the patient cell lines displayed a significant change in the levels of 
H3K4me2 following DRB treatment, the binding of the histone lysine demethylase 
LSD1 was also investigated. 
 
Figure 41: Levels of LSD1 measured via ChIP of untreated and 5 h DRB treated EBV-cell lines. 
Presented is the mean of two independent experiments, the variation between experiments is 
usually +/- 5 % for each primer pair. Following DRB treatment LSD1 increased over the pausing 
site of GM14 and GM15, whereas GM16 displays a shift of LSD1 towards the 5’ end of FXN. 
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Both untreated patient cell lines displayed similar levels of LSD1 around the pausing 
site, whereas the control cell line exhibits slightly less. Interestingly, inhibiting S2-
phosphorylation of the RNA pol II CTD during the 5 h DRB treatment changed the 
recruitment of LSD1 to FXN. GM15 exhibits a nearly 3 fold and GM14 an ~ 2.5 fold 
increase of LSD1 at the pausing site. In the case of GM15 this occurs in parallel with 
a substantial increase of H3K4me2 at the pausing site (Fig. 38). Therefore, it is 
possible that an abnormal increase of H3K4me2 triggers an additional recruitment of 
LSD1 to the RNA pol II pausing site. Interestingly, the control GM14 cell line, 
although showing an increase of LSD1, displayed only a minor increase in H3K4me2 
levels at this site. It is possible that, in the case of a normal GAA repeat length the 
accumulation of H3K4me2 might be simply compensated by additional LSD1, 
whereas the presence of an abnormal GAA repeat expansion hampers this 
mechanism. Untreated cells show in the case of extremely low expression of FXN 
(GM16) an additional increase around the promoter region. Strikingly, this correlates 
with the level of H3K4me2 detected and will be discussed further in the Discussion. 
 
In order to investigate these observations further it is necessary to account for the 
actual FXN mRNA changes after a 5 h DRB treatment. 
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Figure 42: FXN mRNA levels of untreated and 5 h DRB treated EBV-cell lines. Displayed are 
relative FXN mRNA levels, normalised to untreated GM14 (dark orange). Untreated samples are 
displayed in dark colour, DRB treated in the corresponding lighter version. Each FXN ct-value 
has been normalised to beta-actin. RNA was Q-real-time measured twice in triplicate and serial 
dilutions. The error-bars indicate the standard deviation of two independent experiments. The 
most decrease of FXN levels is seen in the control GM14 cell line.  
 
As displayed in figure 42, following DRB treatment for 5 h, the largest effect on FXN 
mRNA levels is seen in the control GM14 cell line, which shows a decrease of 40 %. 
This might be explained by the observation that the available RNA pol II S2 at the 
pausing site was fully used at some point during the 5 hours and further elongation 
was then no longer possible. In order to address more precisely when this scenario 
occurred, further time point experiments will be necessary. Considering that the 
H3K4me2 pattern hardly changed (Fig. 38) (indicating previously transcribed 
chromatin), it is possible that the final usage of S2 phosporylated RNA pol II had 
occurred earlier rather than later. In contrast, even after DRB treatment the patient 
cell line GM15 exhibits RNA pol II S2 at the pausing site (Fig. 35). Although 
elongation competent S2-phosphorylated RNA pol II is still available, this cell line 
exhibits only a slight reduction in FXN mRNA (minus ~ 18 %) in response to DRB 
treatment. Furthermore the large increase of the negative elongation factor NELF-E, 
seen occurring predominantly in the GM15 cell line might hamper the release of the 
RNA pol II S2 (Fig. 35 + 37). To further address these possibilities the H3K4me2 
levels obtained can be considered. Following a 5 h DRB treatment GM15 lost its 
active H3K4me2 mark over the GAA repeat and additionally displayed a significant 
peak of H3K4me2 at the pausing site, resembling a similar pattern to that obtained 
for the untreated GM16 cell line that expresses FXN at a very low level. In yeast, 
H3K4 is methylated by the Set1 domain, which targets the S5 phosphorylation of 
RNA pol II (Peters and Schubeler, 2005) By analogy, as GM15 exhibited an increase 
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in RNA pol II S5 phosphorylation at the pausing site, the pronounced H3K4me2 peak 
might be due to the recruitment of a SET-domain K4 methylase. Moreover, these 
results might also partly explain the H3K4me2 pattern observed in the presence of 
very little FXN mRNA as is seen in GM16. Here, the lack of sufficient RNA pol II S2 
escape from the pausing site might facilitate the increased H3K4me2 signal over the 
pausing site by a similar mechanism (Fig. 38). Noteworthy, that so far a peak of 
H3K4me2 over the pausing site was not detected in any primary cells of FRDA 
patients, potentially indicating a very late event in the evolution of the FRDA disease. 
Still, surprisingly, both FRDA patient samples seemed to be less affected by a 5 h 
DRB treatment than the control cell line. One explanation might be that after a 5 h 
period the lack of elongation does not affect the patient cell line as much as the 
control cells, since the RNA pol II S2 escape occurs to a lesser extent to begin with, 
when compared to the control cell line. Therefore, in the control cell line the 
hampered elongation occurring due to additional recruitment of NELF-E, or missing 
elongation, is more distinct. In summary, this experiment gave further evidence for a 
hampered escape of RNA pol II from the pausing site in the presence of an abnormal 
GAA repeat expansion. 
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LSD1 inhibitor Tranylcypromine 
The detection of LSD1 accompanied by the intriguing “dip” of the active H3K4me2 
chromatin mark at the pausing site led to the idea that LSD1 might be part of the 
mechanism regulating the RNA pol II pausing and its release. In order to test this 
possibility EBV-cell lines were treated with Tranylcypromine to inhibit the 
demethylase activity of LSD1. Tranylcypromine is a non-hydrazine monoamine 
oxidase inhibitor (Yang et al., 2007). For this experiment the EBV-cell lines were 
treated for 24 h in order to account for possible chromatin changes occurring after 
mitosis and replication. The treatment was then followed by chromatin extraction and 
immunoprecipitation. Firstly, the RNA pol II S5 ChIP results will be discussed.  
 
 
 
Figure 43: ChIP against RNA pol II S5 of EBV-cell lines treated with LSD1 inhibitor 
Tranylcypromine for 24 h. Presented is the mean of two experiments, the variation between 
experiments is usually +/- 5 % for each primer pair After this treatment the control GM14 cell line 
displays unchanged RNA pol II S5 levels, however GM15 displays a significant decrease and 
GM16 an increase.  
 
Again, the untreated samples display a pronounced peak of RNA pol II S5 at the 
pausing site and the highest peak is seen for the patient GM15 cell line. Following a 
24 h Tranylcypromine treatment this situation is altered. The control cell line displays 
a slightly higher peak for RNA pol II S5 compared to the untreated sample, whereas 
for the patient GM15 cell line a decrease at the pausing site is detectable (minus 
40 %). Interestingly, the patient GM16 cell line now exhibits a sharper and also 
slightly increased peak at the pausing site. Furthermore, a drop in overall 
RNA pol II S5 levels is seen only in the patient GM16 cell line, whereas the control 
GM14 cell line demonstrates a slight increase after the pausing site.  
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Performing ChIP against the active chromatin H3K4me2 mark also revealed an 
interesting change after the Tranylcypromine treatment.  
 
 
 
Figure 44: ChIP against H3K4me2 after 24h Tranylcypromine treatment of three EBV-cell lines. 
Presented is the mean of two IP experiments, the variation between experiments is usually +/- 
5 % for each primer pair Now GM14 displays a sight peak over the pausing site, although the 
H3K4me2 pattern 3’ of the pausing site is more or less unchanged. The FRDA GM15 and GM16 
EBV-cell lines both display a significant increase in H3K4me2 levels over the pausing site. In 
case of GM15 this is also accompanied by a dramatic decrease of H3K4me2 levels 3’ of the 
pausing site.  
 
Untreated EBV-cell lines display a peak of H3K4me2 only in the patient GM16 cell 
line at the RNA pol II pausing site, whereas this is lacking in the control GM14 and 
the patient GM15 cell line. Notably, after a 24 h Tranylcypromine treatment this 
pattern changed remarkably in the patient GM15 cells, which carry a GAA repeat 
expansion. GM15 not only displays a dramatic increase in H3K4me2 over the 
pausing site, but in addition there is a marked drop in H3K4me2 3’ of this site. This 
might be indicative of reduced transcriptional elongation, and similar to the 
observation made after DRB treatment (Fig. 38). No dramatic change following 
Tranylcypromine treatment was detected in the GM16 cell line, which unlike GM15 
did not initially exhibit a pronounced H3K4me2 pattern after the pausing site. 
Additionally, for GM16 a further increase of H3K4me2 levels was seen over the 
pausing site. Interestingly, the control GM14 cell line displays only a minor increase 
of H3K4me2 at the pausing site, however relative to the overall H3K4me2 level this 
might still be significant. Again, the overall H3K4me2 pattern of the GM14 cell line, 
similar to the result obtained for the DRB treatment, does not seem to change 
significantly. This is consistent with transcriptional elongation occurring despite the 
inhibition of LSD1 activity.  
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The binding of the negative elongation factor NELF-E was also investigated, because 
the GM15 cell line seemed to lack sufficient RNA pol II elongation, indicated by 
reduced levels of H3K4me2, despite the accumulation of RNA pol II at the pausing 
site. 
 
 
 
Figure 45: ChIP against NELF-E of three EBV-cell lines with and without 24 hour 
Tranylcypromine treatment. Presented is the mean of two experiments, the variation between 
experiments is usually +/- 5 % for each primer pair. Following the treatment, all three EBV-cell 
lines display an increase of NELF-E over the pausing site. 
 
In the case of LSD1 inhibition a marked increase of NELF-E was detected at the 
pausing site, especially in the control GM14 line. Interestingly, this increase of up to 
~ 40 units is as pronounced as that seen after the Nicotinamide treatment (Fig. 12). 
Similar to the Nicotinamide treatment the patient GM15 cell line again shows an 
increase of NELF-E over the pausing site but the change is not as pronounced as 
that seen for GM14. For the patient GM16 cell line the NELF-E pattern differs slightly 
from that seen following Nicotinamide or DRB treatment (Fig. 12 + 37). Here, the 
NELF-E seems to be located predominantly at the pausing site rather than further 
along the FXN gene. 
 
Interestingly, recent publications (Metzger et al., 2005) indicate that under certain 
circumstances LSD1 is able to demethylate H3K9me3/2. In order to test this 
possibility ChIP was performed against H3K9me3. 
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Figure 46: ChIP against H3K9me3 of untreated and 24 h Tranylcypromine treated EBV-cell lines. 
Presented is the mean of two experiments, the variation between experiments is usually +/- 5 % 
for each primer pair. Following treatment, a dramatic increase in H3K9me3 levels was seen in 
the FRDA cell line GM15 only. GM14 and GM16 displayed more or less similar pattern for 
H3K9me3. 
 
As discussed before, the inactive H3K9me3 histone mark is only pronounced in the 
patient GM16 cell line that also shows a very low expression of FXN. Although the 
control and the patient GM15 cell line show a slight peak of H3K9me3 immediately 
after the pausing site, no significant H3K9me3 level was observed around the GAA 
repeat expansion. Following a 24 h treatment with the LSD1 inhibitor 
Tranylcypromine, this situation changed significantly for the patient GM15 cell line. In 
line with the observed decrease of H3K4me2 after the pausing site, H3K9me3 
increased considerably after the inhibition of LSD1. Notably, the inactive mark 
H3K9me3 did not change after Nicotinamide treatment (Fig. 28), despite the severe 
decrease of H3K4me2 after the pausing site. In this scenario the LSD1 activity would 
be expected to be unaffected by the Nicotinamide treatment and therefore, despite 
the lack of H3K4me2, the establishment of H3K9me3 might have been prevented by 
LSD1. However, since the DRB treatment also increased H3K9me3 levels, although 
to a lesser extent, it might be that simply the lack of RNA pol II release and 
elongation provoked the establishment of heterochromatic marks such as H3K9me3. 
As during Nicotinamide treatment the elongation should be slightly enhanced since 
FXN mRNA levels increased, heterochromatinisation could have been prevented 
simply through transcription without the involvement of LSD1. However, since the 
H3K9me3 levels after Tranylcypromine treatment seem to be more pronounced than 
following DRB treatment it is possible that LSD1 also plays a role in preventing 
heterochromatisation at the abnormal expanded GAA repeat through its potential 
demethylating activity on H3K9. LSD1 present at the FXN locus would then not only 
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demethylate H3K4me2 around the pausing site but also H3K9me2/3 around the GAA 
repeat and its possible expansions, thereby opposing heterochromatisation of FXN.  
 
However, in the control cell line GM14 and the low expressing GM16 cell line the 
absence of LSD1 activity caused only a slight increase of H3K9me3 levels around 
the GAA repeat, again demonstrating that a GAA repeat expansion is in theory able 
to acquire heterochromatic marks. Thus, in the particular case of FXN, this 
phenomenon might be prevented either via active transcription or/and by the 
presence of LSD1. Considering, the initially pronounced H3K9me3 levels of the low 
FXN expressing patient GM16 cell line, it is possible that no further increase was 
seen after LSD1 inhibition. In order to obtain a better idea of the changes observed 
after Tranylcypromine treatment, it was important to verify whether the inhibition of 
LSD1 activity had any effect on the actual LSD1 distribution along the FXN locus.  
 
 
Figure 47: ChIP against LSD1 before and after 24 h Tranylcypromine treatment of three EBV-cell 
lines. Presented is the mean of two experiments, the variation between experiments is usually 
+/- 5 % for each primer pair. Following treatment, GM14 and GM15 displayed a slight change in 
LSD1 levels, only GM16 displayed a ~ 3 fold increase in LSD1 levels over the FXN locus. 
 
In general, following a 24 h Tranylcypromine treatment the amount of detectable 
LSD1 increased especially at the promoter (P_2) and around the pausing site. 
Interestingly, the patient GM15 cell line displayed the lowest increase, whereas the 
normal GM14 cell line showed ~ double the amount of LSD1 binding. Surprisingly, 
the patient GM16 cell line showed a ~ threefold increase across the FXN locus. This 
phenomenon might also explain the minor increase of H3K9me3 as more LSD1 is 
bound to FXN, and therefore even in the presence of an inhibitor a certain activity 
might be present. After inhibition of the demethylase activity, increased LSD1 binding 
is surprising, however, one way of balancing the lack of activity might be to 
compensate by recruiting additional enzymes. Nevertheless, the differences 
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observed in the amount of LSD1 present, in each cell line, are neither expected nor 
obvious.  
 
Finally it was decided to investigate the levels of CTCF after Tranylcypromine 
treatment, as this protein was also found to bind at the RNA pol II pausing site.  
 
 
 
Figure 48: ChIP against CTCF before and after a 24 h Tranylcypromine treatment of EBV-cell 
lines. Presented is the mean of two experiments, the variation between experiments is usually 
+/- 5 % for each primer pair. Following treatment the control GM14 cell line displayed an 
increase of CTCF over the pausing site, whereas CTCF levels of the FRDA GM15 cell line 
seemed to be unchanged. In contrast, GM16 displayed a decrease of CTCF at this site. 
 
Interestingly, when investigating untreated samples, CTCF seems to be more 
pronounced at the RNA pol II pausing site in the presence of a GAA repeat 
expansion, when the cell line expresses FXN reasonably (GM15). Then again, the 
control GM14 and the patient GM16 cell line exhibit similar CTCF levels over the 
pausing site. However, after a 24 h Tranylcypromine treatment this pattern changes. 
The healthy GM14 cell line now shows an increase of ~ 50 % CTCF binding over the 
pausing site, whereas both patient cell lines exhibit a decrease of ~ 25 %. This 
phenomenon might be explained by the fact that both patient cell lines show a 
dramatic change in the H3K4me2 pattern over the RNA pol II pausing site (Fig. 44), 
which might hamper CTCF binding, whereas the control GM14 cell line exhibited a 
more or less unchanged H3K4me2 pattern over the pausing site. As CTCF is known 
to function as an insulator element and GM14 also showed the highest increase of 
NELF-E, CTCF might also play a crucial part in the regulation of FXN mRNA levels. 
Possible roles of CTCF at the pausing site will be explored further in the Discussion. 
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In order to fully explain the observed chromatin and DNA binding protein changes at 
the FXN locus it was necessary to measure the actual changes in FXN mRNA levels 
following a 24 h Tranylcypromine treatment. 
 
 
Figure 49: FXN mRNA levels after a 24 h Nicotinamide and Tranylcypromine treatment of three 
EBV-cell lines. Displayed are relative FXN mRNA levels, each treatment of each cell line has 
been normalised to its respective untreated level and set 100 % (red). Nicotinamide treated 
samples are displayed in orange, Tranylcypromine treated samples in yellow. Each FXN ct-value 
has been normalised to beta-actin. RNA was Q-real-time measured twice in triplicate and serial 
dilutions. The error-bars indicate the standard deviation of two independent experiments. 
Tranylcypromine treatment had the most severe effect on FXN levels of the FRDA GM15 EBV-
cell line and a severe effect on GM16. The control GM14 EBV-cell-line showed only a minor 
decrease of ~20 % on FXN mRNA levels. 
 
 
An additional Nicotinamide treatment was performed in order to control the mRNA 
measurement. Nicotinamide treatment for 24 h showed the expected results with an 
~ 1.3 fold increase, therefore the assay was verified. The control GM14 cell line 
responded with a relatively minor decrease of ~ 20 %. However, the greatest effect, 
with a decrease in FXN mRNA of ~ 70 % was seen in the relatively well expressing 
patient GM15 cell line. This is also in complete contrast to the levels detected after a 
5 h DRB treatment, where the biggest effect was seen in the control GM14 cell line, 
whereas the FRDA GM15 cell line seemed hardly affected (Fig. 42). Interestingly, 
after 24 h of Tranylcypromine treatment GM16 shows also a more pronounced 
decrease of FXN mRNA levels (minus ~ 40 %). 
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In summary, the FXN mRNA levels measured are well in accordance with the 
observed H3K4me2 and H3K9me3 levels. The least affected GM14 cell line still 
exhibits similar levels of H3K4me2 and H3K9me3 when compared to the untreated 
sample. However, the negative elongation factor NELF-E and the insulator factor 
CTCF are more pronounced at the pausing site, probably accounting for a slight 
delay in releasing the elongating RNA pol II, which leads to a reduction in FXN 
mRNA levels. After the inhibition of LSD1, the patient GM15 cell line, showed a 
dramatic drop in the active mark H3K4me2 as well as a marked increase in the 
inactive H3K9me3 histone mark, which corresponds well with the decrease of FXN 
mRNA levels. Furthermore, in the case of an abnormal GAA repeat expansion a 
putative role for LSD1 in maintaining the open chromatin structure was suggested, by 
preventing heterochromatisation via the demethylation activity on H3K9me3. 
Moreover the additional amount of NELF-E at the pausing site might further hamper 
RNA pol II elongation, finally resulting in the ~ 80 % decrease of FXN mRNA. 
Interestingly, in this scenario the boundary factor, CTCF, decreased by ~ 25 %. 
Similar to the DRB treatment, the patient GM16 cell line does not exhibit a marked 
change in the pattern of H3K4me2 although an increase was observed at the 
pausing site. Moreover, the inactive H3K9me3 mark did not seem to change 
considerably, possibly because of the additional significant LSD1 recruitment and its 
extremely low initial level of FXN expression. Nevertheless after a 24 h 
Tranylcypromine treatment, the level of NELF-E increased and may possibly hamper 
the RNA pol II release additionally, resulting in a final decrease of ~ 40 % in FXN 
mRNA levels. In that scenario the patient GM15 cell line also showed decreased 
binding of the boundary factor CTCF (~ 25 %) to the RNA pol II pausing site. The 
differences observed in the decrease of FXN mRNA levels between the two patient 
cell lines might be caused by the existence of different rates of release from 
RNA pol II pausing. When untreated samples are compared, GM15 shows in contrast 
to GM16 a higher level of H3K4me2 indicating a higher rate of RNA pol II elongation. 
Therefore, after a period of 24 h Tranylcypromine treatment, the effect of additional 
NELF-E on FXN expression might be more severe in the low expressing GM15 cell 
line than in the very low expressing GM16 cell line.  
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Discussion 
 
Following the identification of an abnormal GAA repeat expansion as the cause of 
FRDA, many studies have focused on the properties of GAA repeat expansions. 
Although experiments showed the potential inhibitory effect of GAA repeat 
expansions on RNA elongation and chromatin structure (Bidichandani et al., 1998; 
Grabczyk et al., 2007; Grabczyk and Usdin et al., 2007; Krasilnikova et al., 2007; 
Krasilnikova and Mirkin, 2004), one has to bear in mind that most of these studies 
were conducted on plasmids and reporter genes. These artificial conditions may not 
reflect the actual cell response to an abnormal DNA/chromatin structure occurring at 
the FXN locus in humans. Since the GAA repeat is flanked by poly AAA sequences 
that are conserved in the chimpanzee and the human, it is possible that this 
sequence might have evolved a specific function in the human FXN (Fig. 6).  
 
To date, in human no general promoter elements of FXN have been found (Greene 
et al., 2005), and surprisingly few studies have looked in detail at the regulatory 
elements of this locus. It is possible that the normal GAA repeat expansion has a 
function in regulating the human FXN gene. Furthermore, elements lying ~1000 bp 
5’ of the GAA repeat were recently proposed to contribute to the down-regulation of 
FXN (Greene et al., 2007). In this thesis it was demonstrated via ChIP and 
quantitative real-time PCR that FXN mRNA levels are relatively low (Fig. 10). 
Moreover, an over-expression of Frataxin was suggested to be toxic (Fleming et al., 
2005). One can speculate that FXN transcription may be subject to tight regulation to 
ensure low levels of Frataxin. However, the progressive nature of FRDA and the 
mechanism underlying the severe down regulation of FXN transcription is still 
unclear.  
 
In this thesis ChIP experiments revealed a RNA pol II transcriptional pausing site 
within a scarcely methylated CpG- island at exon 1 of the human FXN locus (Fig. 10). 
Gene regulation via RNA pol II pausing has been observed for a number of genes 
that are tightly regulated such as c-myc, HSP70, MKP-1 and HIV (Fivaz et al., 2000; 
Krumm et al., 1995; Li et al., 1996; Palangat et al., 1998; Schneider et al., 1999). 
Thereby, the access and initiation of the basal transcription machinery is permitted, 
but further RNA pol II elongation is subject to negative regulation by factors that are 
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still mostly unknown (Svetlov et al., 2007). Therefore, this element may be a key 
regulatory feature of the FXN locus. Interestingly, genes regulated via pausing of the 
RNA pol II, such as c-myc, possess a triplex forming repeat structure downstream of 
this regulatory element (Belotserkovskii et al., 2007), suggesting a possible role for 
the triplex-forming GAA repeat in the function of the RNA pol II pausing site at the 
human FXN locus.  
 
Each gene bearing an RNA pol II pausing site seems to possess a specific regulatory 
mechanism which may be triggered by hormones, heat-shock or specific transcription 
factors (Li et al., 1996; Mooney and Landick, 2003; Schneider et al., 1999; Wu et al., 
2003), making it difficult to predict the factors involved in fine-tuning the regulation of 
the FXN gene. For example, Frataxin is thought to protect against cytotoxic stress 
that might also contribute to the fine-tuning of FXN gene regulation (Jiralerspong et 
al., 2001). In addition, NELF-E and CTCF previously identified on other RNA pol II 
pausing sites (Bao et al., 2007; Chernukhin et al., 2007; Wu et al., 2003; Yamaguchi 
et al., 1999; Zhang et al., 2007) were also found at the FXN pausing site and are 
therefore likely to play a regulatory role (Fig. 12 + 40). Notably, a regulatory response 
has been seen at the RNA pol II pausing site following treatment with the HDACi, 
Nicotinamide (Fig. 28). The FXN chromatin structure of the control GM14 cell line 
was modified as expected by increased levels of H4K16ac (Fig. 28), However, the 
ensuing effects on transcription may have been antagonised by the concomitant 
recruitment of NELF-E to the RNA pol II pausing site (Fig. 12). Furthermore, the 
treatment with increased concentrations of Nicotinamide (1 - 10 mM) showed a linear 
but only minor increase of FXN mRNA levels (up to 1.4 fold) (Fig. 27). Notably the 
other chromatin modifications tested were more or less unaffected (Fig. 10).  
 
Given that NELF-E possesses an RNA-recognition-motif (Rao et al., 2006; Zhang et 
al., 2007) one can speculate that the RNA pol II pausing site may act in concert with 
the first intronic primary transcript of FXN. This RNA may also include the normal 
range of GAA repeats. The results from Nicotinamide treatment suggest two 
plausible regulatory mechanisms for FXN. The first mechanism could be due to the, 
increased transcription rate, which is facilitated by the enhanced open chromatin 
structure, leading to higher levels of RNA (primary intron 1). This in turn may 
feedback on NELF-E, leading ultimately to enhanced NELF-E levels at the pausing 
site, subsequently delaying the release of RNA pol II, and thereby antagonising 
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excessive FXN transcription (Fig. 30). The second mechanism is exclusively based 
on the chromatin structure change. Here, elevated levels of H4 acetylation and the 
resulting chromatin conformational change may trigger the additional recruitment of 
NELF-E to the pausing site. Interestingly, a recent study on HIV demonstrated an 
increase of transcription and replication of the virus after the depletion of NELF-E 
(Zhang et al., 2007), demonstrating a role for NELF-E in transcriptional regulation. 
Moreover, after NELF-E depletion elevated levels of acetylated H4 were observed, 
suggesting coupling of transcription elongation and chromatin remodeling (Zhang et 
al., 2007).  
 
To date, the role of CTCF at the pausing site is not very well understood but it has 
been shown that CTCF is a component of the RNA pol II protein complex interacting 
directly with the RNA pol II (Chernukhin et al., 2007). Furthermore, CTCF shows 
different binding kinetics to each of the diverse RNA pol II phosphorylation states 
depending on its own phosphorylation status (Chernukhin et al., 2007). A stronger 
interaction was seen between CTCF and the unphosphorylated RNA pol II when 
compared to the hyperphosphorylated form of RNA pol II (Chernukhin et al., 2007). 
The fact that CTCF can be phosphorylated on multiple sites opens various 
possibilities for the influence of CTCF on the RNA pol II and its arrest or release 
(Chernukhin Igor et al., 2007). However, the lack of appropriate antibodies against 
the diverse phosphorylation states of CTCF, make it difficult at present to investigate 
these potential mechanisms in detail. Nevertheless, the potential role for CTCF as an 
activator was demonstrated in experiments where a single CTCF target site was 
sufficient to activate the transcription from a promoter-less reporter gene (Chernukhin 
Igor et al., 2007).  
 
Considering the presented ChIP results on control cells and information from 
publications to date (Barski et al., 2007), one can envisage a new model for the 
transcriptional regulation of FXN in the case of a normal GAA repeat length. The 
presence of H3K4me2/me3 around the transcriptional initiation site and H3K27me1, 
H3K36me3, H4K20me1 and H2BK5me1 further downstream would be consistent 
with an open chromatin structure in the regions flanking the pausing site (Fig. 24). 
Furthermore, inactive marks are missing, such as H3K9me2/me3, H3K79me1, me2 
and me3, potentially allowing access to the transcriptional machinery (Fig. 25). 
Assuming tight regulation of FXN is necessary, the identified factors NELF-E, CTCF 
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and LSD1 (Fig. 12 + 40 + 30) may play a role in the regulation of FXN. Moreover, at 
the pausing site a specific chromatin structure predominates allowing potential 
regulatory factors to bind (Fig. 10). The presence of both S5 and S2 phosphorylated 
forms of RNA pol II (Fig. 35 + 36) suggest an area where a switch from “initiated” to 
“sufficient” elongation may occur, probably partly regulated via the previously 
mentioned factors. 
 
This new model seems consistent with the finding that following the inhibition of the 
kinase p-TEFb via DRB, the RNA pol II S2 phosphorylated form is no longer present 
and an ~ 40 % reduction of FXN mRNA levels occurs (Fig. 42). Considering that 
during a period of 5 h there was little change to the H3K4me2 pattern (indicating 
previously transcribed chromatin), it is possible that the final usage of S2 
phosphorylated RNA pol II occurred towards the end of the 5 h treatment. It is 
noteworthy that, the levels of RNA pol II S5 did not change, showing the important 
function of p-TEFb, performing the switch from initiated to the efficient elongation 
form of RNA pol II S2 at the pausing site (Fig. 35 + 36). Therefore the almost 
unchanged H3K4me2 pattern may be explained via previously available 
RNA pol II S2 at the pausing site. Although at some point no efficient elongation was 
possible, the H3K4me2 pattern is still detectable, indicating a rather recent event. In 
order to address more precisely at which point this scenario occurred, further time 
point experiments will be necessary. NELF-E is also affected by the inhibition of DRB 
demonstrated by an increase of NELF-E at the pausing site (Fig. 37), which may lead 
to a delay in RNA pol II S2 release. This in turn may subsequently contribute to the 
40 % decrease in overall FXN levels observed when compared to the untreated 
samples (Fig. 42).  
 
The intriguing presence of the demethylase LSD1 at the pausing site led to the 
hypothesis that the demethylation of H3K4me2 may be an essential requirement for 
the establishment of the RNA pol II pausing site. Therefore, a Tranylcypromine 
treatment, which inhibits LSD1 demethylase activity, was performed for 24 h (Yang et 
al., 2007). Interestingly, the control GM14 cell line responded with a relatively minor 
decrease in FXN mRNA levels of ~ 20 % (Fig. 49), despite a slight increase of 
H3K4me2 (Fig. 44) and LSD1 levels around the pausing site (Fig. 46). The overall 
pattern of H3K4me2 and H3K9me3 was more or less unchanged (Fig. 44 + 46). 
However, the negative elongation factor NELF-E and the boundary factor CTCF 
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seemed to be more pronounced at the pausing site, the former probably accounting 
for a slight delay in releasing the productive-elongating RNA pol II, contributing to the 
observed reduction in FXN mRNA levels (Fig. 49). Despite an increase in H3K4me2 
levels, the establishment of the RNA pol II S5 pausing at exon 1 was not disturbed by 
Tranylcypromine treatment, therefore it is unlikely that the activity of LSD1 alone is 
responsible for the set-up of the FXN pausing site. However, a minor negative effect 
on the FXN transcription rate was seen, accompanied by increased CTCF, NELF-E 
and LSD1 levels. This again suggests a change in the balance of factors at the 
RNA pol II pausing site, associated with the interruption of the usual configuration of 
an RNA pol II pausing site. It is tempting to speculate that the physiological role of 
the pausing site may strictly limit the level of FXN mRNA and up regulation may only 
occur in response to appropriate signals. The type of effects seen here following 
pharmacological manipulations and the effects of the GAA repeat expansion suggest 
that feedback mechanisms exist to impose limits on the level of Frataxin. Such 
mechanisms are likely to involve both the pausing element and the chromatin 
structure and will need to be considered when attempting to increase FXN levels via 
drug treatments that act on chromatin or influence RNA pol II pausing.  
 
By using the primary transcript RNA FISH method it was evident that FXN expression 
although bi-allelic was not constant (Fig. 17). Here, the “5’ probe” recognised the 
RNA 5’ of the GAA repeat directly downstream of the RNA pol II pausing site (Fig. 6). 
Although ChIP experiments showed a clear presence of RNA pol II at exon 1, 
suggesting that this is true for most cells, not every cell displayed a primary transcript 
signal. In primary cells from a control individual, 77 % of cells displayed two signals 
for FXN expression, indicating a bi-allelic expression (Fig. 17). The remaining cells 
displayed either zero or one signal, possibly reflecting the paused RNA pol II in these 
cells, or a phenomenon similar to PEV (Fig. 17). Interestingly, further downstream, 
covering intron 3 and intron 4, less cells (65 %) displayed bi-allelic expression, 
indicating a loss in efficient expression along the FXN gene even in the presence of a 
normal repeat length (Fig. 17). 
 
Taken together, it seems likely that the RNA pol II pausing site is partly regulated via 
factors such as NELF-E, CTCF and LSD1 and may interact with the primary 
transcript RNA levels produced as well as with the chromatin state of the FXN locus. 
Since NELF-E has already been suggested to act as a transcriptional attenuator 
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being important for controlling the duration and magnitude of transcriptional 
responses (Aida et al., 2006; Ping and Rana, 2001; Yamaguchi et al., 1999) this 
regulation is likely to occur at the FXN locus. Furthermore, the finding that several 
different drug approaches increased FXN mRNA only slightly by up to ~ 2 fold 
(Burnett et al., 2006; Gottesfeld, 2007; Herman et al., 2006) could be explained by 
the existing tight regulatory mechanism responding to changes either in chromatin 
structure or amounts of primary transcript RNA. 
 
HP1-γ was detected at the RNA pol II pausing site. This occurred independently of 
the GAA repeat length, transcription or chromatin state (Fig. 12). HP1-γ has been 
shown to bind to some euchromatic regions (Lomberk et al., 2006) and growing 
evidence exists that the evolutionary conserved HP1’s are involved in gene-specific 
regulation within both heterochromatin and euchromatin as activator and/or repressor 
molecules. Additionally, it was suggested that HP1γ acts as an anchor between 
heterochromatic and euchromatic regions of the nucleus (Lomberk et al., 2006). The 
presence of HP1-γ at the pausing site is intriguing and certainly warrants further 
investigation. 
 
 
Chromatin structure of patients 
Unexpectedly, the FRDA GM15 cell line derived from a patient with early stage FRDA 
demonstrated higher levels of open chromatin marks (H3K4me2 and H4K16ac) than 
the control GM14 cell line (Fig. 10), and possessed even less CpG- island 
methylation (Fig. 32). The finding that primary cells from FRDA patients also showed 
higher levels of H3K4me2/3 than controls (Fig. 19 + 20), questions the original 
hypothesis that a certain number of cells would attract heterochromatin via the GAA 
repeat expansions, resulting in a PEV similar phenomenon. Hereby, only a proportion 
of cells would still be able to fully transcribe FXN, ultimately leading to the severe 
decrease in FXN levels demonstrated in FRDA patient cells. However, the pattern 
found in the EBV-cell line GM16 demonstrates the potential of heterochromatin 
formation over the gene in case of a GAA expansion (Fig. 10). In this case, only a 
proportion of cells might be able to fully transcribe FXN, ultimately leading to the 
severe decrease in FXN levels. Such differences between patients may reflect 
different stages in the evolution of the disease and/or different extents of variegation.  
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The elevated levels of H4K16ac detected in cases with an abnormal GAA repeat 
expansion may occur as a physiological response to overcome the triplex structure 
provoked by the expanded GAA repeats (Jain et al., 2002; Mariappan et al., 1999). 
As previously discussed in the introduction, chromatin can be severely modified by 
the neutralization of the lysine charge through acetylation, thereby alleviating 
chromatin decondensation by increasing the accessibility to the nucleosomal DNA 
(Annunziato and Hansen, 2000; Kouzarides, 2000). In contrast to H3 acetylation, 
ensuring the proper control of gene expression, the acetylation of H4K16 seems to 
be more important for the chromatin structure and the regulation of the DNA topology 
(Chiani et al., 2006; Shogren-Knaak et al., 2006; Vaquero et al., 2007). Additionally, 
H4K16ac antagonizes certain residues connected to inactive chromatin marks, such 
as H3K9me3 (O’Neill et al., 2006; Vaquero et al., 2004).  
 
Moreover, H4K16 acetylation has also been linked to DNA repair. DNA double strand 
breaks (DSB) can be repaired via homologous recombination and non-homologous 
end joining (Kruszewski and Szumiel, 2005; Murr et al., 2006; Pollard et al., 2007). 
Importantly, following DNA damage, acetylation occurs at specific residues of histone 
H4 such as K16 (Murr et al., 2006). In spite of this, these modifications are not 
involved in the repair process per se, but instead facilitate DNA repair by globally 
relaxing the chromatin, thereby allowing improved access to the repair machinery 
(Vaquero et al., 2007). Since GAA repeats and DNA triplexes have been reported to 
be prone to recombination events (Panyutin and Neumann, 1994; Panyutin et al., 
2005; Ziemba et al., 2001), and triplet-repeat instability has been shown to be 
dependent on DNA repair pathways (Collins et al., 2007; Pollard et al., 2007), one 
can speculate that the “DNA damage response machinery” may be recruited to the 
FXN locus in FRDA patients. Furthermore, recent experiments in E. coli showed the 
involvement of RecA-dependent pathways in ensuring the integrity of expanded GAA 
repeats (Pollard et al., 2007). RecA is responsible for the post-replicative DNA repair 
(Spies and Kowalczykowski, 2006). Consequently, to secure further mitosis events 
the acetylation of H4K16 at the FXN locus of FRDA patients may be triggered in 
order to allow access for DNA repair and/or protection for the unusual chromatin 
structure (Pollard et al., 2007).  
 
In contrast to the early-stage GM15 cell line, the late-stage FRDA patient GM16 cell 
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line lacked elevated H4K16ac marks, even with similar GAA repeat length (Fig. 10). 
Despite the similarity in repeat length, the chromatin situation may be different due to 
the low rate of expression occurring at the FXN locus. The phenomenon of 
heterochromatin at satellite repetitive DNAs may explain the difference between 
these two cell lines. Satellite repeats are usually predominantly heterochromatic, 
rarely transcribed and potentially prone to homologous recombination and non-
homologous end-joining events (Warburton et al., 1993). These threats to DNA 
integrity are thought to be prevented by the establishment of heterochromatin (Yunis 
and Yasmineh, 1971). Since the GM16 cell line also displays a disturbed RNA pol II 
pausing site, this may lead to a lack of sufficient transcription and subsequently allow 
the formation of heterochromatin indicated by elevated H3K9me3 levels over the 
expanded GAA repeat, thereby possibly preventing further DNA damage at the FXN 
locus (Fig. 10).  
 
Consequently, the DNA damage response machinery would target a GAA repeat 
expansion only if FXN is frequently transcribed. As this does not seem to be the case 
for GM16, this specific DNA protection mechanism would not be recruited and the 
second protective mechanism “heterochromatinisation” would take precedence in 
order to assure DNA integrity (Fig. 10). This model may also explain the 
phenomenon observed by Saveliev et al., (2003). Their repeat expansion was 
located downstream of the human CD2 transgene, and since these repeats were 
probably not transcribed they were therefore able to initiate heterochromatin 
formation (Saveliev et al., 2003).  
 
It is noteworthy that in primary cells of FRDA patients a lack of H3K4me2 levels 
downstream of the pausing site has not been detected to date (Fig. 19). This may 
indicate a very late event rather than a predisposition for the FRDA onset or severity 
of the disease (Fig. 10). Since a transcription coupled repair mechanism was 
previously shown (Andressoo and Hoeijmakers, 2005), it seems possible that the 
RNA pol II itself serves as a tool for recognising DNA damage. Interestingly, the 
inhibition of elongation via DRB and Tranylcypromine treatment in the FRDA GM15 
patient cell line (Fig. 39 + 46) induced an increase of H3K9me3 levels. Again this 
suggests that the activation of the DNA damage response machinery at FXN largely 
depends on the elongation activity of the RNA pol II. If this crucial factor is missing at 
the FXN locus, a GAA expansion has the potential to establish inactive chromatin 
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marks such as H3K9me3 (Fig. 10), possibly in order to prevent further DNA damage. 
However, this scenario seems to be an upstream event depending on the missing 
elongation rather than the prevention of RNA pol II elongation because of existing 
heterochromatin.  
 
Notably, the levels of H3K4me2 and me3 observed at the beginning of FXN 
correspond to the length of GAA repeats (Fig. 20). Therefore, it is possible that a 
certain number of factors belonging to the DNA damage response machinery are 
recruited to the FXN locus, equivalent to the length of the GAA repeat. This in turn 
would lead, depending on the length of the GAA repeat, to a slowing down of the 
RNA pol II elongation. This may increase the probability of the methylation of H3K4 
through Set1 (Santos-Rosa et al., 2002), leading to the observed repeat dependent 
increase of H3K4me2 levels (Fig. 20). Interestingly, a persistently stalled RNA pol II 
can result in either arrest of the cell cycle or pre-programmed cell death (Laine and 
Egly, 2006; van den Boom et al., 2002). This phenomenon may be one explanation 
for the progressive duration of FRDA, since in certain cell types, the problem of 
stalled RNA pol II at the GAA repeat may eventually lead to cell death, resembling 
the typical symptoms and features of ataxia (McLeod, 1971).  
 
The proven increase of DNA methylation (Greene et al., 2007) at certain FXN areas 
of FRDA patients may be a further measurement of DNA protection to prevent mis-
segregation or recombination events at GAA repeat expansions. The treatment of 
EBV-cell lines with the DNA methylation inhibitor 5-aza-2-deoxycytidine resulted 
typically in a decrease of ~ 40 % of FXN mRNA levels, and this may indicate the 
importance of certain amounts of DNA methylation at specific sites (Fig. 34). 
However, since 5-aza-2-deoxycytidine acts genome-wide (Ballestar et al., 2006) the 
detected down-regulation may also be secondary and be provoked by other factors 
influencing the regulation of FXN.  
 
In addition to the differences seen in the chromatin structure around the expansion of 
GAA repeats the early stage FRDA GM15 patient cell line also displayed increased 
NELF-E, CTCF and LSD1 levels compared to the control GM14 cell line at the 
RNA pol II pausing site (Fig. 12 + 30 + 40). The increase of NELF-E may be caused, 
as explained earlier, either by an additional amount of FXN intronic RNA which may 
or may not include the abnormal GAA repeat expansion, or may simply be due to the 
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presence of acetylated H4 due to the GAA repeat expansion. However, to fully 
explain the presence of LSD1 at the pausing site (Fig. 30) in EBV-cell lines, one has 
to consider the results obtained following the 24 h Tranylcypromine treatment.  
 
Here, the most dramatic effect of Tranylcypromine treatment on FXN mRNA levels 
was seen in the FRDA GM15 cell line (minus ~ 80 %) compared to the control GM14 
(minus ~ 20 %) and the FRDA GM16 cell line (minus ~ 40 %) (Fig. 49). Furthermore, 
a severe increase in NELF-E levels over the pausing site was shown in all three 
EBV-cell lines (Fig. 45). Noteworthy is that the control GM14 cell line showed the 
highest increase despite the smallest effect seen on the mRNA level (Fig. 49). Since 
the elongation of the control GM14 cell line did not seem to be drastically affected, 
the NELF-E binding may partly depend on the transcribed FXN RNA. Here, again, in 
the case of lacking LSD1 activity a balancing mechanism was seen via the additional 
recruitment of NELF-E to the pausing site (Fig. 45).  
 
Importantly, the inhibition of LSD1 led to a severe increase of H3K9me3 levels 
around the GAA repeat expansion in GM15 that was not seen in the control GM14 or 
the FRDA GM16 cell line (Fig. 46). However, the actual mechanism leading to this 
phenomenon is not easy to analyse. Two possibilities seem fitting. Firstly, the 
missing LSD1 activity at the pausing site may lead, to a disruption of the RNA pol II 
release, depending on the GAA repeat expansion. Thereby the missing RNA pol II 
elongation promotes the establishment of heterochromatic marks at the GAA repeat 
expansion in order to prevent possible DNA damage. However, this scenario seems 
not entirely convincing considering that the elongation of the control GM14 cell line 
was hardly affected by LSD1 inhibition, despite the increase of H3K4me2 at the 
pausing site. Here, a reasonable, although slightly delayed elongation was detected 
by the measurement of FXN mRNA levels (- 20 %) (Fig. 49) possibly via increased 
NELF-E levels. Therefore the second possibility gains more weight, where the 
inhibition of LSD1 may lead to the inactivation of its second crucial task, the 
demethylation of H3K9 at the expanded GAA repeat (Fig. 10). This may occur during 
RNA pol II elongation in order to allow the establishment of chromatin relaxing 
histone marks such as H4K16ac (Fig. 10).  
 
Noteworthy is that following DRB treatment the amount of RNA pol II S5 at the 
pausing site of GM15 was slightly increased following the establishment of 
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heterochromatin when compared to the control GM14 (Fig. 36). This may additionally 
indicate a delay or disturbance of the switch from initiated (S5) to efficient elongation 
(S2 phosphorylation) of RNA pol II in case of present heterochromatic marks. 
Therefore, the unusual chromatin structure may prevent the escape from the pausing 
site and its efficient elongation as seen in the FRDA GM16 cell line by preventing this 
crucial step at the pausing site (Fig. 10).  
 
Moreover, the FRDA GM16 cell line displays elevated LSD1 levels around the site 
where H3K9Kme3 occurs, however, for some reason the potential demethylation is 
not sufficient, and may also depend on the transcriptional rate. Unexpectedly, 
following Tranylcypromine treatment the amount of LSD1 increased in all three EBV-
cell lines at the FXN locus, however the FRDA GM16 cell line shows an approximate 
threefold increase whereas the other two show roughly double the amount (Fig. 47). 
This raises the question whether LSD1 is fully functional in this cell line and the noted 
chromatin modifications of GM16 may be due to deregulation or dysfunction of LSD1. 
Furthermore, only GM16 displays an additional peak for the demethylase JARID1b at 
the pausing site (Fig. 39) that may be triggered through a missing demethylase LSD1 
activity in this cell line (Fig. 47). However, another possibility for elevated levels of 
H3K4me2 at the pausing site of GM16 may occur in order to recruit more RNA pol II 
to overcome the present heterochromatic state (Fig. 10).  
 
By measuring the levels of transcribed 5’ UTR of FXN, it was shown that the FRDA 
patient GM15 cell line displayed ~ 2.2 fold of the control GM14. Since this method 
measures mRNA as well as primary transcript this result is surprising since FXN 
mRNA level of GM15 are considerably lower (Fig. 13). Therefore, this may be due to 
the more severe RNA pol II pausing or its delayed release from exon 1. This also 
indicates some sort of protection for the 5’ UTR-RNA in the case of the paused 
RNA pol II (Fig. 10). Interestingly, the very low expressing GM16 cell line showed 
only 60 % of the 5’ UTR levels present in the control GM14 cell line, suggesting two 
things. Firstly, the disrupted RNA pol II pausing site (Fig. 10) leads ultimately to less 
initiation of RNA pol II demonstrated via decreased levels of 5’ UTR-RNA. Secondly, 
the 5’ UTR present at the cytoplasmic mRNA may not be as stable or long-lived as 
the primary transcript 5’ UTR present in the nucleus, since GM16 displays merely 
10 % of the mRNA level that GM14 does, but still exhibits nearly 60 % of the 
measured 5’ UTR (Fig. 13).  
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A delay in the release of the RNA pol II pausing site in the presence of a GAA repeat 
was also demonstrated via primary transcript RNA-FISH (Fig. 17). Since primary 
transcript RNA-FISH represents a snapshot of the actual transcription at a certain 
point in time, the observed differences between the control individual and the FRDA 
heterozygous and homozygous individuals are helpful (Fig. 17). Here, RNA-FISH 
experiment were performed on cells of a heterozygous and homozygous carrier for a 
GAA expansion, hybridized with a probe that recognises primary transcripts 3’ of the 
pausing site. Both types showed a bi-allelic expression and roughly the same amount 
of cells displaying two signals (50 %) (Fig. 17). Since both types display different 
amounts of FXN mRNA levels (Fig. 33) this suggests that although the RNA pol II 
release may be affected in both cases, the elongation through the expanded GAA 
repeat is a crucial impediment to the ultimate amount of cytoplasmic mRNA.  
 
A similar finding was observed for the RNA pol II ChIP experiment were both 
individuals presented an equally disturbed pattern over the pausing site (Fig. 19). 
However, 3’ of the GAA repeat expansion the situation changed again, and as 
expected, the heterozygous individual showed less cells that did not express FXN 
(41 % versus 51 %) and had a higher percentage of cells possessing one or two 
signals (Fig. 17). This possibly accounts for the undisturbed elongation through the 
unexpanded allele following the delayed release of the RNA pol II pausing site.  
 
Furthermore, the DRB treatment performed substantiates the idea of a delay of 
RNA pol II pausing release depending on the GAA repeat expansion (Fig. 35 to 42). 
Here, the largest effect on FXN mRNA levels is seen in the control GM14 cell line 
(minus 40 %) (Fig. 42) whereas the FRDA GM15 cell line merely displayed a 
decrease of 18 %. Unexpectedly, after a 5 h inhibition of RNA pol II S2 
phosphorylation, the patient cell line GM15 still exhibits a reasonable amount of 
RNA pol II S2 (Fig. 35). The obvious explanation may be that after a 5 h period the 
lack of elongation is not as dramatic in the patient cell line when compared to the 
control GM14 cell line, since the RNA pol II S2 escape occurs to a lesser extent to 
begin with. Moreover, in contrast to the control GM14 line (Fig. 35), the pool of 
elongation competent S2-phosphorylated RNA pol II is still available and no 
adequate H3K4me2 levels are detectable, which would indicate elongation 3’ of the 
pausing site. This may however be explained by the severe increase in the negative 
elongation factor NELF-E seen occurring predominantly in the GM15 cell line 
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(Fig. 37), thereby possibly hampering the release of the RNA pol II S2 (Fig. 35). 
Since GM15 also shows an increase in levels of RNA pol II S5 at the pausing site 
(Fig. 36), the pronounced H3K4me2 peak (Fig. 38) might occur through the additional 
targeting of Set1-like enzymes to the pausing site. These observations may also 
partly explain the observed H3K4me2 pattern in the presence of very little FXN 
mRNA as seen in GM16 (Fig. 8), where a redirection of Set1 methylation to the 
pausing site seems possible (Fig. 4).  
 
Apparently, the FXN regulatory element is able to counteract chromatin or expression 
changes via various factors to balance these at the FXN locus. This was also seen 
following Nicotinamide treatment (Fig. 30). Here, the FRDA cell lines showed not only 
a slight increase in RNA pol II and FXN mRNA levels but also increased levels of 
NELF-E, MECP2 and LSD1 at the pausing site (Fig. 28 + 30). As discussed earlier 
one possibility is that NELF-E responds sensitively to increased H4 acetylation. 
Therefore, the relatively minor increase observed in NELF-E levels following 
Nicotinamide treatment may be due to the little changed H4K16ac state (Fig. 28). 
More surprising, the FRDA GM15 cell line lost the pronounced H3K4me2 mark 3’ of 
the pausing site, accompanied by a binding of the demethylase JARID1 within the 
pausing site (Fig. 31). This indicates that the FXN locus possessing expanded GAA 
repeats is particularly sensitive to increased transcription rate or additional chromatin 
change mediated via a sirtuin inhibitor such as Nicotinamide. In this case an 
additional factor such as JARID1b is recruited (Fig. 31) and potential positive effects 
may get cleared. This result might also explain the rather poor increase in FXN levels 
after exposing EBV and primary cells to HDAC inhibitors in general (Gottesfeld, 
2007; Grant et al., 2006; Hebert and Whittom, 2007; Sarsero et al., 2003).  
 
 
Summary 
It seems likely that in the case of an abnormal GAA repeat expansion occurring in 
FRDA patients, two events influence the transcription of FXN. Firstly, in the presence 
of a correctly functioning RNA pol II pausing site with a relatively frequent 
transcription rate, an open chromatin structure is established (Fig. 10). Thereby, 
access for the binding of proteins belonging to the DNA damage response machinery 
may be allowed in order to secure the integrity of the GAA expansion. This in turn 
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potentially slows down the RNA pol II elongation, however H4K16ac seems to be a 
sign of successful DNA repair (Murr et al., 2006), assuring the integrity of the DNA 
and allowing RNA pol II elongation even if at a slower speed. Secondly, the 
regulatory element represented by the RNA pol II pausing site seems to be 
additionally negatively influenced by the presence of a GAA repeat expansion. This 
may be triggered either via the abnormal chromatin structure and/or the occurring 
primary RNA transcript bearing the expanded GAA repeats. Therefore, initially a 
severe delay in RNA pol II release from the pausing site and subsequently an 
additional slowing down of the RNA pol II occurs through the expanded GAA repeats. 
These two events together lead to the observed severe drop in FXN mRNA levels 
(Fig. 8). Therefore, the RNA pol II pausing site may be a more suitable target for 
possible treatments for FRDA since the chromatin of the repeat probably should not 
be changed and furthermore the chromatin structure and/or the RNA of the GAA 
repeat itself might influence this regulatory element.  
 
Identifying the factors and components, such as NELF-E and parts of the primary 
transcript RNA, playing a part in the orchestration of RNA pol II pausing and its 
release, may reveal a suitable and more specific drug target. Perhaps bypassing the 
inhibitory signal triggered by the GAA expansion to the RNA pol II release may lead 
to a more sufficient and stable increase in FXN levels. FRDA Acadian patients may 
be a valuable source in identifying these potential targets. This group of patients has 
a late onset with a much milder FRDA phenotype, despite long GAA repeats. 
Acadian FRDA patients may possess a disturbed feedback function on the pausing 
and release mechanism, which may allow more efficient transcription despite an 
expansion of the GAA repeat. That the sequence of the GAA repeat may indeed be 
important in regulating the RNA pol II pausing site is further suggested by the 
observation that expanded repeats bearing an interruption of (GAGGAA)65 did not 
reveal any signs of FRDA (Cossee et al., 1997).  
 
Future  
Having identified the possibly crucial regulatory element of FXN, in the future it will be 
necessary to purify the protein complex mediating the RNA pol II pausing, thereby 
additional drug targets may be identified to allow a more specific drug design in order 
to enhance FXN transcription.  
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However, it will be important to clarify whether proteins belonging to the DNA 
damage response machinery, such as TIP60 or TRRAP, actually mediate the 
integrity of expanded GAA repeats. Furthermore, it will be essential to investigate 
whether stalling of the RNA pol II at the GAA repeat expansion indeed triggers 
apoptosis under certain circumstances. This scenario may be true for specific cell-
types or certain transcription rates of FXN, and has to be investigated in detail in 
order to identify whether this phenomenon can be prevented in any way. This is a 
crucial point since apoptosis of the cell would be triggered because of the GAA 
repeat expansion, even if the lack of FXN would be supplemented e.g. via viruses 
possessing FXN. 
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Materials and Methods 
General techniques 
Deionised water (18.2 MΩ) was used to prepare all stock solutions and reactions. 
The only exceptions were fluorescence in situ hybridisation and RNA experiments 
where RNase-free sterile distilled water was used (BDH). All reagents were 
purchased from Sigma and all solutions and reactions were made up in water unless 
otherwise stated. All small volume centrifugation steps were carried out at room 
temperature using a desktop centrifuge (Eppendorf) and at 4°C in a refrigerated 
centrifuge (Beckman). A refrigerated centrifuge (Heraeus 1.0R) was used for larger 
universal and falcon tubes. DNA containing solutions were stored at -20°C in the 
short term and at -80°C in the long term. Solutions containing RNA were generally 
snap frozen and stored at -80°C. Mouse tissues were stored at -80°C. All antibodies 
were stored for short term at 4°C and long term at -20°C - if necessary in the dark. 
Oligonucleotide primers were obtained from SigmaGenosys, and stock solutions 
(100 µM) and aliquots (10 µM) were stored at -20°C. Commonly used solutions and 
buffers are shown below 
 
5x TBE    450 mM Trisborate, 10 mM EDTA 
 
10x TAE    400 mM Trisacetate, 10 mM EDTA 
 
20x SSC    3 M NaCl, 0.3 M sodium citrate 
 
10x TE     100 mM Tris-HCl, 10 mM EDTA 
 
100x Denhardt’s solution  2% (w/v) BSA, 2% (w/v) Ficoll 400, 2% (w/v) 
polyvinylpyrrolidone 
 
Phenol:chloroform:isoamylalcohol 25:24:1 equilibrated with 10 mM Tris-HCl, 
pH 7.5 
 
PBS (phosphate buffered saline)  171 mM NaCl, 3.3 M KCl, 10.1 mM Na2PO4, 
1.8 mM KH2PO4 
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Lysis solution 100 mM Tris-HCl pH 5.5, 5 mM EDTA, 
200 mM NaCl, 0.2 % (w/v) SDS 
 
LB-broth 1 % (w/v) bactotryptone, 0.5 % (w/v) bactoyeast 
extract, 1 % (w/v) NaCl 
 
LB-agar L-broth with 1.5 % (w/v) bactoagar 
 
ChIP IP- buffer 150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 5 mM 
EDTA, NP-40 (0.5 % vol/vol), Triton X-100 
(1.0 % vol/vol). If necessary, add freshly 
prepared 0.5 µl 0.1 M PMSF in isopropanol and 
1:1000 protease inhibitor cocktail (Sigma) per 
ml IP-buffer.  
 
ChIP-beads Protein-G-Agarose / Salmon Sperm DNA 50 % 
slurry from Upstate 
 
Gel electrophoresis of DNA 
Agarose gel electrophoresis was used to separate 50 bp - 10 kb DNA fragments. 
Electrophoresis was carried out using a horizontal gel electrophoresis apparatus 
(Gibco BRL), connected to a power supply (Biorad Powerpac 300). Agarose gels 
were usually made from 0.7 - 1.2 % agarose melted in 1x TAE buffer. After the 
agarose was cooled down to ~ 60°C, 0.5 µg/ml of ethidium bromide solution was 
added and mixed well. The agarose was cast in a horizontal gel tray and wells were 
formed with a suitable comb. The electrophoresis buffer consisted of 1x TAE. DNA 
solutions were re-suspended in 1x loading buffer (0.125 % w/v orange G; 1x TAE; 
30 % glycine), prior to loading into the wells for the gel. Electrophoresis was carried 
out at 60 V. DNA size markers (DNA Ladder, Low Range or High Range and MBI 
Fermentas) were run simultaneously with the samples. DNA was visualised with a 
GelDoc 2000 (Biorad) system using Quantity One software linked to an Apple 
Macintosh G4 computer. 
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DNA digestion with restriction endonucleases 
DNA was digested with restriction enzymes using the manufacturers’ supplied 
10x restriction buffers and digestion temperatures (Boehringer Mannheim or New 
England Biolabs). Plasmid DNA was digested for one to two hours at the appropriate 
temperature, with 1x restriction buffer and 1x BSA if necessary. Generally 3 units of 
enzyme were used for each µg DNA with the volume of restriction enzyme not 
exceeding one tenth of the reaction volume. 
 
Phenol: chloroform extraction of DNA from proteins 
Proteins were removed from aqueous solutions of DNA by extraction with equal 
volumes of phenol: chloroform: isoamylalcohol (25 : 24 : 1). Centrifugation at 
12,000 g for 15 minutes at room temperature separated the phases. The aqueous 
(upper) phase was retrieved, avoiding contamination with any protein at the interface 
between the organic and aqueous phases. A further equal volume 
phenol : chloroform : isoamylalcohol 25 : 24 : 1 extraction was performed and again 
the aqueous phase retrieved. Finally the solution was extracted with equal volumes 
of chloroform to remove traces of phenol and the DNA was recovered by ethanol 
precipitation. For genotyping transgenic mice by PCR no precipitation was 
performed. One µl of the aqueous phase was used per reaction following the first 
phenol : chloroform : isoamylalcohol extraction. 
 
Precipitation of DNA 
DNA was precipitated from low salt solutions by mixing with one tenth of the volume 
with 3 M of sodium acetate (NaOAc) at a pH of 5.0 and precipitated by mixing it with 
two volumes of 100 % ethanol. Occasionally when DNA was precipitated from a large 
volume, one volume of 100 % isopropanol was substituted for absolute ethanol. The 
remainder of the procedure was identical. DNA yield was determined by 
spectrophotometry with NanoDrop (ND- 1000). 
 
Measurement of DNA concentration  
The concentration of DNA in an aqueous solution was determined by the absorption 
of ultra violet light (UV- light) at 260 nm. As the fraction of the absorbed UV radiation 
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is directly proportional to the concentration of DNA, an optical density value (OD260) of 
1 equals a concentration of 50 µg/ml. The purity of the solution is given by the ratio of 
A260/280. This ratio should be around 1.8. 
 
Purification of DNA from agarose gels 
DNA fragments from 120 bp to 10 kb were isolated from TAE agarose gels using the 
Qiagen-kit following the manufacturers’ instructions. The gel slice was weighed and 
dissolved at 50°C in an appropriate volume of dissolving buffer (provided with the kit). 
The DNA/agarose solution was loaded onto a microfuge spin column and spun for 
1 min at 13,000 rpm. DNA adsorbed to the column and was washed with 750 µl of 
the provided washing buffer. The DNA was eluted by adding 30 µl of water onto the 
column and incubated for 1 min at room temperature before centrifugation at 
13,000 rpm for 1 min. 
 
Transformation of bacteria and purification of recombinant DNA 
Chemically competent E. coli DH5α (Invitrogen) cells were routinely used. 50 µg/ml of 
ampicillin was used in agar plates and bacterial growth media to select for the 
pCR®4-TOPO (4.0 kb) plasmid.  
2 µl of the ligation reaction were mixed with 25 µl of competent cells (Invitrogen) and 
kept on ice for 30 minutes. The cells were heat shocked at 42°C for 30 seconds, 
followed by the addition of 250 µl of SOC-medium and incubated at 37°C for 1 hour. 
Cells were plated onto LB-agar plates containing ampicillin and incubated at 37°C 
overnight. Single colonies were picked, inoculated into 3 ml of LB-broth containing 
ampicillin and again cultured overnight at 37°C. 
 
Extraction of total RNA with Trizol (Invitrogen) 
Total RNA was extracted from human lymphocytes and mouse tissues using Trizol. 
~106 cells were washed in PBS by centrifugation at 1,300 rpm for 7 minutes at 4 °C. 
The cell pellet was gently loosened and resuspun in 1 ml of Trizol. Lymphocytes 
were homogenised by pipetting up and down, mouse tissues were homogenised by 
using the ultra-thorax. Samples were then incubated for 5 minutes at room 
temperature. 200 µl Chloroform per 1 ml Trizol was then added and samples were 
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vigorously shaken for at least 15 seconds and incubated for further 2 to 3 minutes at 
room temperature. Samples were centrifuged at 12.000 g for 15 minutes at 4°C. The 
upper aqueous phase was then transferred into a fresh tube and 500 µl Isopropyl 
alcohol (per 1 ml Trizol) was added. Samples were incubated at room temperature 
for 10 minutes and again centrifuged at full speed for 10 minutes at 4°C. The RNA-
pellet was washed once with 1 ml of 75 %-ethanol (DEPC-water) and centrifuged at 
7.500 g for 5 minutes. The RNA pellet was briefly dried for 5 to 10 minutes and re-
spun in DEPC-water. Samples were stored at -80°C.  
 
Complementary DNA (cDNA) amplification (RT-PCR) 
For the reverse transcription reaction, ~5 µg of RNA were mixed with 1 µl of random 
primers (hexamers), 1 µl dNTP and water to obtain a final volume of 12 µl. The mix 
was heated up to 65°C for 5 minutes and immediately chilled on ice. Afterwards, 8 µl 
of well vortexed 4 µl 5x first strand buffer, 2 µl DTT and 1 µl RNasin were added. The 
mixture was then incubated for 2 minutes at 25°C. To start the reaction 1 µl of 
ThermoScript II (Invitrogen) was added and incubated for 10 minutes at 25°C, 
followed by 1 hour at 50°C. To neutralise the remaining RNA, 2 µl of RNase H 
(10 units) was added followed by an incubation at 37°C for 30 minutes. To inactivate 
RNase H the samples were incubated for 5 minutes at 85 °C and then kept at -20 °C.  
 
EBV-transformed cell lines 
Lymphoblastoid cell lines were obtained from Coriell Cell Repositories4 that had been 
established by Epstein-Barr virus transformation of peripheral blood mononuclear 
cells using phytohemaglutinin as a mitogen. The basic culture conditions for 
lymphoblasts were 15 ml of RPMI 1640 Medium (plus 2 mM of L-glutamine, 15 % 
heat inactivated fetal calf serum (FCS), and 100 µg/ml of Penicillin/Streptomycin 
(GIBCO) in T25 tissue culture flasks. 
 
GM14926: healthy individual, male, 38, Caucasian.  
GM15850: early onset not specified, blood sample taken at the age of 13, GAA 
repeats (650/1030), male, Caucasian.  
                                                
4 http://locus.umdnj.edu/nigms/nigms_cgi/quick.cgi 
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GM16234: onset at 20 years, blood sample taken at the age of 39, GAA repeats 
(580/1030), female, Caucasian. All stated repeat lengths are published by Coriell, 
and were determined by southern-blot analysis. 
 
EBV transformation of blood 
The patients’ blood was diluted 1:1 with RPMI (+ 20 % heat inactivated FCS) and 
carefully layered over 15 ml of Ficoll-paque in a 50 ml universal tube (ethical 
approval is in place). The blood was then continuously centrifuged at 2,000 rpm for 
20 minutes. The lymphocyte layer was carefully removed with a sterile plastic pipette. 
The lymphocytes obtained were washed twice with RPMI (+10 % FCS), first at 
1,800 rpm for 4 minutes and a second time at 1,200 rpm for 4 minutes. After the 2nd 
centrifugation the lymphocytes were counted and re-spun with an aliquot of EBV-
virus. The suspension was incubated for 1 hour at 37°C in a water bath. The cells 
were then distributed between the wells of a 24-well plate at approximately 2x 106 
cells/well in a volume of 1.5 ml/well with 10 µg/ml of PHA (1 % of the final 
concentration of a previously prepared 1mg/ml stock). The cells were cultured and 
split as required. Usually it took at least 8 weeks till enough cells were grown in order 
to store them in liquid nitrogen for future experiments.  
 
Preparation of EBV-virus suspension 
A vial of B95-8 marmoset cell line was thawed in a 37°C water bath and transferred 
to a 15 ml test tube. 10 ml of medium RPMI (+ 20 % FCS) was added a drop at a 
time. The cells were then centrifuged at 800 rpm for 5 minutes, the supernatant was 
removed and the cells washed again. Afterwards the cells were re-spun in 50 ml of 
medium (+10% FCS) and transferred into a 75 cm2 flask. The cells were then grown 
to a high density and the medium was changed within 2 days. Finally the flask was 
cultured for 7 days until the medium was bright yellow. The cells were then 
centrifuged at 1,200 rpm for 5 minutes and the supernatant was filtered through a 
0.22 µm filter into freezing vials. The vials were frozen in liquid nitrogen and the cells 
were frozen separately in 107 cells/vial according to the cell freezing protocol.  
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Freezing cells 
For the freezing of cells, 1.5 ml of 10 % DMSO in RPMI and 30 % FCS were added 
drop wise with constant agitation to the re-spun cell pellet (25 cm2 flask). The cell 
suspension was dispensed into labelled freezer vials and placed into “Mr. Frost”. 
Cells were stored for at least 3 days at -80°C and then transferred into liquid 
nitrogen.  
 
FICOLL for lymphocyte extraction of human blood 
To separate lymphocytes from human blood, 15 ml of Ficoll was placed in a 50 ml 
Falcon tube and topped up with 30 ml of whole blood/PBS suspension. The 
suspension was spun at 1,500 rpm for 20 minutes at room temperature. The top 
layer was discarded and the inter-phase containing the lymphocyte layer were 
transferred into a 15 ml Falcon tube containing 5 ml of pre-warmed PBS/10% FCS 
and centrifuged at 1,200 rpm for 5 minutes. The lymphocyte pellet was washed twice 
in 10 ml 1x PBS at 4°C. Finally the cells were suspended in 1 ml PBS and 
immediately spotted onto poly-L-coated slides. 
 
GAA-genotype human 
In order to differentiate between heterozygous and homozygous samples a PCR 
reaction with the Expand High fidelity Kit (Roche) was performed. All steps were 
done on ice. First Mix1 was set-up containing 1 µl NTP’s, 1 µl Primer Left, 1 µl Primer 
Right, 0.8 µl DNA and 22.2 µl H2O, per reaction. Mix1 was vortexed briefly and the 
Mix2 was prepared to contain 19.25 µl H2O, 5 µl Buffer and 0.75 µl enzyme. After 
slight vortexing Mix2 was added onto Mix1 and again mixed. The program was 
performed as followed: 94°C for 2 min; 10 cycles of 94°C for 15 sec, 53 °C for 
30 sec, 68°C for 4 min; 20 cycles of 94°C for 15 sec, 58°C for 30 sec, 72°C for 4 min; 
72°C for 7 min; 12°C indefinitely. Primer Left: ACTTTGGGAGGCCTAGGAAG  
Primer Right: TCCAGAGATGCTGGGAAATC 
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Primary transcript RNA FISH in situ hybridisation 
Fixation of cells for RNA in situ hybridisation 
Two small spots (~ 15 µl) of a single cell suspension were immediately pipetted onto 
poly-L-coated slides. The cells were allowed to settle for 90 seconds and carefully 
transferred into fixative.  
The fixation-tray (22.5 cm x 40 cm) was filled with 500 ml of Fixation solution (4 %-
formaldehyde, 5 % acetic-acid in normal saline). 
After 17 minutes fixation, slides were washed three times in 3 different Coplin jars in 
1x PBS for 5 minutes each. After washing, slides were dehydrated for 5 minutes in 
70 % ethanol (DEPC) and stored in 70 % ethanol at -20°C.  
 
Protocol for preparation of single-stranded DIG-labelled DNA probes for 
RNA-FISH 
300 µg of plasmid DNA was linearised in a volume of 300 µl containing 100 units of 
the appropriate restriction enzyme for 2.5 hours at 37°C. The digest was analysed on 
an agarose gel and the DNA extracted with the Qiagen Extraction-Kit according to 
manufacturer’s instructions. The DNA was re-spun in 100 µl RNase-free water.  
For the in vitro transcription, 10 µg DNA, 10 µl of rNTP’s (100 mM), 29 µl water, 20 µl 
5x T7 buffer, 1 µl RNasin and 10 µl of either T3 or T7 polymerase were mixed and 
incubated at 37°C for 4 hours. After incubation 2 µl of DNase I (20 units) were added 
and incubated for 20 minutes at 37°C. To extract the RNA, 40 µl of 6.6M NH4Ac and 
140 µl phenol/chloroform (pH 4.5) were added. The mixture was carefully vortexed 
and centrifuged at full speed for 10 minutes. After centrifugation most of the soluble 
phase was removed and the remaining back-extracted with an additional 30 µl of 
water. The ‘back extract’ and the soluble phase were combined and chloroform 
extraction performed. To precipitate the RNA 425 µl ice cold ethanol was added to 
the soluble phase and incubated overnight at –20°C. After incubation the RNA was 
spun at 13,000 rpm (4°C) and the pellet washed once with 70 % ethanol (DEPC-
water), the pellet was briefly air-dried and dissolved in 100 µl DEPC-water. An aliquot 
was run on an agarose gel to ensure the RNA was intact and the OD was measured 
to check purity and concentration. 
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Reverse transcription reaction  
For the reverse transcription reaction ~5 µg of RNA was mixed with 0.5 – 1.5 µl of 
random primers (hexamers) and 7.3 µl dNTP-dDIG (or later dUTP-FITC, dUTP-
Tetramethylrhodamine) Water was added to obtain a 12 µl final volume. The mix was 
heated up to 65°C for 5 minutes and immediately chilled on ice. Afterwards, 4 µl of 
well vortexed 5x first strand buffer, 2 µl DTT and 1 µl RNasin were added. The 
mixture was then incubated for 2 minutes at 25°C. To start the reaction 1 µl of 
ThermoScript II (Invitrogen) was added and incubated for 10 minutes at 25°C, 
followed by 1 hour at 50°C. To neutralise the remaining RNA, 2 µl of RNase H (10 
units) was added followed by incubation at 37°C for 30 minutes. If the cDNA was 
labelled for an RNA-FISH probe, the probe was purified using the Qiaquick 
Nucleotide Removal Kit and eluted into 50 µl ddH2O.  
 
Prehybridisation treatment 
Slides were equilibrated for 5 minutes in 70 % ethanol followed by 5 minutes 
equilibration in 0.1 M Tris-HCl (pH 7.5), 0.15 M NaCl (TS) at RT. To access the nuclei 
a 0.01 % pepsin digest was performed in 0.01 M HCl for 5 minutes at 37°C. Slides 
were rinsed briefly in distilled, DEPC-treated H2O, to neutralise most of the pepsin 
and fixed for 5 minutes in 3.7 % formaldehyde/PBS at RT. After fixation, slides were 
washed in PBS for 5 minutes at RT and stepwise dehydrated in 70 %, 90 % and 
100 % ethanol (3 minutes each) and air-dried.  
 
Negative control 
To test if the protocol recognised RNA only, separated slides were incubated with 
100 µg/ml RNase (Roche, DNase free) in 1x PBS for 25 minutes at 37°C prior to 
hybridisation, followed by three washes of 5 minutes each and a stepwise 
dehydration as described before. 
  
Hybridisation 
The hybridisation mix contained 1-5 ng/µl of a single stranded DNA probe. With 
slides lying flat, the hybridisation mix with the denatured probe was applied 
immediately, adjacent to the spot of cells (40 µl). The slides were gently covered with 
cover slips and incubated in a humidified chamber (2x SSC plus 25 % formamide) at 
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37°C over night. After incubation cover slips were removed by dipping the slides 
briefly in 2x SSC. The slides were then washed three times for 10 minutes in pre-
warmed 2x SSC at 37°C. One additional wash was performed for 5 minutes in 0.1 M 
Tris-HCl, pH 7.5, 0.15 M NaCl, 0.05 % TWEEN 20 (TST) at RT.  
 
Depending on the labelling of the probe, slides were blocked pre-incubation in 0.1 M 
Tris-HCl, pH 7.5, 0.15 M NaCl, containing blocking reagent from Roche5 (TSB). 
100 µl of TSB was applied directly onto the slide while lying flat and covered with 
24 x 60 mm cover slips. Slides were incubated for 30 minutes in a humidified 
chamber (TS soaked paper) at room temperature. After removing the cover slip and 
the excess blocking solution the first primary antibody diluted in 100 µl of TSB was 
applied, covered with a cover slip and incubated in a humidified chamber for 
30 minutes at room temperature. After incubation, slides were washed twice for 
5 minutes in TST at room temperature, followed by application of the secondary 
antibody diluted in 100 µl of TSB and covered with cover slips and incubated in a 
humidified chamber for 30 minutes at room temperature. After applying and 
incubating all necessary antibodies, slides were washed twice for 5 minutes in TST at 
room temperature followed by 10 minutes DAPI-staining in TST- solution. Slides were 
again washed for 5 minutes in TST and washed for 5 minutes in TS at room 
temperature. Finally the slides were stepwise dehydrated in 70 %, 90 %, 
100 % ethanol (3 minutes each) and air-dried. Mounting media was applied and 
sealed-in with a coverslip. 
Slides were analysed with a Delta-vision microscope set-up from Olympus and 
images were processed with SoftWorX software. Slides were stored at 4°C for up to 
6 months. 
 
Chi-square test 
A very quick and simple statistical test to determine the probability of the obtained 
results by chance, under a specific hypothesis, is the chi-square test. In this case the 
chi-square test is ideal to evaluate the statistically significant differences between 
proportions of two or more groups in a data set. For this purpose the normal 
individual is used as the standard, and the heterozygous and homozygous patient 
present the samples tested. 
                                                
5 Blocking Reagent number 1 112 589 
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χ2=  
 
By adding the obtained χ2 values for each different signal distribution reveal 
differences between groups when compared to the normal standard.  
 
Chromatin Immuno-Precipitation 
Preparation of in vivo cross-linked chromatin (Joel D Nelson et al., 2006) 
Recipes for the buffer used in the preparation and immuno-precipitation of chromatin 
are found on page 130. Cells were fixed in vivo by the addition of 40 µl of 37 % 
formaldehyde per ml RPMI-medium and incubation for 15 min at room temperature. 
The cross-linking reaction was quenched by the addition of 125 mM of glycine and 
incubated for 5 minutes. Fixed cells were then pelleted by centrifugation at 1,200 rpm 
for 8 minutes and washed twice with ice cold PBS. Cells were lysed by adding 1 ml of 
IP-buffer containing protease inhibitors, resuspending the pellet and pipetting up and 
down several times in a micro-centrifuge tube. Nuclei were then centrifuged at 
12,000 g for 1 min at 4°C and then supernatant aspirated. The nuclear pellet was 
washed again with 1 ml IP-buffer (+ inhibitors). To shear the chromatin, the washed 
pellet was re-suspended in 1 ml IP-buffer (+ inhibitors) per 10 million cells and 
sonicated for 30 minutes at a high level for 15 sec with a pause of 25 sec in ice 
water. The lysate was cleared by centrifugation at 12,000 g for 10 min at 4°C. The 
supernatant was distributed into new tubes, snap frozen and stored at -80°C. One 
vial was used for isolate all the DNA, to determine shearing efficiency and as a 
control for the amount of input DNA used in precipitation.  
 
For immunoprecipitation the antibody of choice with the recommended 
concentration was added to the chromatin and incubated in an ultrasonic water bath 
for 30 minutes at 4°C. Afterwards chromatin was spun at 12,000 g for 10 min at 4°C. 
Protein-G-Agarose beads (20 µl per IP sample) which had been washed three times, 
were added to new tubes and ~ 90 % of cleared IP-chromatin was added and 
incubated for at least 2 hours on a rotating wheel (20 to 30 rotations per min) at 4°C. 
As a control for unspecific binding, chromatin with no added antibody was added to 
the same amount of beads. Following incubation samples where washed five times 
with 1 ml of IP-buffer (without inhibitors). 
(Sample – Standard)2 
Standard 
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DNA was isolated by adding 100 µl of 10 % Chelex-100 slurry to washed IP-samples. 
Samples were briefly vortexed and boiled for 10 minutes. The boiled suspension was 
centrifuged for 1 min at 12,000 g at 4°C and 80 µl of the supernatant were transferred 
into a new tube. Afterwards 120 µl of water (NANOpure) was added to the beads, 
vortexed for 10 s and again centrifuged. This supernatant was then pooled with the 
previous one and used for further real-time PCR analysis. The purified DNA can be 
used in PCR at up to 25 % of the reaction volume.  
 
ChIP-chop assay 
The ChIP-chop assay published by Sasha Preuss and Craig Pikaard (2007) was 
slightly modified and performed as the figure below describes.  
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Figure 50: Visualisation of ChIP-chop technique. For each reaction, 100 µl post-IP chromatin was 
used. Adapted from Preuss et al., 2007.  
 
Real-time PCR analysis 
Recovered DNA was quantified by real-time PCR amplification using the Jumpstart 
SYBR Green Pre-mix kit (Sigma) and the standard curve method. A 20 µl reaction 
was set up containing 10 µl pre-mix and 100 to 200 nM primers. Standard curves (7 
points of 2- fold serial dilutions) and samples for each primer pair were set up in 
duplicate and analysed on a Chromo4 DNA engine (MRJ), running the appropriate 
Opticon acquisition and analysis software. A typical PCR program was 94°C for 
2 minutes followed by 39 cycles of 94°C for 40 seconds, 59°C for 40 seconds, 72°C 
for 40 seconds, plate read, 75°C for 1 second, plate read, 80°C for 1 second, plate 
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read, 82°C for 1 second and plate read. This program was followed by a melting 
curve analysis (74°C to 96°C, plate read every 0.2°C, 1 second hold at each 
temperature) to ensure the absence of primer dimmers and that the plate was read at 
an adequate temperature for each primer pair. The cycle threshold was arbitrarily set 
on an intersection with the linear range of the amplification curves observed on a 
logarithmic scale. The Delta-Delta CT method was used to obtain an approximate 
change in values for control versus target samples. As this method assumes that the 
reference (beta-actin for mRNA levels and GAPDH for ChIP) and target gene (FXN) 
have similar efficiencies, each designed primer pair was tested to meet this criteria. 
In case of validating mRNA levels, measurements were performed in three serial 
dilutions order to ensure accuracy. In case of validating ChIP experiments each CT 
per tested antibody was normalised against the CT of histone H3. In order to validate 
the ChIP efficiency H3 was normalised to 10 % of the Input. Furthermore, to account 
for cell line differences each patient EBV-cell line was normalised to the control 
GM14 cell line. All analysis of real-time PCR values was performed using Microsoft 
Excel software. 
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Primers 
PCR primer design 
Oligonucleotides for use in PCRs were all designed using Primer3 software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) (Rozen and Skaletsky, 
2000). 
 
Primers for human FISH probes 
Primer name Sequence Product length 
FXN probe 5’ GAA repeat Left TTCCTGGAACGAGGTGAAAC 
FXN probe 5’ GAA repeat Right CTCCGGAGAGCAACACAAAT 560 bp 
In4Probe2L TGGCAACCCGATAGCAGTA 
In4Probe2R GGGCTAGTTCATCCACCTCA 504 bp 
In3Probe3L GTGGCCACTGTCTGTGCTAA 
In3Probe3R TGATGTCTCTCCTGCCTCCCT 942 bp 
In4Probe4L CTGGGCGACAGAGTGAGACT 
In4Probe4R CTGGAGTGCAGTGGTGTGAT 863 bp 
In2Probe6L CAACAAGAAGCCACCGGTAT 
In2Probe6R CGTAGGAGAGGCTGGTTGAC 555 bp 
In1Probe7L GATGGTACCTGGTGGCTGTT 
In1Probe7R GTAGATGCAAGGGGTGGAGA 372 bp 
In3newLeft GAAGCGTGCATTTTGGATTC 
In3newRight AACCAAACGCAGCTGCTAGA 680 bp 
 
 
CD19 primer for RNA FISH on human 
Primer name Sequence Product length 
CD19 In4/5 L CTGCAATTCACAAACCCAAC 
CD19 In4/5 R CAGACTCAAAGTCCCAAGCTG 315 bp 
CD19 In7/8 L CACTCTCCTCATCCCTCCAA 
CD19 In7/8 R GAGAGGGGCATTGTAAGACG 360 bp 
CD19 cDNA L AGAACCAGTACGGGAACGTG 
CD19 cDNA R AACATTGCTCCAGAGGTTGG 741 bp 
CD19In4-5(2)L GGGCATCCTTCTTTTTCCTC 
CD19In4-5(2)r TCTCAAGGAACCGCAAGTCT 749 bp 
CD19In5-6(2)L GGCCAGTCTGACAACCATCT 
CD19In5-6(2)R GTGCCTGTAATCCAGCACT 393 bp 
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Human Primers for genotyping GAA repeats 
Primer name Sequence Product length 
GAA-PrLeft ACTTTGGGAGGCCTAGGAAG 
GAA-PrRight TCCAGAGATGCTGGGAAATC  ~250+ GAA 
Pr5ChIP_2trL GCTGCGTCTTTAACGTTTCC 
Pr5ChIP_2trR CACACTCAGCCCCTTACCAT 247 bp 
 
Human Primers for real time RNA FXN levels 
Primer name Sequence Product length 
UTR and Exon 1 Left AGCAGCATGTGGACTCTC 
UTR and Exon 1 Right CAGGTCGCATCGATGTCG 157 bp 
Exon 4 to Exon 5 Left ATCCAGTGGGGACCTAAGC 
Exon 4 to Exon 5 Right AAGGAAGACAAGTCCAG 132 bp 
Exon 1 to Exon 5 Left GACATCGATGCGACCTG 
Exon 1 to Exon 5 Right CAGTCCAGTCATAACGC 376 bp 
Exon 2 to Exon 5 Left GAACCAACGTGGCCTCA 
Exon 2 to Exon 5 Right CAGTCCAGTCATAACGC 338 bp 
Beta-actin RT Left GCGGGAAATCGTGCGTGACATT 
Beta-actin RT Right GATGGAGTTGAAGGTAGTTTCGTG 220 bp 
 
Human Primers for ChIP 
Primer name Sequence Product length 
P1 upstream FXN 6114bp Left GGGATTTCTTTTCCCCAGAG 
P1 upstream FXN 6114bp Right ACCTTGCAGGACACCAAAAC 190 bp  
P2 upstream FXN 1735bp Left CCCCACATACCCAACTGCTG 
P2 upstream FXN 1735bp Right GCCCGCCGCTTCTAAAATTC 127 bp 
CpG_1 FXN Exon 1 1322bp Left GGAGCAGCATGTGGACTCTC 
CpG_1 FXN Exon 1 1322bp Right CGGCGCGGATACTTACTG 189 bp 
CpG_2 FXN Intron 1 1006bp Left CTCCCGGTTGCATTTACACT 
CpG_2 FXN Intron 1 1006bp Right GTGACAAGCATGGAGACAGC 155 bp 
P3 FXN Intron 1 633bp Left CTGACCCGACCTTTCTTCCA 
P3 FXN Intron 1 633bp Right TGGGCGTCACCTTTATCTTC 123 bp 
P4 FXN Intron 1 383bp Left GAAACCCAAAGAATGGCTGTG 
P4 FXN Intron 1 383bp Right TTCCCTCCTCGTGAAACACC 116 bp 
P5 FXN Intron 1 241bp 3’ G Left CTGGAAAAATAGGCAAGTGTGG 
P5 FXN Intron 1 241bp 3’ G Right CAGGGGTGGAAGCCCAATAC 117 bp 
P6 FXN Intron 1 878bp 3’ G Left CCCTTGCACATCTTGGGTAT 
P6 FXN Intron 1 878bp 3’ G Right GAGAAAAGGGTGGGGAAGAG 177 bp 
P7 FXN Intron 1 5494bp 3’ G Left AGCCCCACATTCTCAGACAC 
P7 FXN Intron 1 5494bp 3’ G Right ACGCACCAAAGGGTAACTTG 172 bp 
CpG_In2 FXN Intron 2 Left ACCGTGTTATCTGCCTGC 
CpG_In2 FXN Intron 2 Right CTGGTCTGAACTCGTGAC 176 bp 
Beta-globin Exon 2 Left GCTGGTGGTCTACCCTTGGA 
Beta-globin Exon 2 Right AGGTTGTCCAGGTGAGCCAG 150 bp 
GAPDH gene Exon 4 Left CACCGTCAAGGCTGAGAACG 
GAPDH gene Exon 4 Right ATACCCAAGGGAGCCACACC 134 bp 
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Antibodies 
Antibody Company Dilution used 
RAT anti- Dinitrophenyl hapten Serotec, MCA 1212 1.25 : 1000 
FITC-donkey – anti- GOAT Jackson ImmunoResearch Number: 705-
096-147 
1:50 – 1:200 
FITC-goat - anti RAT Jackson ImmunoResearch Number: 112-
096-068 
1:50 – 1:200 
Sheep anti- Digoxigenin Roche, 1333089 1:800 
Rhodamine Red-X-conjugated 
anti- SHEEP 
Jackson ImmunoResearch Number: 713-
295-003 
1:500 
 
Antibodies for Chromatin Immunoprecipitation 
Antibody Company Concentration Amount 
used 
H3 K9 tri methyl, rabbit 
polyclonal 
Abcam, ab8898  400 µg/ml 2-4 µg per 
IP 
Anti-HP1α, mouse monoclonal 
IgG1 
Upstate, Cat. 05-689, 
Lot 30223 
0.57 µg/µl 2-4 µg per 
IP (5 µl) 
Anti-HP1γ, mouse monoclonal 
IgG1 
Upstate, Cat. 05-690, 
Lot 0608038477 
2 µg/µl 2-4 µg per 
IP (3 µl) 
Anti-H3, rabbit polyclonal IgG Upstate, Cat. 06-755 0.9 µg/µl 2-4 µg per 
IP (3 µl) 
Anti-H3 K4 di-methyl, rabbit 
polyclonal IgG 
Abcam, ab7766 0.5 µg/µl 2-4 µg per 
IP 
Anti-H3 K4 tri-methyl, rabbit 
polyclonal 
Abcam, ab8580 Concentration 
varies 
2-4 µg per 
IP 
Anti-H3 K9 di methyl, rabbit 
polyclonal IgG 
Abcam, ab7312 Concentration 
varies 
2-4 µg per 
IP 
Anti-H3 K9 acetyl, rabbit 
polyclonal IgG 
Upstate, Cat. 06-942 2 µg/µl 2-4 µg per 
IP 
Anti-H3 K9 acetyl, rabbit 
polyclonal ChIP grade 
Abcam, ab4441 1 µg/µl 2-4 µg per 
IP 
Anti-H3 S10 phospho, mouse 
monoclonal 
Upstate, Cat. 05-598, 
Lot 26436 
2 µg/µl 2-4 µg per 
IP 
Anti-H3 K14 acetyl, rabbit 
polyclonal IgG 
Upstate, Cat. 06-911,  2 µg/µl 2-4 µg per 
IP 
Anti-H3 acetyl Upstate, Cat. 06-599, 
Lot 29505 
1 µg/µl 2-4 µg per 
IP 
Anti-H4 K16 acetyl, rabbit 
antiserum  
Upstate, Cat. 07-329, 
Lot 26818 
2 µg/µl 2-4 µg per 
IP 
Anti-H4 K20 tri methyl rabbit 
polyclonal IgG 
Abcam, ab9053 500 µg/ml 2-4 µg per 
IP 
Anti-UBF Santa Cruz, SC-13125, 
Lot K0805 
0.2 µg/ml 2 µg per IP 
Anti-MeCP2, rabbit polyclonal Upstate, Cat. 07-013 2 µg/µl 2-4 µg per 
IP 
Anti-H3, rabbit polyclonal Abcam, ab1791 Concentration 
varies 
2 µg per IP 
Anti-RNA polymerase II CTD 
repeat YSPTSPS (phospho S2) 
Abcam, ab5095 Concentration 
varies 
5 µg per IP 
Anti-RNA polymerase II CTD Abcam, ab5131 Concentration 5 µg per IP 
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repeat YSPTSPS (phospho S5) varies 
Anti-SUV39H1, mouse 
monoclonal, ChIP grade 
Abcam, ab12405 2.3 µg/µl 5-10 µg per 
IP 
Anti-NELFe, sheep polyclonal Abcam, ab28038 Whole 
antiserum 
5-10 µl per 
IP 
Anti-CTCF, rabbit polyclonal Abcam, ab10571 0.3 µg/µl 15 µl per IP 
Anti-LSD1, rabbit polyclonal Abcam, ab17721 1 µg/µl  5 µg per IP 
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Abbreviations 
 
 A  adenine 
 ac  acetylated 
 AR  androgen receptor 
 ATP  adenosine 5’-triphosphate 
 BAC  bacterial artificial chromosome 
 bp  base pair 
 BSA  bovine serum albumin 
 C  cytosine 
 cDNA  complementary deoxyribonucleic acid 
 CHD1  chromodomain helicase DNA binding protein 1 
 ChIP  chromatin immunoprecipitation 
 Co A  coenzyme A 
 CO2  carbon dioxide 
 CpG  cytosine-phospho-guanine 
 CTCF  CCCTC-binding factor 
 CTD  C-terminal domain 
 DAPI  4',6-diamidino-2-phenylindole 
 ddH2O  double distilled water 
 DDR  deoxyribonucleic acid damage response 
 DIG  digoxigenin 
 DNA  deoxyribonucleic acid 
 DNase  deoxyribonuclease 
 Dnmt  deoxyribonucleic acid methyl transferase 
 DPE  downstream promoter element 
 DRB  5,6-dichloro-1β-ribofuranosylbenzimidazol 
 DSB  deoxyribonucleic acid double strand break 
 dsDNA  double-stranded DNA 
 DSIF  DRB sensitivity-inducing factor 
 dUTP  2’-deoxyuridine 5’-triphosphate 
 E. coli  Escherichia coli 
 EDTA  ethylendiamintetraacetatic acid 
 ES  embryonic stem 
 e. g.  for example 
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 EGFP  enhanced green fluorescence protein 
 et al.  et alii 
 EtOH  ethanol 
 FCS  fetal calf serum 
 Fig.  Figure 
 FISH  fluorescence in situ hybridisation 
 FITC  fluorescein isothiocyanate 
 FRDA  Friedreich’s ataxia 
 FXN  human frataxin locus 
 Fxn  mouse frataxin locus 
 G  guanine 
 GCN5  general control non-derepressible 5 
 H  histone 
 h  hour 
 HAT  histone acetyl transferase 
 HDAC  histone deacetylase 
 HDACi  histone deacetylase inhibitor 
 Het  heterozygous 
 HIV  human immunodeficiency virus 
 HKMT  histone lysine methyltransferase 
 HMT  histone methyl transferase 
 Hom  homozygous 
 HP1  heterochromatin protein 1 
 HSV-1  herpes simplex virus 1 
 i.e.  that is 
 ISC  iron sulfur cluster 
 Jmj  Jumanji 
 K  lysine 
 kb  kilobase pairs 
 kg  kilo gram 
 l  litre 
 M  molar 
 M&M  materials and methods 
 MDa  mega Dalton 
 MBD  methyl CpG binding domain 
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 me  methylated 
 mg  milligram 
 min  minutes 
 MitoQ  mitochondrial targeted Idebenone 
 ml   millilitre 
 mM  millimolar 
 mRNA  messenger RNA 
 N  adenine / cytosine / guanine / thymine 
 NELF  negative elongation factor 
 ng  nano gram 
 NMR  nuclear magnetic resonance 
 NP  neural progenitor 
 NTP  nucleotide triphosphate 
 NuRD  nucleosomal remodelling and histone deacetylase 
 NURF  nucleosomal remodelling factor complex 
 ODx  optical density at a wavelength of x nm 
 PAF  polymerase associated factor 
 PBS  phosphate buffered saline 
 PCR  polymerase chain reaction 
 PEV  position effect variegation 
 pH  pH value 
 ph  phosphorylated 
 PK  protein kinase 
 pol  polymerase 
 p-TEFb positive transcription elongation factor b 
 HxRx  histonex at argininex 
 R  purine 
 RB  retinoblastoma 
 RNase  ribonuclease  
 RNA  ribonucleic acid 
 rpm  rounds per minute 
 RT  room temperature 
 SDS  sodiumdodecylsulfate 
 sec  second(s) 
 Ser  serine 
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 SIR  silent information regulator 
 SSC  sodium chloride / sodium citrate 
 ssDNA  single stranded DNA 
 S/T  serine/threonine 
 SUMO  sumoylated 
 T  thymine 
 Tab.   Table 
 TAE  tris-acetate-EDTA-buffer 
 TE  tris-EDTA-buffer 
 Tris  tris (hydroxymethyl)-aminomethane 
 ub  ubiquitinylated 
 UTR   untranslated region 
 UV  ultra violet 
 Vol  volume(s) 
 Wt  wild type 
 Y  pyrimidine 
 YAC  yeast artificial chromosome 
 YFH1  yeast frataxin homolog 
 %  percent 
 °C  degree Celsius 
 %w/v  weight/volume 
 %v/v  volume/volume 
 
 
                                                                                                                                         
 
153 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
 
 
 
                                                                                                                                         
 
154 
Appendix 
 
Experiments on transgenic mice 
Friedreich’s ataxia is a tissue specific disease where the main pathogenic sites are 
the heart, the cerebellum, the dorsal root ganglion and the spinal cord (McLeod, 
1971). Evidently, it is difficult to obtain these affected tissues from patients. 
Therefore, a mouse model should be the ideal source to overcome this problem. As 
stated in the introduction, several mouse models are already available with each 
holding advantages and disadvantages in studying Friedreich’s ataxia. During the 
course of this project the results of a murine chromatin modification genome-wide 
mapping approach became available (Mikkelsen et al., 2007), and to complete the 
picture, the murine frataxin locus will be investigated in the following paragraph. 
 
Chromatin modifications genome wide map approach6 
In Mikkelsens et al. article, the application of single-molecule-based sequencing 
technology for high-throughput profiling of histone modifications in mammalian cells 
was the central theme. Chromatin marks such as H3K4me3, H3K9me3, H3K27me3, 
H3K36me3 and H4K20me3 were investigated on different cell types, like ES-cells, 
neural progenitor (NP) cells and embryonic fibroblasts (MEF). As a basic principal it 
was found that H3K4 and H3K27 trimethylation effectively discriminate genes that 
are expressed, poised for expression, or stably repressed, and therefore reflect cell 
state and lineage potential. The trimethylation of lysine 9 and lysine 20 was detected 
at satellite, telomeric and active long terminal repeats, being able to spread into 
proximal unique sequences. Imprinted regions were found to hold lysine 4 and lysine 
9 tri-methylation marks. Finally, they were able to show that the chromatin state can 
be read in an allele-specific manner by using single nucleotide polymorphisms.  
 
Chromatin modifications at the Fxn locus 
The transcription of the murine frataxin starts from the opposite strand of the DNA 
and the most pronounced signal of histone marks available is the H3K4me3 at the 
                                                
6Nature articles: doi:10.1038/nature06008: genome wide maps of chromatin state in pluripotent and 
lineage-committed cells, TS Mikkelsen et al., 2007  
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beginning of the gene, indicating active transcription (Bernstein et al., 2002). Since 
there are no data available for the promoter or the untranslated region, it was not 
possible to investigate this region in detail. Nevertheless, chromatin data sets for 
three different cell types of Fxn are available, showing a minor difference between all 
three cell types for the H3K4me3 mark. The signal in the more specialised NP cell 
although not as broad is equally high as in the ES cell. The H3K36me3 modification 
indicates recently transcribed chromatin (Barski et al., 2007), increases towards the 
end of the gene and does vary between all three cell lines. The H3K27me3, 
H3K9me3 and H4K20me3 modifications, indicating inactive chromatin (Barski et al., 
2007), show minor peaks throughout the gene and no significant differences between 
the three cell types. The IP data for the RNA pol II at the Fxn locus was not available. 
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Figure 51: Displayed are H3K4me3 (K4), H3K27me3 (K27), H3K36me3 (K36), H4K20me3 (K20) at 
the murine Fxn in embryonic stem cells. In general the active marks predominate versus the 
inactive ones. Position of exons is indicated in green bars, the arrows indicate direction of 
transcription. Exact position of Fxn at chromosome 19 is given in top scale.  
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The following figure 52 shows the histone modifications detected at the Fxn in neural 
progenitor cells. In general no obvious major change is detectable between these two 
cell types. 
 
 
 
Figure 52: Displayed are H3K4me3 (K4), H3K27me3 (K27), H3K36me3 (K36) and H3K9me3 (K9) of 
NP-cells. Again the active mark H3K36me3 predominates along Fxn. Position of gene is given in 
top scale, exact position of exons is given in corresponding green bars below histone diagrams.  
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The following figure 53 illustrates the same histone marks for MEF- cells. Here an 
increase in the active H3K36me3 mark is seen. However, the other available 
modifications show similar pattern to the ES and the NP cells.  
 
Figure 53: Displayed are H3K4me3 (K4), H3K27me3 (K27), H3K36me3 (K36) and H3K9me3 (K9). 
Only the active H3K36me3 mark displays slightly higher levels compared to the cell types 
introduced earlier. Again position of gene is given in top black scale, exact position of Fxn 
exons is given in green bars below.  
 
To summarise, the murine Fxn displays similar to the human, mainly active chromatin 
marks. These do vary between certain tissues to a certain extend suggesting that 
these histone modifications might play a part, or reflect, tissue-specific transcriptional 
regulation of the Fxn gene. The next section will discuss the tissue specific 
expression of Fxn in more detail.  
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Murine frataxin expression levels in different tissue types7 
The database introduced in this article, also provides information on mRNA 
expression levels obtained from the GNF expression atlas 2 (GNF1M Mouse Chip). 
For the murine frataxin mRNA the following levels were obtained and stated in the 
table below. Fxn mRNA levels are categorised into relatively high expressed (on the 
website marked in light red), moderately expressed (marked in dark red), and weakly 
expressed (marked in green). Tissues where there was no data available are marked 
in black.  
 
Relatively high 
expressed 
Moderately 
expressed 
Weakly expressed No data available 
Thymus 
B-cells  
CD8+-T-cells 
Bone 
Skeletal muscle 
Vomeronasal organ 
Placenta  
Embryo at day 6.5 
Spleen 
Bone marrow 
Heart 
CD4+-T-cells 
Thyroid  
Large intestine 
Snout epidermis 
Tongue 
Embryo at day 9.5 
Embryo at day 10.5 
Frontal cortex 
Substantia nigra 
Amygdala 
Hypothalamus 
Dorsal stratium 
Eye 
Lower spinal cord 
Dorsal root ganglia 
Lymph node 
Mammary gland 
Prostate 
Adipose tissue 
Brown fat 
Bladder 
Uterus 
Stomach 
Small intestine 
Lung 
Epidermis 
Testis 
Oocyte 
Fertilised egg 
Blastocysts 
Cerebellum 
Hippocampus 
Preoptic 
Olfactory bulb 
Upper Spinal cord 
Trigeminal 
Adrenal gland 
Pituitary 
Salivary gland 
Pancreas 
Kidney 
Liver 
Trachea 
Digits 
Embryo at day 7.5 
Embryo at day 8.5 
 
Table 6: Diverse mouse tissues show certain Fxn expression level. Data was obtained from GNF 
expression atlas 2 (GNF1M Mouse Chip) provided Mikkelsens et al. 
 
Additional information is given for developmental stage-specific expression. Here, the 
investigation of embryonic day 14.5, revealed weak expression in the spinal cord, the 
medulla oblongata, the dorsal root ganglia and the lung. At post-natal (P) day 14, the 
                                                
7 Nature articles: doi:10.1038/nature06008 
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Fxn expression in the dorsal root ganglia is restricted to the cortical region where the 
sensory neuron cell bodies are located. In non-neural tissues, a strong expression 
was seen in the developing liver from day E10.5 onwards. Moreover, murine frataxin 
expression was detected in the heart and the cortex of the developing kidney from 
day E12.5 onwards. High expression was observed in the brown adipose tissue in 
small islands around the neck and back at day E14.5, then highly abundant during 
days E16.5 and E18.5 but disappeared from the brown adipose tissue from day P14 
onwards. On day E14.5 until post-natal life, expression was also seen in the thymus 
and the developing gut. Prominent Fxn expression was found on day P14 in the 
spleen whereas in the thymus this was restricted to the proliferating cells in the 
cortical zone.  
 
From this analysis, most affected tissues in human Friedreich’s ataxia, like spinal 
cord and dorsal root ganglia, are naturally low expressed in mice. However, one 
cannot assume that the same situation is true for the human but parallels could still 
exist. For this reason the following scenarios are thinkable. The inhibiting effect of the 
expanded GAA repeat might be more severe in the case of tissues expressing at low 
levels. One can speculate that the cell should have a self-regulating ability; thus, it 
might be able to up-regulate frataxin expression in response to low protein levels. 
However, following the idea presented in the result section I and II that humans might 
possess a strict regulatory mechanism of FXN, it seems that in human this regulatory 
mechanism is not controlled by the amount of frataxin protein levels. A simple and 
very efficient regulation for the cell would therefore be a regulation controlled via the 
produced primary transcript RNA, possibly implicating the normal GAA repeat 
expansion. Consequently, an abnormal GAA expansion would greatly disturb this in 
low expressing tissues even tighter regulated mechanism, primarily affecting tissues 
with a tight frataxin regulation such as the spinal cord where only low levels naturally 
occur. Since the mouse does not exhibit a GAA repeat naturally, it seems unlikely 
that this part of the DNA or RNA plays a role in the tight regulation the normal Fxn 
regulation. Therefore in mice, although a lack of sufficient Fxn might lead to a similar 
phenotype, the underlying mechanism leading to the dramatic decrease in low 
expressing tissues might be different.  
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Homology mouse and man 
Considering the argument above, there might be an additional explanation why a 
mouse model using the murine frataxin fails to present a phenotype. Even though a 
homology on the mRNA level of ~ 85 % occurs between mouse and man, the first 
exon along with the intron does not seem to have any homology at all. Demonstrated 
in Results I and II before, the human FXN exon 1 has a rather crucial function in 
regulating gene expression as no common promoter was identified so far. Moreover, 
the GAA repeat is flanked by special sequences already implicated in the RNA pol II 
pausing. This structure along with the GAA repeat is highly conserved in primates but 
absent from mice.  
 
 
Figure 54: Homology between mouse and man is marked with red bars. Exons and introns are 
depicted only schematic not in proportion. Exon 1 and intron 1 show no homology between 
mouse and man. Homology between chimpanzee and human is marked in purple.  
 
This could indicate a different frataxin regulatory mechanism between mouse and 
man. If the normal sized GAA repeat did play a role in the human frataxin regulation, 
the mouse model might not show the same severe effects in tissues normally 
affected in FRDA patients, as the GAA repeat does not naturally contribute to the 
regulation of the murine Fxn. The observed down regulation of the murine frataxin 
would therefore purely demonstrate a hampered transcription of frataxin because of 
the introduced GAA repeat. However, this itself might not be sufficient to create a 
FRDA phenotype in mice as the additional severe reduction in humans provoked by 
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the in human occurring RNA pol II pausing possibly involving the GAA repeat site is 
missing.  
 
YAC transgenic mice with human frataxin 
Considering the earlier findings, it was decided that a transgenic mouse carrying the 
human frataxin gene with its appropriate surrounding genomic DNA sequences 
should be a good working model. These mice were obtained by introducing a GAA 
expansion into a 370 kb human genomic YAC clone, 37FA12 (Al-Mahdawi et al., 
2004) possessing the entire FXN gene with 9 GAA repeats. The human wt YAC was 
able to rescue the lethal phenotype of Fxn-/- in mice. Homologous recombination 
between a plasmid containing a GAA(230) expansion and a retrofitted YAC 37FA12 
resulted in a final modified YAC that contained GAA(190) repeats (Al-Mahdawi et al. 
2004). After microinjection, Al-Mahdawi et al. obtained a mouse having one YAC, 
including one GAA(190) expansion, called YG22. To ensure a phenotype, these mice 
should ideally be crossed with mice exhibiting a homozygous knock-out for the 
murine Fxn (Hall et al., 2002). However, RT-PCR and western blot analysis of tissues 
from both transgenic lines detected relatively high levels of human FXN mRNA and 
protein expression in all tissues studied. The following figure is exctracted from Al-
Mahdawi et al., 2004 and slightly modified (Fig. 55).  
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Figure 55: Frataxin levels of human, non-transgenic and Y22 transgenic mice. (A) Displayed are 
mouse and human frataxin mRNA levels. Mouse frataxin product has been digested in order to 
differentiate human from mouse. (B) Western blot of human and mice frataxin (Extracted from 
Al-Mahdawi et al., 2004). 
 
ChIP against histone antibodies 
In order to examine the human frataxin locus in affected tissues, chromatin 
immunoprecipitation (ChIP) was performed on formaldehyde fixed thymus, heart, 
liver and cerebellum. Liver was included as reports from collaborators (personal 
communication M. Pandolfo) mentioned liver as a tissue that expresses frataxin at a 
high level. 
 
As only limited chromatin material was available, the three histone marks H3K9me2, 
H3K4me2 and H4K16ac were investigated. Each diagram shows the results of one 
histone modification of all tissues investigated. Chromatin was extracted from tissues 
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of two mice. Each IP was measured in triplicate. Every value displayed was firstly 
normalised to H3 and then to GAPDH in order to avoid tissue specific differences. 
For better comparison, each corresponding antibody result of the human lymphocyte 
cell line GM15 is displayed in green.  
 
 
Figure 56: Histone modifications of the human frataxin transgene in different mouse tissues. 
Each value has been normalised to H3 and to GAPDH. The results of GM15 are shown in green 
for comparison. Primers for FXN are the same used for experiments performed on human 
(Fig. 6). Each tissue seems to posses its own unique histone modification pattern. 
 
The YAC human frataxin holds well presented H3K4me2 levels in all tissues 
investigated, although generally higher than the ones found in the human 
lymphocytes. However, the thymus (orange graph) displaying the organ closest to 
the human lymphocytes tested, does not exhibit a similar pattern to the GM15 cell 
line (green). Moreover, the histone modification H3K4me2 peaks strongly at the 
RNA pol II pausing site. This peak differs to the pattern obtained for GM15, perhaps 
indicating a not fully functional element in the mouse thymus. The liver (brown) 
displays even higher levels of H3K4me2 and additionally lacks the “dip” at the 
RNA pol II pausing site, which is characteristic for the human frataxin. The liver does 
show a striking drop of the positive mark after the GAA expansion. Furthermore, of all 
mouse tissues investigated, cerebellum (pink) exhibits the lowest H3K4me2 level, 
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even though these are still higher than the ones measured for the human 
lymphocytes. So far, cerebellum is the only mouse tissue investigated displaying a 
slight “dip” around the pausing site, suggesting an at least partly working RNA pol II 
pausing element in this tissue. 
 
While investigating the inactive histone mark H3K9me3 within the cerebellum, high 
levels were found with a minor increase around the GAA expansion site. This 
increase was not detectable adjacent 5’ and 3’ of the GAA expansion, excluding a 
spreading of this inactive mark from the GAA repeat into the locus. A similar even 
more pronounced increase occurred in the thymus, accompanied by a sharp drop 
after the GAA expansion. Consistent with the finding that the liver expresses Fxn 
mRNA at comparatively high levels (brown) it was found to have a lower level of the 
H3K9me3 modification which was previously associated with “silent” heterochromatin 
(Almeida R et al., 2006). 
 
Due to a lack of material the highly active mark H4K16ac was investigated only on 
liver and cerebellum. Overall the H4K16ac amounts correlate well with the levels 
obtained from the human GM15 cell line. However, as the amount of the other 
histone modifications is generally higher in the mouse context than in the human, the 
actual effect of the H4K16ac modification is presumably less pronounced in the 
mouse. Moreover, liver shows a small peak where the characteristic “dip” in humans 
occurs. Furthermore, in this context the GAA repeat does not seem to influence the 
H4K16ac level positively, most likely because the GAA expansion is not as dramatic 
as the one occurring in GM15 with over 1090 repeats. However, the cerebellum 
sample, although lacking the “dip” of H4K16ac at the pausing site, shows a slight 
increase of H4K16ac around the GAA repeat which is lost further downstream.  
 
ChIP results with DNA binding antibodies 
In order to verify if the proteins already found to bind at the first part of the frataxin 
locus in human lymphocytes were also binding at the same site of the human 
transgene in the mouse, ChIP experiments were performed using antibodies against 
RNA pol II S2, HP1γ and NELF-E. Each value obtained was normalised to H3 ChIP 
and then further normalised to murine GAPDH in order to account for tissue specific 
differences.  
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The results obtained for the antibody against RNA pol II show a peak around the 
putative RNA pol II pausing site in all tissues investigated. Nevertheless, the peaks 
obtained for the different mouse tissues are less pronounced than the ones received 
for the human GM15 and GM14 cell line. The high levels of elongating RNA pol II 
detected 5’ and 3’ of exon 1 is in accordance with the high frataxin mRNA and protein 
levels detected by Pook and colleagues (Al-Mahdawi et al., 2004). This result 
suggests that the human pausing element also accumulates RNA pol II in the mouse 
context.  
 
 
Figure 57: ChIP against RNA pol II, HP1γ and NELF-E. All values displayed are normalised to H3 
and GAPDH. Each ChIP has been performed on liver (brown), cerebellum (pink) and thymus 
(orange). Values obtained from ChIP on GM15 are displayed for comparison. As control the 
levels of NELF-E at the murine and the human GAPDH gene are shown. Primers and their 
location are shown in figure 6.  
 
The thymus (orange) shows the highest levels of elongating RNA pol II over the area 
investigated although also having the highest degree of the inactive mark H3K9me3. 
This clearly indicates the need for discussing histone mark results in the context of 
other factors, rather than studying the level of one single mark. In the mouse context 
the RNA pol II is already detected at higher levels even 6000 bp 5’ of the human FXN 
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gene UTR, compared to the results obtained in the human cell line. Despite of that, 
the pausing site seems to arrest the RNA pol II at least partly, as levels drop after the 
putative pausing site by ~ 40 %. Furthermore, 3’ of the GAA expansion, the level of 
elongating RNA pol II increased in the thymus as well as in the cerebellum. Although 
liver and cerebellum seem to hold similar RNA pol II levels along the FXN gene, the 
pausing in cerebellum seems to be more pronounced or stronger along the first CpG-
island than in the other tissues investigated. Additionally, adjacent to the GAA 
expansion, liver and cerebellum display an opposite pattern. In the cerebellum the 
level of RNA pol II 5’ of the repeat is lower than for the rest of the gene, with an 
increase 3’ of the repeat. The liver shows similar RNA pol II levels 5’ and 3’ of the 
GAA expansion, however, directly 5’ of the GAA repeat an increase of RNA pol II is 
detectable. The control gene GAPDH showed similar levels of NELF-E and 
RNA pol II on all mouse tissues examined (Fig. 56 + 57), suggesting that the 
detected significant differences in RNA pol II levels might be real.  
 
Interestingly, HP1γ ChIP results present a peak at the RNA pol II pausing site in 
cerebellum and thymus compared to the human cell lines (GM15 as example). Only 
liver shows twice the amount of HP1γ. Additionally, the HP1γ peak in thymus is 
extended across the first CpG-island. All mouse tissues reveal an additional peak 5’ 
of the GAA expansion that is not detectable in human samples.  
 
The mouse ChIP signals obtained for NELF-E exhibit similar levels to the ones 
detected in humans although each tissue seems to have its particular level. Except 
for thymus all tissues displayed a sharp peak at the pausing site, whereas liver 
shows the highest level and cerebellum the lowest. However, thymus shows a 
relatively low and broad peak around the site of RNA pol II pausing. This experiment 
might reflect tissue differences in the regulation of frataxin, but in order to estimate 
the influence of the GAA repeat, the control mouse exhibiting the YAC FXN with 
normal repeats is needed.  
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Primary transcript RNA-FISH on EBV-cells show that GAA expansion slows 
frataxin mRNA expression and reveals additional influencing factors of long 
GAA repeats (Results beginning 2005). 
 
Patients with different severities but the same GAA repeat expansion may provide an 
opportunity to identify modifying factors. Therefore, an informative patient 
combination might be two patients with different severity and onset of the FRDA 
disease but with the same GAA repeat length. As late onset FRDA patients with long 
repeats are very rare it was necessary to study EBV-transformed B-lymphocyte cell 
lines from patients exhibiting a similar repeat length but a different onset and severity 
of FRDA. In order to investigate if additional factors would influence the transcription 
process, both patient cell lines and a control cell line were hybridised with the probe 
shown in Fig. 6 recognising the RNA 5’ or 3’ of the GAA repeat.  
 
For each EBV-transformed B-cell line two independent experiments were performed. 
For each experiment two slides per cell line were processed and 60 cells per slide 
were counted. The results presented display the average percentage of all counted 
slides and the indicated error-bars show the standard deviation.  
 
In order to assess possible differences due to the presence of an expansion of the 
GAA repeat between healthy and FRDA cell lines on a single cell level, primary 
transcript RNA-FISH was performed. 
 
These results show that all three different EBV-transformed cell lines hybridised with 
the probe recognising the primary transcript RNA 5’ of the GAA expansion showed a 
similar frataxin signal distribution (Fig. 58). Whereas the bi-allelic expression showed 
the greatest variation of between 48 % and 55 %, the mono-allelic expression varied 
between 7 % and 13 % and the cells with no detectable signal showed the smallest 
variation at 37 %. However, after hybridisation with a probe recognising the RNA 3’ of 
the GAA expansion, a different signal distribution was detectable when compared to 
the 5’ result for each cell line. In cells of the control line the mono-allelic cells 
increased (19 %) and the bi-allelic expressing cells decreased (46 %), whereas the 
non-expressing cells stayed more or less the same (Fig. 58). A similar finding was 
observed 3’ of the GAA repeat (even if not expanded) when primary lymphocytes 
from a normal individual were analysed.  
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Figure 58: Primary transcript RNA-FISH. One type of cell line is displayed in each row. In each 
case the left diagram represents results obtained with a probe recognising the RNA 5’ of the 
GAA repeat whereas the right diagram displays results obtained with a probe recognising intron 
3 and 4 respectively. The dark brown column shows how frequently a cell with no signal has 
been counted. The orange column indicates cells with one signal and the yellow column 
represents cells where two signals for frataxin were counted. 
 
Interestingly, when probed 3’ of the GAA expansion the early onset GM15 cell line 
cells, did not show a frataxin signal in ~ 68 % of cells, whereas in the late-onset 
GM16 cell line only 49 % of cells did not reveal a signal compared to the control. 
Furthermore, the proportion of cells expressing frataxin mono-allelic did not differ 
between the patient cell lines, but the proportion of bi-allelic expressing cells deviated 
much more. Moreover, cells derived from the early-onset GM15 cell line showed bi-
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allelic expression in only 5 % of cells whereas 24 % of cells derived from the late-
onset patient GM16 were still able to transcribe frataxin bi-allelic (Fig. 58).  
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